# PeptideScanner evidence objects: Teriparatide

Every published version of the records placed with Teriparatide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/teriparatide.json. Selected public evidence only; not medical advice.

- Objects: 153
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00000400-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00000400

> PeptideScanner retained ClinicalTrials.gov record NCT00000400 at 2026-07-30T21:55:56.630Z. Its registry update date was 2013-12-09, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00000400-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-12-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00000400-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00000400-teriparatide-v1
- Content SHA-256: `22ac46f397ac4a32d4b997ba7fa30fdfedfe8d4f5831396002fe556e024ae5b6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00000400 ([`ctg-observation-nct00000400-2013-12-09-aeb21965961d`](#source-ctg-observation-nct00000400-2013-12-09-aeb21965961d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00000400 at 2026-07-30T21:55:56.630Z. Its registry update date was 2013-12-09, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00000400-2013-12-09-aeb21965961d`](#source-ctg-observation-nct00000400-2013-12-09-aeb21965961d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00000400 at 2026-07-30T21:55:56.630Z. Its registry update date was 2013-12-09, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00000400-2013-12-09-aeb21965961d`](#source-ctg-observation-nct00000400-2013-12-09-aeb21965961d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00000400-2013-12-09-aeb21965961d`](#source-ctg-observation-nct00000400-2013-12-09-aeb21965961d))

### Sources

<a id="source-ctg-observation-nct00000400-2013-12-09-aeb21965961d"></a>
- **ClinicalTrials.gov record NCT00000400 · retained source version 2013-12-09:aeb21965961d5de6591ed71f1ecdef8a73251bb63586a144fcc3d4f841975d47** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00000400) (`ctg-observation-nct00000400-2013-12-09-aeb21965961d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00000400." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00000400-teriparatide-v1 SHA-256: 22ac46f397ac4a32d4b997ba7fa30fdfedfe8d4f5831396002fe556e024ae5b6.

---

<a id="clinicaltrials-gov-nct00005006-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00005006

> PeptideScanner retained ClinicalTrials.gov record NCT00005006 at 2026-07-30T21:41:27.764Z. Its registry update date was 2015-08-19, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00005006-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-08-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00005006-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00005006-teriparatide-v1
- Content SHA-256: `88e963a5b2b77ec6d276cad37776c583dd271683f9c2b21f7fc657ddaf2af239`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00005006 ([`ctg-observation-nct00005006-2015-08-19-0369c5431f98`](#source-ctg-observation-nct00005006-2015-08-19-0369c5431f98))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00005006 at 2026-07-30T21:41:27.764Z. Its registry update date was 2015-08-19, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00005006-2015-08-19-0369c5431f98`](#source-ctg-observation-nct00005006-2015-08-19-0369c5431f98))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00005006 at 2026-07-30T21:41:27.764Z. Its registry update date was 2015-08-19, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00005006-2015-08-19-0369c5431f98`](#source-ctg-observation-nct00005006-2015-08-19-0369c5431f98))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00005006-2015-08-19-0369c5431f98`](#source-ctg-observation-nct00005006-2015-08-19-0369c5431f98))

### Sources

<a id="source-ctg-observation-nct00005006-2015-08-19-0369c5431f98"></a>
- **ClinicalTrials.gov record NCT00005006 · retained source version 2015-08-19:0369c5431f98ed231855677838da7b673ed3b847606a76badce17f8fa55c216f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00005006) (`ctg-observation-nct00005006-2015-08-19-0369c5431f98`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00005006." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00005006-teriparatide-v1 SHA-256: 88e963a5b2b77ec6d276cad37776c583dd271683f9c2b21f7fc657ddaf2af239.

---

<a id="clinicaltrials-gov-nct00035256-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00035256

> PeptideScanner retained ClinicalTrials.gov record NCT00035256 at 2026-07-30T22:39:13.109Z. Its registry update date was 2007-05-15, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00035256-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2007-05-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00035256-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00035256-teriparatide-v1
- Content SHA-256: `f447a739b47e467bf0cf594b33bf08d0d2865b52957ef9eb557f0d558d230249`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00035256 ([`ctg-observation-nct00035256-2007-05-15-8f826c50b13e`](#source-ctg-observation-nct00035256-2007-05-15-8f826c50b13e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00035256 at 2026-07-30T22:39:13.109Z. Its registry update date was 2007-05-15, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00035256-2007-05-15-8f826c50b13e`](#source-ctg-observation-nct00035256-2007-05-15-8f826c50b13e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00035256 at 2026-07-30T22:39:13.109Z. Its registry update date was 2007-05-15, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00035256-2007-05-15-8f826c50b13e`](#source-ctg-observation-nct00035256-2007-05-15-8f826c50b13e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00035256-2007-05-15-8f826c50b13e`](#source-ctg-observation-nct00035256-2007-05-15-8f826c50b13e))

### Sources

<a id="source-ctg-observation-nct00035256-2007-05-15-8f826c50b13e"></a>
- **ClinicalTrials.gov record NCT00035256 · retained source version 2007-05-15:8f826c50b13e136db1f79be7f1014d618137b187f79ba83add3898b8f57e38e5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00035256) (`ctg-observation-nct00035256-2007-05-15-8f826c50b13e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00035256." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00035256-teriparatide-v1 SHA-256: f447a739b47e467bf0cf594b33bf08d0d2865b52957ef9eb557f0d558d230249.

---

<a id="clinicaltrials-gov-nct00046137-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00046137

> PeptideScanner retained ClinicalTrials.gov record NCT00046137 at 2026-07-30T22:49:18.183Z. Its registry update date was 2006-07-20, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00046137-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2006-07-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00046137-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00046137-teriparatide-v1
- Content SHA-256: `d6354bb469d751e9084594387ab7eee7e39a0dbe60399780c19e493cd823d466`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00046137 ([`ctg-observation-nct00046137-2006-07-20-996514d4e878`](#source-ctg-observation-nct00046137-2006-07-20-996514d4e878))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00046137 at 2026-07-30T22:49:18.183Z. Its registry update date was 2006-07-20, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00046137-2006-07-20-996514d4e878`](#source-ctg-observation-nct00046137-2006-07-20-996514d4e878))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00046137 at 2026-07-30T22:49:18.183Z. Its registry update date was 2006-07-20, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00046137-2006-07-20-996514d4e878`](#source-ctg-observation-nct00046137-2006-07-20-996514d4e878))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00046137-2006-07-20-996514d4e878`](#source-ctg-observation-nct00046137-2006-07-20-996514d4e878))

### Sources

<a id="source-ctg-observation-nct00046137-2006-07-20-996514d4e878"></a>
- **ClinicalTrials.gov record NCT00046137 · retained source version 2006-07-20:996514d4e878f11eeadba419a4d05a06740dda67fb23089b577e31bbfef52397** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00046137) (`ctg-observation-nct00046137-2006-07-20-996514d4e878`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00046137." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00046137-teriparatide-v1 SHA-256: d6354bb469d751e9084594387ab7eee7e39a0dbe60399780c19e493cd823d466.

---

<a id="clinicaltrials-gov-nct00051558-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00051558

> PeptideScanner retained ClinicalTrials.gov record NCT00051558 at 2026-07-30T22:26:45.005Z. Its registry update date was 2009-03-12, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00051558-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2009-03-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00051558-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00051558-teriparatide-v1
- Content SHA-256: `8c40a13ff5fa48e1902e73b4dfe11b1300f026812363e9101d80a4b45ffd6035`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00051558 ([`ctg-observation-nct00051558-2009-03-12-0d276999e40d`](#source-ctg-observation-nct00051558-2009-03-12-0d276999e40d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00051558 at 2026-07-30T22:26:45.005Z. Its registry update date was 2009-03-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00051558-2009-03-12-0d276999e40d`](#source-ctg-observation-nct00051558-2009-03-12-0d276999e40d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00051558 at 2026-07-30T22:26:45.005Z. Its registry update date was 2009-03-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00051558-2009-03-12-0d276999e40d`](#source-ctg-observation-nct00051558-2009-03-12-0d276999e40d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00051558-2009-03-12-0d276999e40d`](#source-ctg-observation-nct00051558-2009-03-12-0d276999e40d))

### Sources

<a id="source-ctg-observation-nct00051558-2009-03-12-0d276999e40d"></a>
- **ClinicalTrials.gov record NCT00051558 · retained source version 2009-03-12:0d276999e40db3fce74f25473f4f362beead48be3d41e3a156cffcd811af6846** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00051558) (`ctg-observation-nct00051558-2009-03-12-0d276999e40d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00051558." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00051558-teriparatide-v1 SHA-256: 8c40a13ff5fa48e1902e73b4dfe11b1300f026812363e9101d80a4b45ffd6035.

---

<a id="clinicaltrials-gov-nct00079924-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00079924

> PeptideScanner retained ClinicalTrials.gov record NCT00079924 at 2026-07-30T22:39:13.107Z. Its registry update date was 2007-05-25, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00079924-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2007-05-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00079924-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00079924-teriparatide-v1
- Content SHA-256: `32eaa5f5166870a079cbe22c61a1c385506423606e9253e459695a3614ac17b9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00079924 ([`ctg-observation-nct00079924-2007-05-25-420b152d6ab2`](#source-ctg-observation-nct00079924-2007-05-25-420b152d6ab2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00079924 at 2026-07-30T22:39:13.107Z. Its registry update date was 2007-05-25, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00079924-2007-05-25-420b152d6ab2`](#source-ctg-observation-nct00079924-2007-05-25-420b152d6ab2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00079924 at 2026-07-30T22:39:13.107Z. Its registry update date was 2007-05-25, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00079924-2007-05-25-420b152d6ab2`](#source-ctg-observation-nct00079924-2007-05-25-420b152d6ab2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00079924-2007-05-25-420b152d6ab2`](#source-ctg-observation-nct00079924-2007-05-25-420b152d6ab2))

### Sources

<a id="source-ctg-observation-nct00079924-2007-05-25-420b152d6ab2"></a>
- **ClinicalTrials.gov record NCT00079924 · retained source version 2007-05-25:420b152d6ab2d600763409743f8616c278559c0b57c9002b3e7be3bae4de860c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00079924) (`ctg-observation-nct00079924-2007-05-25-420b152d6ab2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00079924." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00079924-teriparatide-v1 SHA-256: 32eaa5f5166870a079cbe22c61a1c385506423606e9253e459695a3614ac17b9.

---

<a id="clinicaltrials-gov-nct00190944-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00190944

> PeptideScanner retained ClinicalTrials.gov record NCT00190944 at 2026-07-30T22:39:13.107Z. Its registry update date was 2007-10-12, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00190944-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2007-10-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00190944-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00190944-teriparatide-v1
- Content SHA-256: `16b9522d0e1981ddf24007a87259ef40005fec87392b345e1c81c528d5543290`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00190944 ([`ctg-observation-nct00190944-2007-10-12-da4db19151f7`](#source-ctg-observation-nct00190944-2007-10-12-da4db19151f7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00190944 at 2026-07-30T22:39:13.107Z. Its registry update date was 2007-10-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00190944-2007-10-12-da4db19151f7`](#source-ctg-observation-nct00190944-2007-10-12-da4db19151f7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00190944 at 2026-07-30T22:39:13.107Z. Its registry update date was 2007-10-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00190944-2007-10-12-da4db19151f7`](#source-ctg-observation-nct00190944-2007-10-12-da4db19151f7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00190944-2007-10-12-da4db19151f7`](#source-ctg-observation-nct00190944-2007-10-12-da4db19151f7))

### Sources

<a id="source-ctg-observation-nct00190944-2007-10-12-da4db19151f7"></a>
- **ClinicalTrials.gov record NCT00190944 · retained source version 2007-10-12:da4db19151f7466d6538cd67b4d3bf2ef034883f65afa0fedc76c3b6ae88b016** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00190944) (`ctg-observation-nct00190944-2007-10-12-da4db19151f7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00190944." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00190944-teriparatide-v1 SHA-256: 16b9522d0e1981ddf24007a87259ef40005fec87392b345e1c81c528d5543290.

---

<a id="clinicaltrials-gov-nct00191321-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00191321

> PeptideScanner retained ClinicalTrials.gov record NCT00191321 at 2026-07-30T22:39:13.108Z. Its registry update date was 2007-01-26, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00191321-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2007-01-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00191321-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00191321-teriparatide-v1
- Content SHA-256: `fcee7969a653e8044d0cc4fca7092267fd7222e6cceb05f5a214352f8642cd33`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00191321 ([`ctg-observation-nct00191321-2007-01-26-228c4e2f78eb`](#source-ctg-observation-nct00191321-2007-01-26-228c4e2f78eb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00191321 at 2026-07-30T22:39:13.108Z. Its registry update date was 2007-01-26, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00191321-2007-01-26-228c4e2f78eb`](#source-ctg-observation-nct00191321-2007-01-26-228c4e2f78eb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00191321 at 2026-07-30T22:39:13.108Z. Its registry update date was 2007-01-26, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00191321-2007-01-26-228c4e2f78eb`](#source-ctg-observation-nct00191321-2007-01-26-228c4e2f78eb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00191321-2007-01-26-228c4e2f78eb`](#source-ctg-observation-nct00191321-2007-01-26-228c4e2f78eb))

### Sources

<a id="source-ctg-observation-nct00191321-2007-01-26-228c4e2f78eb"></a>
- **ClinicalTrials.gov record NCT00191321 · retained source version 2007-01-26:228c4e2f78eb1a51726fc8611f60932f956de18e76dfe18b2d0bb4ccd020f535** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00191321) (`ctg-observation-nct00191321-2007-01-26-228c4e2f78eb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00191321." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00191321-teriparatide-v1 SHA-256: fcee7969a653e8044d0cc4fca7092267fd7222e6cceb05f5a214352f8642cd33.

---

<a id="clinicaltrials-gov-nct00191867-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00191867

> PeptideScanner retained ClinicalTrials.gov record NCT00191867 at 2026-07-30T22:39:13.109Z. Its registry update date was 2007-11-06, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00191867-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2007-11-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00191867-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00191867-teriparatide-v1
- Content SHA-256: `e5d34194220fe044b1109d681f7f78315e4064ff50d49dd47ac2adf5910aa332`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00191867 ([`ctg-observation-nct00191867-2007-11-06-12a9bdb1d4a7`](#source-ctg-observation-nct00191867-2007-11-06-12a9bdb1d4a7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00191867 at 2026-07-30T22:39:13.109Z. Its registry update date was 2007-11-06, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00191867-2007-11-06-12a9bdb1d4a7`](#source-ctg-observation-nct00191867-2007-11-06-12a9bdb1d4a7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00191867 at 2026-07-30T22:39:13.109Z. Its registry update date was 2007-11-06, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00191867-2007-11-06-12a9bdb1d4a7`](#source-ctg-observation-nct00191867-2007-11-06-12a9bdb1d4a7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00191867-2007-11-06-12a9bdb1d4a7`](#source-ctg-observation-nct00191867-2007-11-06-12a9bdb1d4a7))

### Sources

<a id="source-ctg-observation-nct00191867-2007-11-06-12a9bdb1d4a7"></a>
- **ClinicalTrials.gov record NCT00191867 · retained source version 2007-11-06:12a9bdb1d4a71296ca2c8b0198d50aa7959ae7a04315e5f2207fe161f8c19a08** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00191867) (`ctg-observation-nct00191867-2007-11-06-12a9bdb1d4a7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00191867." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00191867-teriparatide-v1 SHA-256: e5d34194220fe044b1109d681f7f78315e4064ff50d49dd47ac2adf5910aa332.

---

<a id="clinicaltrials-gov-nct00191893-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00191893

> PeptideScanner retained ClinicalTrials.gov record NCT00191893 at 2026-07-30T22:39:13.108Z. Its registry update date was 2007-01-26, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00191893-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2007-01-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00191893-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00191893-teriparatide-v1
- Content SHA-256: `717e600c94bb3c0f866077efd16725fea403dbed66bb371b3a5bbdc7fe587222`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00191893 ([`ctg-observation-nct00191893-2007-01-26-2c0809a5796b`](#source-ctg-observation-nct00191893-2007-01-26-2c0809a5796b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00191893 at 2026-07-30T22:39:13.108Z. Its registry update date was 2007-01-26, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00191893-2007-01-26-2c0809a5796b`](#source-ctg-observation-nct00191893-2007-01-26-2c0809a5796b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00191893 at 2026-07-30T22:39:13.108Z. Its registry update date was 2007-01-26, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00191893-2007-01-26-2c0809a5796b`](#source-ctg-observation-nct00191893-2007-01-26-2c0809a5796b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00191893-2007-01-26-2c0809a5796b`](#source-ctg-observation-nct00191893-2007-01-26-2c0809a5796b))

### Sources

<a id="source-ctg-observation-nct00191893-2007-01-26-2c0809a5796b"></a>
- **ClinicalTrials.gov record NCT00191893 · retained source version 2007-01-26:2c0809a5796b95b003e4e7f3dad0db6cfdb5c3e7ec0e1370f9012f3593f089aa** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00191893) (`ctg-observation-nct00191893-2007-01-26-2c0809a5796b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00191893." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00191893-teriparatide-v1 SHA-256: 717e600c94bb3c0f866077efd16725fea403dbed66bb371b3a5bbdc7fe587222.

---

<a id="clinicaltrials-gov-nct00239629-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00239629

> PeptideScanner retained ClinicalTrials.gov record NCT00239629 at 2026-07-30T22:39:13.108Z. Its registry update date was 2007-06-12, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00239629-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2007-06-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00239629-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00239629-teriparatide-v1
- Content SHA-256: `7e3707d2936ed8c832ab227414ec531ce388e3b0221a9947512e2ea26b2094aa`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00239629 ([`ctg-observation-nct00239629-2007-06-12-d11e694cbfcc`](#source-ctg-observation-nct00239629-2007-06-12-d11e694cbfcc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00239629 at 2026-07-30T22:39:13.108Z. Its registry update date was 2007-06-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00239629-2007-06-12-d11e694cbfcc`](#source-ctg-observation-nct00239629-2007-06-12-d11e694cbfcc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00239629 at 2026-07-30T22:39:13.108Z. Its registry update date was 2007-06-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00239629-2007-06-12-d11e694cbfcc`](#source-ctg-observation-nct00239629-2007-06-12-d11e694cbfcc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00239629-2007-06-12-d11e694cbfcc`](#source-ctg-observation-nct00239629-2007-06-12-d11e694cbfcc))

### Sources

<a id="source-ctg-observation-nct00239629-2007-06-12-d11e694cbfcc"></a>
- **ClinicalTrials.gov record NCT00239629 · retained source version 2007-06-12:d11e694cbfcc28a230a3e9019d0b20071ade8ce009396462cc518db1c9719cc7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00239629) (`ctg-observation-nct00239629-2007-06-12-d11e694cbfcc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00239629." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00239629-teriparatide-v1 SHA-256: 7e3707d2936ed8c832ab227414ec531ce388e3b0221a9947512e2ea26b2094aa.

---

<a id="clinicaltrials-gov-nct00259298-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00259298

> PeptideScanner retained ClinicalTrials.gov record NCT00259298 at 2026-07-30T22:25:23.113Z. Its registry update date was 2010-08-11, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00259298-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2010-08-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00259298-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00259298-teriparatide-v1
- Content SHA-256: `0fa3d9b07b0769a850d14f04c2539188abd7c7e63bba11d5b27dadb813d41ac0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00259298 ([`ctg-observation-nct00259298-2010-08-11-35e428679302`](#source-ctg-observation-nct00259298-2010-08-11-35e428679302))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00259298 at 2026-07-30T22:25:23.113Z. Its registry update date was 2010-08-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00259298-2010-08-11-35e428679302`](#source-ctg-observation-nct00259298-2010-08-11-35e428679302))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00259298 at 2026-07-30T22:25:23.113Z. Its registry update date was 2010-08-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00259298-2010-08-11-35e428679302`](#source-ctg-observation-nct00259298-2010-08-11-35e428679302))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00259298-2010-08-11-35e428679302`](#source-ctg-observation-nct00259298-2010-08-11-35e428679302))

### Sources

<a id="source-ctg-observation-nct00259298-2010-08-11-35e428679302"></a>
- **ClinicalTrials.gov record NCT00259298 · retained source version 2010-08-11:35e42867930242f2f04baea8e81bc57ef1198bcdb3845ea4920a9e9ec5997873** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00259298) (`ctg-observation-nct00259298-2010-08-11-35e428679302`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00259298." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00259298-teriparatide-v1 SHA-256: 0fa3d9b07b0769a850d14f04c2539188abd7c7e63bba11d5b27dadb813d41ac0.

---

<a id="clinicaltrials-gov-nct00343252-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00343252

> PeptideScanner retained ClinicalTrials.gov record NCT00343252 at 2026-07-30T22:15:58.895Z. Its registry update date was 2011-05-26, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00343252-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-05-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00343252-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00343252-teriparatide-v1
- Content SHA-256: `3c729d7e9f7b913ca944c0c9881edd0df8f7f4b0a61d283703e9cfd036d34253`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00343252 ([`ctg-observation-nct00343252-2011-05-26-dd9dd0d6a6c1`](#source-ctg-observation-nct00343252-2011-05-26-dd9dd0d6a6c1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00343252 at 2026-07-30T22:15:58.895Z. Its registry update date was 2011-05-26, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00343252-2011-05-26-dd9dd0d6a6c1`](#source-ctg-observation-nct00343252-2011-05-26-dd9dd0d6a6c1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00343252 at 2026-07-30T22:15:58.895Z. Its registry update date was 2011-05-26, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00343252-2011-05-26-dd9dd0d6a6c1`](#source-ctg-observation-nct00343252-2011-05-26-dd9dd0d6a6c1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00343252-2011-05-26-dd9dd0d6a6c1`](#source-ctg-observation-nct00343252-2011-05-26-dd9dd0d6a6c1))

### Sources

<a id="source-ctg-observation-nct00343252-2011-05-26-dd9dd0d6a6c1"></a>
- **ClinicalTrials.gov record NCT00343252 · retained source version 2011-05-26:dd9dd0d6a6c19739287362b60325f6badd9c51f043eff8f991bf693e44e53b5a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00343252) (`ctg-observation-nct00343252-2011-05-26-dd9dd0d6a6c1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00343252." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00343252-teriparatide-v1 SHA-256: 3c729d7e9f7b913ca944c0c9881edd0df8f7f4b0a61d283703e9cfd036d34253.

---

<a id="clinicaltrials-gov-nct00414973-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00414973

> PeptideScanner retained ClinicalTrials.gov record NCT00414973 at 2026-07-30T22:26:45.016Z. Its registry update date was 2009-10-28, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00414973-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2009-10-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00414973-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00414973-teriparatide-v1
- Content SHA-256: `3f487bc52bd4d33776cef92e1b70270ee1f07bad0757b27e8501c97ba0e6d21d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00414973 ([`ctg-observation-nct00414973-2009-10-28-84373898c11a`](#source-ctg-observation-nct00414973-2009-10-28-84373898c11a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00414973 at 2026-07-30T22:26:45.016Z. Its registry update date was 2009-10-28, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00414973-2009-10-28-84373898c11a`](#source-ctg-observation-nct00414973-2009-10-28-84373898c11a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00414973 at 2026-07-30T22:26:45.016Z. Its registry update date was 2009-10-28, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00414973-2009-10-28-84373898c11a`](#source-ctg-observation-nct00414973-2009-10-28-84373898c11a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00414973-2009-10-28-84373898c11a`](#source-ctg-observation-nct00414973-2009-10-28-84373898c11a))

### Sources

<a id="source-ctg-observation-nct00414973-2009-10-28-84373898c11a"></a>
- **ClinicalTrials.gov record NCT00414973 · retained source version 2009-10-28:84373898c11aaec86db0c65214c129be1afb64989422c8c95146777f349e59bf** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00414973) (`ctg-observation-nct00414973-2009-10-28-84373898c11a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00414973." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00414973-teriparatide-v1 SHA-256: 3f487bc52bd4d33776cef92e1b70270ee1f07bad0757b27e8501c97ba0e6d21d.

---

<a id="clinicaltrials-gov-nct00439244-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00439244

> PeptideScanner retained ClinicalTrials.gov record NCT00439244 at 2026-07-30T22:15:58.884Z. Its registry update date was 2011-04-20, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00439244-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-04-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00439244-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00439244-teriparatide-v1
- Content SHA-256: `2dc6476762d6eecf478a3b220c7811ff84c0b3474c27778e9e21364af17d5d2f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00439244 ([`ctg-observation-nct00439244-2011-04-20-371f6bf34802`](#source-ctg-observation-nct00439244-2011-04-20-371f6bf34802))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00439244 at 2026-07-30T22:15:58.884Z. Its registry update date was 2011-04-20, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00439244-2011-04-20-371f6bf34802`](#source-ctg-observation-nct00439244-2011-04-20-371f6bf34802))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00439244 at 2026-07-30T22:15:58.884Z. Its registry update date was 2011-04-20, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00439244-2011-04-20-371f6bf34802`](#source-ctg-observation-nct00439244-2011-04-20-371f6bf34802))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00439244-2011-04-20-371f6bf34802`](#source-ctg-observation-nct00439244-2011-04-20-371f6bf34802))

### Sources

<a id="source-ctg-observation-nct00439244-2011-04-20-371f6bf34802"></a>
- **ClinicalTrials.gov record NCT00439244 · retained source version 2011-04-20:371f6bf348024ea9dd77f96a76421a0f1d4d406e2c94c62669acfaa4e696c5d7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00439244) (`ctg-observation-nct00439244-2011-04-20-371f6bf34802`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00439244." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00439244-teriparatide-v1 SHA-256: 2dc6476762d6eecf478a3b220c7811ff84c0b3474c27778e9e21364af17d5d2f.

---

<a id="clinicaltrials-gov-nct00473265-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00473265

> PeptideScanner retained ClinicalTrials.gov record NCT00473265 at 2026-07-30T21:41:27.762Z. Its registry update date was 2015-07-16, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00473265-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-07-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00473265-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00473265-teriparatide-v1
- Content SHA-256: `046627c2b150428078d5284c15ffe37f932150290687e5f58c2346c7e78a1964`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00473265 ([`ctg-observation-nct00473265-2015-07-16-a51061c5ac52`](#source-ctg-observation-nct00473265-2015-07-16-a51061c5ac52))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00473265 at 2026-07-30T21:41:27.762Z. Its registry update date was 2015-07-16, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00473265-2015-07-16-a51061c5ac52`](#source-ctg-observation-nct00473265-2015-07-16-a51061c5ac52))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00473265 at 2026-07-30T21:41:27.762Z. Its registry update date was 2015-07-16, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00473265-2015-07-16-a51061c5ac52`](#source-ctg-observation-nct00473265-2015-07-16-a51061c5ac52))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00473265-2015-07-16-a51061c5ac52`](#source-ctg-observation-nct00473265-2015-07-16-a51061c5ac52))

### Sources

<a id="source-ctg-observation-nct00473265-2015-07-16-a51061c5ac52"></a>
- **ClinicalTrials.gov record NCT00473265 · retained source version 2015-07-16:a51061c5ac52d32f11cdb17ea307adb2122e568ee065ffe5edf4bfd525bbcc76** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00473265) (`ctg-observation-nct00473265-2015-07-16-a51061c5ac52`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00473265." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00473265-teriparatide-v1 SHA-256: 046627c2b150428078d5284c15ffe37f932150290687e5f58c2346c7e78a1964.

---

<a id="clinicaltrials-gov-nct00532207-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00532207

> PeptideScanner retained ClinicalTrials.gov record NCT00532207 at 2026-07-30T22:39:13.109Z. Its registry update date was 2007-09-20, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00532207-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2007-09-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00532207-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00532207-teriparatide-v1
- Content SHA-256: `6a934e540126aa63266625e07c2fb24a39a6b3263ea38d4ca09847377e21244f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00532207 ([`ctg-observation-nct00532207-2007-09-20-dd692e607e4f`](#source-ctg-observation-nct00532207-2007-09-20-dd692e607e4f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00532207 at 2026-07-30T22:39:13.109Z. Its registry update date was 2007-09-20, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00532207-2007-09-20-dd692e607e4f`](#source-ctg-observation-nct00532207-2007-09-20-dd692e607e4f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00532207 at 2026-07-30T22:39:13.109Z. Its registry update date was 2007-09-20, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00532207-2007-09-20-dd692e607e4f`](#source-ctg-observation-nct00532207-2007-09-20-dd692e607e4f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00532207-2007-09-20-dd692e607e4f`](#source-ctg-observation-nct00532207-2007-09-20-dd692e607e4f))

### Sources

<a id="source-ctg-observation-nct00532207-2007-09-20-dd692e607e4f"></a>
- **ClinicalTrials.gov record NCT00532207 · retained source version 2007-09-20:dd692e607e4fd302d611b53d195cc4de5d945d2342263a1a04dff0c8c05ee72b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00532207) (`ctg-observation-nct00532207-2007-09-20-dd692e607e4f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00532207." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00532207-teriparatide-v1 SHA-256: 6a934e540126aa63266625e07c2fb24a39a6b3263ea38d4ca09847377e21244f.

---

<a id="clinicaltrials-gov-nct00532545-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00532545

> PeptideScanner retained ClinicalTrials.gov record NCT00532545 at 2026-07-30T22:39:13.108Z. Its registry update date was 2007-09-20, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00532545-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2007-09-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00532545-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00532545-teriparatide-v1
- Content SHA-256: `35a465344f0d3f7df46af6972f564b99397f2bc9a2470b08065fd6b8e5e56a81`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00532545 ([`ctg-observation-nct00532545-2007-09-20-f7b445d078a2`](#source-ctg-observation-nct00532545-2007-09-20-f7b445d078a2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00532545 at 2026-07-30T22:39:13.108Z. Its registry update date was 2007-09-20, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00532545-2007-09-20-f7b445d078a2`](#source-ctg-observation-nct00532545-2007-09-20-f7b445d078a2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00532545 at 2026-07-30T22:39:13.108Z. Its registry update date was 2007-09-20, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00532545-2007-09-20-f7b445d078a2`](#source-ctg-observation-nct00532545-2007-09-20-f7b445d078a2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00532545-2007-09-20-f7b445d078a2`](#source-ctg-observation-nct00532545-2007-09-20-f7b445d078a2))

### Sources

<a id="source-ctg-observation-nct00532545-2007-09-20-f7b445d078a2"></a>
- **ClinicalTrials.gov record NCT00532545 · retained source version 2007-09-20:f7b445d078a2ce2f7d9f6377d973f602df938966b060f1037c16cdf0fc1d2ed3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00532545) (`ctg-observation-nct00532545-2007-09-20-f7b445d078a2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00532545." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00532545-teriparatide-v1 SHA-256: 35a465344f0d3f7df46af6972f564b99397f2bc9a2470b08065fd6b8e5e56a81.

---

<a id="clinicaltrials-gov-nct00557310-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00557310

> PeptideScanner retained ClinicalTrials.gov record NCT00557310 at 2026-07-30T22:15:58.883Z. Its registry update date was 2011-11-11, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00557310-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-11-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00557310-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00557310-teriparatide-v1
- Content SHA-256: `b24a56dc28c9379ecb9afa0e61d8ecd16b27fd0555d0ddce53dd14bd731df84b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00557310 ([`ctg-observation-nct00557310-2011-11-11-cd5b8e86d15a`](#source-ctg-observation-nct00557310-2011-11-11-cd5b8e86d15a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00557310 at 2026-07-30T22:15:58.883Z. Its registry update date was 2011-11-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00557310-2011-11-11-cd5b8e86d15a`](#source-ctg-observation-nct00557310-2011-11-11-cd5b8e86d15a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00557310 at 2026-07-30T22:15:58.883Z. Its registry update date was 2011-11-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00557310-2011-11-11-cd5b8e86d15a`](#source-ctg-observation-nct00557310-2011-11-11-cd5b8e86d15a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00557310-2011-11-11-cd5b8e86d15a`](#source-ctg-observation-nct00557310-2011-11-11-cd5b8e86d15a))

### Sources

<a id="source-ctg-observation-nct00557310-2011-11-11-cd5b8e86d15a"></a>
- **ClinicalTrials.gov record NCT00557310 · retained source version 2011-11-11:cd5b8e86d15af51718f25d9298db6870a21062104ce37139c48107b9d216ab93** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00557310) (`ctg-observation-nct00557310-2011-11-11-cd5b8e86d15a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00557310." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00557310-teriparatide-v1 SHA-256: b24a56dc28c9379ecb9afa0e61d8ecd16b27fd0555d0ddce53dd14bd731df84b.

---

<a id="clinicaltrials-gov-nct00670501-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00670501

> PeptideScanner retained ClinicalTrials.gov record NCT00670501 at 2026-07-30T22:36:49.601Z. Its registry update date was 2008-05-01, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00670501-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2008-05-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00670501-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00670501-teriparatide-v1
- Content SHA-256: `17255aa5a9217393038deb1ce1752fbfcf324ce53b49652b1f2cefab0c829960`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00670501 ([`ctg-observation-nct00670501-2008-05-01-9304b4251ada`](#source-ctg-observation-nct00670501-2008-05-01-9304b4251ada))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00670501 at 2026-07-30T22:36:49.601Z. Its registry update date was 2008-05-01, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00670501-2008-05-01-9304b4251ada`](#source-ctg-observation-nct00670501-2008-05-01-9304b4251ada))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00670501 at 2026-07-30T22:36:49.601Z. Its registry update date was 2008-05-01, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00670501-2008-05-01-9304b4251ada`](#source-ctg-observation-nct00670501-2008-05-01-9304b4251ada))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00670501-2008-05-01-9304b4251ada`](#source-ctg-observation-nct00670501-2008-05-01-9304b4251ada))

### Sources

<a id="source-ctg-observation-nct00670501-2008-05-01-9304b4251ada"></a>
- **ClinicalTrials.gov record NCT00670501 · retained source version 2008-05-01:9304b4251ada04ffc129c2af4a0a630ca0c676b9f4d8494cbc3fe8d86c73c61d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00670501) (`ctg-observation-nct00670501-2008-05-01-9304b4251ada`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00670501." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00670501-teriparatide-v1 SHA-256: 17255aa5a9217393038deb1ce1752fbfcf324ce53b49652b1f2cefab0c829960.

---

<a id="clinicaltrials-gov-nct00696644-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00696644

> PeptideScanner retained ClinicalTrials.gov record NCT00696644 at 2026-07-30T22:15:58.886Z. Its registry update date was 2011-05-09, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00696644-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-05-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00696644-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00696644-teriparatide-v1
- Content SHA-256: `cc8f58dfa2b6b06ad6af9be1a45726c6b1b55a9f75ea5bdc160ef2ebf7e5c1e7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00696644 ([`ctg-observation-nct00696644-2011-05-09-653b40934b67`](#source-ctg-observation-nct00696644-2011-05-09-653b40934b67))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00696644 at 2026-07-30T22:15:58.886Z. Its registry update date was 2011-05-09, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00696644-2011-05-09-653b40934b67`](#source-ctg-observation-nct00696644-2011-05-09-653b40934b67))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00696644 at 2026-07-30T22:15:58.886Z. Its registry update date was 2011-05-09, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00696644-2011-05-09-653b40934b67`](#source-ctg-observation-nct00696644-2011-05-09-653b40934b67))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00696644-2011-05-09-653b40934b67`](#source-ctg-observation-nct00696644-2011-05-09-653b40934b67))

### Sources

<a id="source-ctg-observation-nct00696644-2011-05-09-653b40934b67"></a>
- **ClinicalTrials.gov record NCT00696644 · retained source version 2011-05-09:653b40934b673dbbfde3c2972e1d7495859a4a3693a96b8523c01f1585916153** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00696644) (`ctg-observation-nct00696644-2011-05-09-653b40934b67`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00696644." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00696644-teriparatide-v1 SHA-256: cc8f58dfa2b6b06ad6af9be1a45726c6b1b55a9f75ea5bdc160ef2ebf7e5c1e7.

---

<a id="clinicaltrials-gov-nct00754442-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00754442

> PeptideScanner retained ClinicalTrials.gov record NCT00754442 at 2026-07-30T19:40:58.915Z. Its registry update date was 2022-04-01, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00754442-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-04-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00754442-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00754442-teriparatide-v1
- Content SHA-256: `e67b8202aa9964317a5d52a4ac757e50fff32c21278261d5f2cd576f0a73f31d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00754442 ([`ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836`](#source-ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00754442 at 2026-07-30T19:40:58.915Z. Its registry update date was 2022-04-01, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836`](#source-ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00754442 at 2026-07-30T19:40:58.915Z. Its registry update date was 2022-04-01, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836`](#source-ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836`](#source-ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836))

### Sources

<a id="source-ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836"></a>
- **ClinicalTrials.gov record NCT00754442 · retained source version 2022-04-01:4c0bb0f8a836a5fd0e931e1590f8838c6f602f336f707a6d445db60e5face295** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00754442) (`ctg-observation-nct00754442-2022-04-01-4c0bb0f8a836`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00754442." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00754442-teriparatide-v1 SHA-256: e67b8202aa9964317a5d52a4ac757e50fff32c21278261d5f2cd576f0a73f31d.

---

<a id="clinicaltrials-gov-nct00759772-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00759772

> PeptideScanner retained ClinicalTrials.gov record NCT00759772 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-05-11, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00759772-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00759772-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00759772-teriparatide-v1
- Content SHA-256: `d5710f5dfcf546a1bd19c00b726ddabff5f755f9d75f827cce664c00f3f87251`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00759772 ([`ctg-observation-nct00759772-2017-05-11-3a7458b69f75`](#source-ctg-observation-nct00759772-2017-05-11-3a7458b69f75))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00759772 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-05-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00759772-2017-05-11-3a7458b69f75`](#source-ctg-observation-nct00759772-2017-05-11-3a7458b69f75))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00759772 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-05-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00759772-2017-05-11-3a7458b69f75`](#source-ctg-observation-nct00759772-2017-05-11-3a7458b69f75))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00759772-2017-05-11-3a7458b69f75`](#source-ctg-observation-nct00759772-2017-05-11-3a7458b69f75))

### Sources

<a id="source-ctg-observation-nct00759772-2017-05-11-3a7458b69f75"></a>
- **ClinicalTrials.gov record NCT00759772 · retained source version 2017-05-11:3a7458b69f75b9a2147dd422656ad85f7f4e90c2a7f9404c27f979b9f6df1180** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00759772) (`ctg-observation-nct00759772-2017-05-11-3a7458b69f75`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00759772." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00759772-teriparatide-v1 SHA-256: d5710f5dfcf546a1bd19c00b726ddabff5f755f9d75f827cce664c00f3f87251.

---

<a id="clinicaltrials-gov-nct00761332-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00761332

> PeptideScanner retained ClinicalTrials.gov record NCT00761332 at 2026-07-30T22:15:58.887Z. Its registry update date was 2011-06-21, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00761332-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-06-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00761332-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00761332-teriparatide-v1
- Content SHA-256: `4f0ec94c7549d75186ba64dcdf7022a37f5542ab64ff1aa78091d8b5922c40cd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00761332 ([`ctg-observation-nct00761332-2011-06-21-da1520dc178b`](#source-ctg-observation-nct00761332-2011-06-21-da1520dc178b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00761332 at 2026-07-30T22:15:58.887Z. Its registry update date was 2011-06-21, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00761332-2011-06-21-da1520dc178b`](#source-ctg-observation-nct00761332-2011-06-21-da1520dc178b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00761332 at 2026-07-30T22:15:58.887Z. Its registry update date was 2011-06-21, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00761332-2011-06-21-da1520dc178b`](#source-ctg-observation-nct00761332-2011-06-21-da1520dc178b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00761332-2011-06-21-da1520dc178b`](#source-ctg-observation-nct00761332-2011-06-21-da1520dc178b))

### Sources

<a id="source-ctg-observation-nct00761332-2011-06-21-da1520dc178b"></a>
- **ClinicalTrials.gov record NCT00761332 · retained source version 2011-06-21:da1520dc178b914cc6250f93a77a901cf87e9974cce227fbebc2078422e974c5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00761332) (`ctg-observation-nct00761332-2011-06-21-da1520dc178b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00761332." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00761332-teriparatide-v1 SHA-256: 4f0ec94c7549d75186ba64dcdf7022a37f5542ab64ff1aa78091d8b5922c40cd.

---

<a id="clinicaltrials-gov-nct00826228-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00826228

> PeptideScanner retained ClinicalTrials.gov record NCT00826228 at 2026-07-30T21:55:56.618Z. Its registry update date was 2013-07-11, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00826228-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-07-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00826228-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00826228-teriparatide-v1
- Content SHA-256: `62037805f7a05ae0318f869b1384bbba4deb7c8c31a5b722968c04c901f53640`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00826228 ([`ctg-observation-nct00826228-2013-07-11-4a3b377e1138`](#source-ctg-observation-nct00826228-2013-07-11-4a3b377e1138))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00826228 at 2026-07-30T21:55:56.618Z. Its registry update date was 2013-07-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00826228-2013-07-11-4a3b377e1138`](#source-ctg-observation-nct00826228-2013-07-11-4a3b377e1138))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00826228 at 2026-07-30T21:55:56.618Z. Its registry update date was 2013-07-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00826228-2013-07-11-4a3b377e1138`](#source-ctg-observation-nct00826228-2013-07-11-4a3b377e1138))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00826228-2013-07-11-4a3b377e1138`](#source-ctg-observation-nct00826228-2013-07-11-4a3b377e1138))

### Sources

<a id="source-ctg-observation-nct00826228-2013-07-11-4a3b377e1138"></a>
- **ClinicalTrials.gov record NCT00826228 · retained source version 2013-07-11:4a3b377e1138d8b3a69bd3188eaa74fa1dd92cd29a2d1bfaab027a3794f84cf5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00826228) (`ctg-observation-nct00826228-2013-07-11-4a3b377e1138`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00826228." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00826228-teriparatide-v1 SHA-256: 62037805f7a05ae0318f869b1384bbba4deb7c8c31a5b722968c04c901f53640.

---

<a id="clinicaltrials-gov-nct00926380-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00926380

> PeptideScanner retained ClinicalTrials.gov record NCT00926380 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-06-29, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00926380-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-06-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00926380-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00926380-teriparatide-v1
- Content SHA-256: `83071ad05efc722c9f29ad7a179ebdeabeb0c500999578b2c5a37ff8cd25c3b1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00926380 ([`ctg-observation-nct00926380-2018-06-29-3ab5ab7e78da`](#source-ctg-observation-nct00926380-2018-06-29-3ab5ab7e78da))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00926380 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-06-29, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00926380-2018-06-29-3ab5ab7e78da`](#source-ctg-observation-nct00926380-2018-06-29-3ab5ab7e78da))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00926380 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-06-29, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00926380-2018-06-29-3ab5ab7e78da`](#source-ctg-observation-nct00926380-2018-06-29-3ab5ab7e78da))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00926380-2018-06-29-3ab5ab7e78da`](#source-ctg-observation-nct00926380-2018-06-29-3ab5ab7e78da))

### Sources

<a id="source-ctg-observation-nct00926380-2018-06-29-3ab5ab7e78da"></a>
- **ClinicalTrials.gov record NCT00926380 · retained source version 2018-06-29:3ab5ab7e78da1be2a20c78af3eddbd21c68341f53db0ee4d05245a0068dcd280** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00926380) (`ctg-observation-nct00926380-2018-06-29-3ab5ab7e78da`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00926380." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00926380-teriparatide-v1 SHA-256: 83071ad05efc722c9f29ad7a179ebdeabeb0c500999578b2c5a37ff8cd25c3b1.

---

<a id="clinicaltrials-gov-nct00927186-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT00927186

> PeptideScanner retained ClinicalTrials.gov record NCT00927186 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-04-04, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct00927186-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-04-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00927186-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00927186-teriparatide-v1
- Content SHA-256: `2360a392a83c47158708b5e5788262989926635180b5e59555874acbc6f07a95`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00927186 ([`ctg-observation-nct00927186-2013-04-04-8b4a4edfc273`](#source-ctg-observation-nct00927186-2013-04-04-8b4a4edfc273))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00927186 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-04-04, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00927186-2013-04-04-8b4a4edfc273`](#source-ctg-observation-nct00927186-2013-04-04-8b4a4edfc273))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00927186 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-04-04, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct00927186-2013-04-04-8b4a4edfc273`](#source-ctg-observation-nct00927186-2013-04-04-8b4a4edfc273))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00927186-2013-04-04-8b4a4edfc273`](#source-ctg-observation-nct00927186-2013-04-04-8b4a4edfc273))

### Sources

<a id="source-ctg-observation-nct00927186-2013-04-04-8b4a4edfc273"></a>
- **ClinicalTrials.gov record NCT00927186 · retained source version 2013-04-04:8b4a4edfc273b7dc5a8b06b23c48e2a874dfebe78d3b3e92e02a6cead552748e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00927186) (`ctg-observation-nct00927186-2013-04-04-8b4a4edfc273`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00927186." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct00927186-teriparatide-v1 SHA-256: 2360a392a83c47158708b5e5788262989926635180b5e59555874acbc6f07a95.

---

<a id="clinicaltrials-gov-nct01063504-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01063504

> PeptideScanner retained ClinicalTrials.gov record NCT01063504 at 2026-07-30T21:55:56.620Z. Its registry update date was 2013-06-19, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01063504-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-06-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01063504-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01063504-teriparatide-v1
- Content SHA-256: `7a3a3031df230f36e923446bb4e70520498d7cf6a64bbf49bce5de8699103c40`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01063504 ([`ctg-observation-nct01063504-2013-06-19-3ae3c8a8f649`](#source-ctg-observation-nct01063504-2013-06-19-3ae3c8a8f649))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01063504 at 2026-07-30T21:55:56.620Z. Its registry update date was 2013-06-19, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01063504-2013-06-19-3ae3c8a8f649`](#source-ctg-observation-nct01063504-2013-06-19-3ae3c8a8f649))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01063504 at 2026-07-30T21:55:56.620Z. Its registry update date was 2013-06-19, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01063504-2013-06-19-3ae3c8a8f649`](#source-ctg-observation-nct01063504-2013-06-19-3ae3c8a8f649))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01063504-2013-06-19-3ae3c8a8f649`](#source-ctg-observation-nct01063504-2013-06-19-3ae3c8a8f649))

### Sources

<a id="source-ctg-observation-nct01063504-2013-06-19-3ae3c8a8f649"></a>
- **ClinicalTrials.gov record NCT01063504 · retained source version 2013-06-19:3ae3c8a8f649c5183d32ebff95761839dbe54e6729e3d9d13d88bb7168978289** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01063504) (`ctg-observation-nct01063504-2013-06-19-3ae3c8a8f649`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01063504." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01063504-teriparatide-v1 SHA-256: 7a3a3031df230f36e923446bb4e70520498d7cf6a64bbf49bce5de8699103c40.

---

<a id="clinicaltrials-gov-nct01078805-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01078805

> PeptideScanner retained ClinicalTrials.gov record NCT01078805 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-26, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01078805-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-06-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01078805-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01078805-teriparatide-v1
- Content SHA-256: `da82cd45357ad109583ada377ea880fa522aa238269a23ba842cd0eba6952472`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01078805 ([`ctg-observation-nct01078805-2012-06-26-f3b4eaea0a9c`](#source-ctg-observation-nct01078805-2012-06-26-f3b4eaea0a9c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01078805 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-26, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01078805-2012-06-26-f3b4eaea0a9c`](#source-ctg-observation-nct01078805-2012-06-26-f3b4eaea0a9c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01078805 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-26, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01078805-2012-06-26-f3b4eaea0a9c`](#source-ctg-observation-nct01078805-2012-06-26-f3b4eaea0a9c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01078805-2012-06-26-f3b4eaea0a9c`](#source-ctg-observation-nct01078805-2012-06-26-f3b4eaea0a9c))

### Sources

<a id="source-ctg-observation-nct01078805-2012-06-26-f3b4eaea0a9c"></a>
- **ClinicalTrials.gov record NCT01078805 · retained source version 2012-06-26:f3b4eaea0a9c66df32e12aa5848ae64f431cb1e1cdf8269c72873e67bb57f7f0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01078805) (`ctg-observation-nct01078805-2012-06-26-f3b4eaea0a9c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01078805." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01078805-teriparatide-v1 SHA-256: da82cd45357ad109583ada377ea880fa522aa238269a23ba842cd0eba6952472.

---

<a id="clinicaltrials-gov-nct01153425-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01153425

> PeptideScanner retained ClinicalTrials.gov record NCT01153425 at 2026-07-30T21:23:14.757Z. Its registry update date was 2017-08-04, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01153425-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-08-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01153425-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01153425-teriparatide-v1
- Content SHA-256: `954b2f0c5e3b410171ff322ea4b9d4036017d69e60b7a7c17d3114650481d349`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01153425 ([`ctg-observation-nct01153425-2017-08-04-b667366bf73f`](#source-ctg-observation-nct01153425-2017-08-04-b667366bf73f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01153425 at 2026-07-30T21:23:14.757Z. Its registry update date was 2017-08-04, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01153425-2017-08-04-b667366bf73f`](#source-ctg-observation-nct01153425-2017-08-04-b667366bf73f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01153425 at 2026-07-30T21:23:14.757Z. Its registry update date was 2017-08-04, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01153425-2017-08-04-b667366bf73f`](#source-ctg-observation-nct01153425-2017-08-04-b667366bf73f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01153425-2017-08-04-b667366bf73f`](#source-ctg-observation-nct01153425-2017-08-04-b667366bf73f))

### Sources

<a id="source-ctg-observation-nct01153425-2017-08-04-b667366bf73f"></a>
- **ClinicalTrials.gov record NCT01153425 · retained source version 2017-08-04:b667366bf73fd982b7e433b4e8fa8685d763dfcf9c6f76453b1bb8b9d3f0c24e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01153425) (`ctg-observation-nct01153425-2017-08-04-b667366bf73f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01153425." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01153425-teriparatide-v1 SHA-256: 954b2f0c5e3b410171ff322ea4b9d4036017d69e60b7a7c17d3114650481d349.

---

<a id="clinicaltrials-gov-nct01155232-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01155232

> PeptideScanner retained ClinicalTrials.gov record NCT01155232 at 2026-07-30T16:19:36.922Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01155232-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01155232-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01155232-teriparatide-v1
- Content SHA-256: `2b590e8aff7dae2c2a6a276aa6231ab55b4a2b10e4eb5c792512098581521198`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01155232 ([`ctg-observation-nct01155232-2026-05-11-c1d7ec8ba88c`](#source-ctg-observation-nct01155232-2026-05-11-c1d7ec8ba88c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01155232 at 2026-07-30T16:19:36.922Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01155232-2026-05-11-c1d7ec8ba88c`](#source-ctg-observation-nct01155232-2026-05-11-c1d7ec8ba88c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01155232 at 2026-07-30T16:19:36.922Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01155232-2026-05-11-c1d7ec8ba88c`](#source-ctg-observation-nct01155232-2026-05-11-c1d7ec8ba88c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01155232-2026-05-11-c1d7ec8ba88c`](#source-ctg-observation-nct01155232-2026-05-11-c1d7ec8ba88c))

### Sources

<a id="source-ctg-observation-nct01155232-2026-05-11-c1d7ec8ba88c"></a>
- **ClinicalTrials.gov record NCT01155232 · retained source version 2026-05-11:c1d7ec8ba88cbbbd9137b63a9b50d142b10ac559295be42c8c638acd3fe3bcb7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01155232) (`ctg-observation-nct01155232-2026-05-11-c1d7ec8ba88c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01155232." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01155232-teriparatide-v1 SHA-256: 2b590e8aff7dae2c2a6a276aa6231ab55b4a2b10e4eb5c792512098581521198.

---

<a id="clinicaltrials-gov-nct01166958-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01166958

> PeptideScanner retained ClinicalTrials.gov record NCT01166958 at 2026-07-30T21:54:46.558Z. Its registry update date was 2014-09-22, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01166958-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-09-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01166958-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01166958-teriparatide-v1
- Content SHA-256: `b2a5d0e4b1eb016d6d21ffd895737bfe0495639de57954a8f4a428e1b68dcadd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01166958 ([`ctg-observation-nct01166958-2014-09-22-7e8f447f7d5e`](#source-ctg-observation-nct01166958-2014-09-22-7e8f447f7d5e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01166958 at 2026-07-30T21:54:46.558Z. Its registry update date was 2014-09-22, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01166958-2014-09-22-7e8f447f7d5e`](#source-ctg-observation-nct01166958-2014-09-22-7e8f447f7d5e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01166958 at 2026-07-30T21:54:46.558Z. Its registry update date was 2014-09-22, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01166958-2014-09-22-7e8f447f7d5e`](#source-ctg-observation-nct01166958-2014-09-22-7e8f447f7d5e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01166958-2014-09-22-7e8f447f7d5e`](#source-ctg-observation-nct01166958-2014-09-22-7e8f447f7d5e))

### Sources

<a id="source-ctg-observation-nct01166958-2014-09-22-7e8f447f7d5e"></a>
- **ClinicalTrials.gov record NCT01166958 · retained source version 2014-09-22:7e8f447f7d5ef8579722f4e66e720893d2029d2830f4f13fa7023aed043c20dd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01166958) (`ctg-observation-nct01166958-2014-09-22-7e8f447f7d5e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01166958." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01166958-teriparatide-v1 SHA-256: b2a5d0e4b1eb016d6d21ffd895737bfe0495639de57954a8f4a428e1b68dcadd.

---

<a id="clinicaltrials-gov-nct01225055-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01225055

> PeptideScanner retained ClinicalTrials.gov record NCT01225055 at 2026-07-30T18:18:33.512Z. Its registry update date was 2025-12-02, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01225055-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01225055-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01225055-teriparatide-v1
- Content SHA-256: `a2252182087e424e26eca60700b986df8441a1b9a2bfe01d6da05a6f5b2be6d8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01225055 ([`ctg-observation-nct01225055-2025-12-02-f911de7652b6`](#source-ctg-observation-nct01225055-2025-12-02-f911de7652b6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01225055 at 2026-07-30T18:18:33.512Z. Its registry update date was 2025-12-02, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01225055-2025-12-02-f911de7652b6`](#source-ctg-observation-nct01225055-2025-12-02-f911de7652b6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01225055 at 2026-07-30T18:18:33.512Z. Its registry update date was 2025-12-02, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01225055-2025-12-02-f911de7652b6`](#source-ctg-observation-nct01225055-2025-12-02-f911de7652b6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01225055-2025-12-02-f911de7652b6`](#source-ctg-observation-nct01225055-2025-12-02-f911de7652b6))

### Sources

<a id="source-ctg-observation-nct01225055-2025-12-02-f911de7652b6"></a>
- **ClinicalTrials.gov record NCT01225055 · retained source version 2025-12-02:f911de7652b64fb613368a48030ae0914d238dea60bd0c38105faf6a18b23e42** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01225055) (`ctg-observation-nct01225055-2025-12-02-f911de7652b6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01225055." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01225055-teriparatide-v1 SHA-256: a2252182087e424e26eca60700b986df8441a1b9a2bfe01d6da05a6f5b2be6d8.

---

<a id="clinicaltrials-gov-nct01292252-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01292252

> PeptideScanner retained ClinicalTrials.gov record NCT01292252 at 2026-07-30T20:03:05.485Z. Its registry update date was 2021-05-03, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01292252-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-05-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01292252-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01292252-teriparatide-v1
- Content SHA-256: `09b4130938a30f9babf15c3b1f4ae0a0f0116e04d43d8d38eabd4f12303fbe40`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01292252 ([`ctg-observation-nct01292252-2021-05-03-3617b63fb042`](#source-ctg-observation-nct01292252-2021-05-03-3617b63fb042))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01292252 at 2026-07-30T20:03:05.485Z. Its registry update date was 2021-05-03, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01292252-2021-05-03-3617b63fb042`](#source-ctg-observation-nct01292252-2021-05-03-3617b63fb042))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01292252 at 2026-07-30T20:03:05.485Z. Its registry update date was 2021-05-03, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01292252-2021-05-03-3617b63fb042`](#source-ctg-observation-nct01292252-2021-05-03-3617b63fb042))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01292252-2021-05-03-3617b63fb042`](#source-ctg-observation-nct01292252-2021-05-03-3617b63fb042))

### Sources

<a id="source-ctg-observation-nct01292252-2021-05-03-3617b63fb042"></a>
- **ClinicalTrials.gov record NCT01292252 · retained source version 2021-05-03:3617b63fb042392c710a0b1512c6f72c3afa82b78f16eccf51345a826637af20** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01292252) (`ctg-observation-nct01292252-2021-05-03-3617b63fb042`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01292252." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01292252-teriparatide-v1 SHA-256: 09b4130938a30f9babf15c3b1f4ae0a0f0116e04d43d8d38eabd4f12303fbe40.

---

<a id="clinicaltrials-gov-nct01293292-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01293292

> PeptideScanner retained ClinicalTrials.gov record NCT01293292 at 2026-07-30T16:19:36.921Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01293292-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01293292-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01293292-teriparatide-v1
- Content SHA-256: `386977b2de70cfadf7b1b185f02d46748ccb2b6be87fa1040107864fc2385c94`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01293292 ([`ctg-observation-nct01293292-2026-05-19-6d65146b2004`](#source-ctg-observation-nct01293292-2026-05-19-6d65146b2004))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01293292 at 2026-07-30T16:19:36.921Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01293292-2026-05-19-6d65146b2004`](#source-ctg-observation-nct01293292-2026-05-19-6d65146b2004))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01293292 at 2026-07-30T16:19:36.921Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01293292-2026-05-19-6d65146b2004`](#source-ctg-observation-nct01293292-2026-05-19-6d65146b2004))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01293292-2026-05-19-6d65146b2004`](#source-ctg-observation-nct01293292-2026-05-19-6d65146b2004))

### Sources

<a id="source-ctg-observation-nct01293292-2026-05-19-6d65146b2004"></a>
- **ClinicalTrials.gov record NCT01293292 · retained source version 2026-05-19:6d65146b20047475ad6a9135daf7037266598d1b5fd46eed44b4529e1a625ba5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01293292) (`ctg-observation-nct01293292-2026-05-19-6d65146b2004`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01293292." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01293292-teriparatide-v1 SHA-256: 386977b2de70cfadf7b1b185f02d46748ccb2b6be87fa1040107864fc2385c94.

---

<a id="clinicaltrials-gov-nct01309399-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01309399

> PeptideScanner retained ClinicalTrials.gov record NCT01309399 at 2026-07-30T21:34:56.507Z. Its registry update date was 2016-11-23, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01309399-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-11-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01309399-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01309399-teriparatide-v1
- Content SHA-256: `aa3a89a38a10cb0facb222faa43779be865cedebced26225430c6199f972f718`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01309399 ([`ctg-observation-nct01309399-2016-11-23-01c12f800df5`](#source-ctg-observation-nct01309399-2016-11-23-01c12f800df5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01309399 at 2026-07-30T21:34:56.507Z. Its registry update date was 2016-11-23, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01309399-2016-11-23-01c12f800df5`](#source-ctg-observation-nct01309399-2016-11-23-01c12f800df5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01309399 at 2026-07-30T21:34:56.507Z. Its registry update date was 2016-11-23, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01309399-2016-11-23-01c12f800df5`](#source-ctg-observation-nct01309399-2016-11-23-01c12f800df5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01309399-2016-11-23-01c12f800df5`](#source-ctg-observation-nct01309399-2016-11-23-01c12f800df5))

### Sources

<a id="source-ctg-observation-nct01309399-2016-11-23-01c12f800df5"></a>
- **ClinicalTrials.gov record NCT01309399 · retained source version 2016-11-23:01c12f800df534f523fb958c1d689056c05569a2feda1fcb27e213f89ed40297** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01309399) (`ctg-observation-nct01309399-2016-11-23-01c12f800df5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01309399." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01309399-teriparatide-v1 SHA-256: aa3a89a38a10cb0facb222faa43779be865cedebced26225430c6199f972f718.

---

<a id="clinicaltrials-gov-nct01360424-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01360424

> PeptideScanner retained ClinicalTrials.gov record NCT01360424 at 2026-07-30T21:41:27.767Z. Its registry update date was 2015-09-29, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01360424-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-09-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01360424-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01360424-teriparatide-v1
- Content SHA-256: `acb7cfbf4479201998487608c4f808f5ddfb36809db1eb7f68e68142fd674371`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01360424 ([`ctg-observation-nct01360424-2015-09-29-f99e50fc3130`](#source-ctg-observation-nct01360424-2015-09-29-f99e50fc3130))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01360424 at 2026-07-30T21:41:27.767Z. Its registry update date was 2015-09-29, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01360424-2015-09-29-f99e50fc3130`](#source-ctg-observation-nct01360424-2015-09-29-f99e50fc3130))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01360424 at 2026-07-30T21:41:27.767Z. Its registry update date was 2015-09-29, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01360424-2015-09-29-f99e50fc3130`](#source-ctg-observation-nct01360424-2015-09-29-f99e50fc3130))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01360424-2015-09-29-f99e50fc3130`](#source-ctg-observation-nct01360424-2015-09-29-f99e50fc3130))

### Sources

<a id="source-ctg-observation-nct01360424-2015-09-29-f99e50fc3130"></a>
- **ClinicalTrials.gov record NCT01360424 · retained source version 2015-09-29:f99e50fc3130c603ef02c151223ca71683acf90ce8f88ac991b44b2056627b64** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01360424) (`ctg-observation-nct01360424-2015-09-29-f99e50fc3130`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01360424." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01360424-teriparatide-v1 SHA-256: acb7cfbf4479201998487608c4f808f5ddfb36809db1eb7f68e68142fd674371.

---

<a id="clinicaltrials-gov-nct01400516-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01400516

> PeptideScanner retained ClinicalTrials.gov record NCT01400516 at 2026-07-30T21:24:24.225Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01400516-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01400516-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01400516-teriparatide-v1
- Content SHA-256: `982854265467e7a1b628487a9db3ae7a624949fd06771eae01867d979bd42e65`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01400516 ([`ctg-observation-nct01400516-2017-04-11-b7d9dbdd435f`](#source-ctg-observation-nct01400516-2017-04-11-b7d9dbdd435f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01400516 at 2026-07-30T21:24:24.225Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01400516-2017-04-11-b7d9dbdd435f`](#source-ctg-observation-nct01400516-2017-04-11-b7d9dbdd435f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01400516 at 2026-07-30T21:24:24.225Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01400516-2017-04-11-b7d9dbdd435f`](#source-ctg-observation-nct01400516-2017-04-11-b7d9dbdd435f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01400516-2017-04-11-b7d9dbdd435f`](#source-ctg-observation-nct01400516-2017-04-11-b7d9dbdd435f))

### Sources

<a id="source-ctg-observation-nct01400516-2017-04-11-b7d9dbdd435f"></a>
- **ClinicalTrials.gov record NCT01400516 · retained source version 2017-04-11:b7d9dbdd435fc35ba59b63302e952fa01d19cc9b910223f2debb823ec814c2c1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01400516) (`ctg-observation-nct01400516-2017-04-11-b7d9dbdd435f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01400516." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01400516-teriparatide-v1 SHA-256: 982854265467e7a1b628487a9db3ae7a624949fd06771eae01867d979bd42e65.

---

<a id="clinicaltrials-gov-nct01430104-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01430104

> PeptideScanner retained ClinicalTrials.gov record NCT01430104 at 2026-07-30T21:55:56.620Z. Its registry update date was 2013-01-14, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01430104-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-01-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01430104-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01430104-teriparatide-v1
- Content SHA-256: `a1587318b93b2bfad76ba7d32e15534c8e5f014d26a12c60db6873495ed5c2d9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01430104 ([`ctg-observation-nct01430104-2013-01-14-8c7c875cf166`](#source-ctg-observation-nct01430104-2013-01-14-8c7c875cf166))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01430104 at 2026-07-30T21:55:56.620Z. Its registry update date was 2013-01-14, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01430104-2013-01-14-8c7c875cf166`](#source-ctg-observation-nct01430104-2013-01-14-8c7c875cf166))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01430104 at 2026-07-30T21:55:56.620Z. Its registry update date was 2013-01-14, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01430104-2013-01-14-8c7c875cf166`](#source-ctg-observation-nct01430104-2013-01-14-8c7c875cf166))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01430104-2013-01-14-8c7c875cf166`](#source-ctg-observation-nct01430104-2013-01-14-8c7c875cf166))

### Sources

<a id="source-ctg-observation-nct01430104-2013-01-14-8c7c875cf166"></a>
- **ClinicalTrials.gov record NCT01430104 · retained source version 2013-01-14:8c7c875cf166b0894257741518712245982d914a95ef313bc5b3de88781afbe7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01430104) (`ctg-observation-nct01430104-2013-01-14-8c7c875cf166`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01430104." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01430104-teriparatide-v1 SHA-256: a1587318b93b2bfad76ba7d32e15534c8e5f014d26a12c60db6873495ed5c2d9.

---

<a id="clinicaltrials-gov-nct01440803-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01440803

> PeptideScanner retained ClinicalTrials.gov record NCT01440803 at 2026-07-30T20:42:14.438Z. Its registry update date was 2019-12-11, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01440803-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-12-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01440803-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01440803-teriparatide-v1
- Content SHA-256: `12eaf6be4c561ded356bdb3061cbb4e8c2ef534f96edec45f9cf8b6bd7e7e17c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01440803 ([`ctg-observation-nct01440803-2019-12-11-59064590a080`](#source-ctg-observation-nct01440803-2019-12-11-59064590a080))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01440803 at 2026-07-30T20:42:14.438Z. Its registry update date was 2019-12-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01440803-2019-12-11-59064590a080`](#source-ctg-observation-nct01440803-2019-12-11-59064590a080))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01440803 at 2026-07-30T20:42:14.438Z. Its registry update date was 2019-12-11, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01440803-2019-12-11-59064590a080`](#source-ctg-observation-nct01440803-2019-12-11-59064590a080))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01440803-2019-12-11-59064590a080`](#source-ctg-observation-nct01440803-2019-12-11-59064590a080))

### Sources

<a id="source-ctg-observation-nct01440803-2019-12-11-59064590a080"></a>
- **ClinicalTrials.gov record NCT01440803 · retained source version 2019-12-11:59064590a080f5fe2e32f44cf1048173884608c52d5cfea7956e212e59320026** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01440803) (`ctg-observation-nct01440803-2019-12-11-59064590a080`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01440803." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01440803-teriparatide-v1 SHA-256: 12eaf6be4c561ded356bdb3061cbb4e8c2ef534f96edec45f9cf8b6bd7e7e17c.

---

<a id="clinicaltrials-gov-nct01473589-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01473589

> PeptideScanner retained ClinicalTrials.gov record NCT01473589 at 2026-07-30T21:42:40.788Z. Its registry update date was 2015-04-16, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01473589-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-04-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01473589-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01473589-teriparatide-v1
- Content SHA-256: `b34cb6c82e1386e970d953048040b852ca02fdb1607518cab795afd91731ab16`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01473589 ([`ctg-observation-nct01473589-2015-04-16-688ef94c2352`](#source-ctg-observation-nct01473589-2015-04-16-688ef94c2352))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01473589 at 2026-07-30T21:42:40.788Z. Its registry update date was 2015-04-16, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01473589-2015-04-16-688ef94c2352`](#source-ctg-observation-nct01473589-2015-04-16-688ef94c2352))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01473589 at 2026-07-30T21:42:40.788Z. Its registry update date was 2015-04-16, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01473589-2015-04-16-688ef94c2352`](#source-ctg-observation-nct01473589-2015-04-16-688ef94c2352))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01473589-2015-04-16-688ef94c2352`](#source-ctg-observation-nct01473589-2015-04-16-688ef94c2352))

### Sources

<a id="source-ctg-observation-nct01473589-2015-04-16-688ef94c2352"></a>
- **ClinicalTrials.gov record NCT01473589 · retained source version 2015-04-16:688ef94c23523b95fef7f2d015bc43e89f2669c31165173361e362aa0b061b6b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01473589) (`ctg-observation-nct01473589-2015-04-16-688ef94c2352`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01473589." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01473589-teriparatide-v1 SHA-256: b34cb6c82e1386e970d953048040b852ca02fdb1607518cab795afd91731ab16.

---

<a id="clinicaltrials-gov-nct01473602-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01473602

> PeptideScanner retained ClinicalTrials.gov record NCT01473602 at 2026-07-30T21:42:40.804Z. Its registry update date was 2015-04-16, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01473602-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-04-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01473602-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01473602-teriparatide-v1
- Content SHA-256: `fd1d5a7fb89146f89dcbabaa9d0824bd827605dde7869b893bfda0319c3bb38e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01473602 ([`ctg-observation-nct01473602-2015-04-16-7ebc7d61f5ec`](#source-ctg-observation-nct01473602-2015-04-16-7ebc7d61f5ec))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01473602 at 2026-07-30T21:42:40.804Z. Its registry update date was 2015-04-16, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01473602-2015-04-16-7ebc7d61f5ec`](#source-ctg-observation-nct01473602-2015-04-16-7ebc7d61f5ec))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01473602 at 2026-07-30T21:42:40.804Z. Its registry update date was 2015-04-16, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01473602-2015-04-16-7ebc7d61f5ec`](#source-ctg-observation-nct01473602-2015-04-16-7ebc7d61f5ec))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01473602-2015-04-16-7ebc7d61f5ec`](#source-ctg-observation-nct01473602-2015-04-16-7ebc7d61f5ec))

### Sources

<a id="source-ctg-observation-nct01473602-2015-04-16-7ebc7d61f5ec"></a>
- **ClinicalTrials.gov record NCT01473602 · retained source version 2015-04-16:7ebc7d61f5ec76415e154b3fca40e09c4dc830ba122bfeea3276f93c202e01d3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01473602) (`ctg-observation-nct01473602-2015-04-16-7ebc7d61f5ec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01473602." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01473602-teriparatide-v1 SHA-256: fd1d5a7fb89146f89dcbabaa9d0824bd827605dde7869b893bfda0319c3bb38e.

---

<a id="clinicaltrials-gov-nct01611571-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01611571

> PeptideScanner retained ClinicalTrials.gov record NCT01611571 at 2026-07-30T21:54:46.552Z. Its registry update date was 2014-03-04, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01611571-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-03-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01611571-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01611571-teriparatide-v1
- Content SHA-256: `c607f1c543c1a10d986ee30001c38362914a7ba2aead0adbc5e32c534ba1c20a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01611571 ([`ctg-observation-nct01611571-2014-03-04-4f4e4a284b1c`](#source-ctg-observation-nct01611571-2014-03-04-4f4e4a284b1c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01611571 at 2026-07-30T21:54:46.552Z. Its registry update date was 2014-03-04, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01611571-2014-03-04-4f4e4a284b1c`](#source-ctg-observation-nct01611571-2014-03-04-4f4e4a284b1c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01611571 at 2026-07-30T21:54:46.552Z. Its registry update date was 2014-03-04, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01611571-2014-03-04-4f4e4a284b1c`](#source-ctg-observation-nct01611571-2014-03-04-4f4e4a284b1c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01611571-2014-03-04-4f4e4a284b1c`](#source-ctg-observation-nct01611571-2014-03-04-4f4e4a284b1c))

### Sources

<a id="source-ctg-observation-nct01611571-2014-03-04-4f4e4a284b1c"></a>
- **ClinicalTrials.gov record NCT01611571 · retained source version 2014-03-04:4f4e4a284b1cd8e2bd3bd3e745a655e369c7afec21734ee62254abeef22fc67d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01611571) (`ctg-observation-nct01611571-2014-03-04-4f4e4a284b1c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01611571." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01611571-teriparatide-v1 SHA-256: c607f1c543c1a10d986ee30001c38362914a7ba2aead0adbc5e32c534ba1c20a.

---

<a id="clinicaltrials-gov-nct01705587-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01705587

> PeptideScanner retained ClinicalTrials.gov record NCT01705587 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-12-12, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01705587-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-12-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01705587-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01705587-teriparatide-v1
- Content SHA-256: `8ee2f3f719560fd8cd512ce162d73532050bed91f8dab01e584fdd8596882c70`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01705587 ([`ctg-observation-nct01705587-2017-12-12-30798d18abd7`](#source-ctg-observation-nct01705587-2017-12-12-30798d18abd7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01705587 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-12-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01705587-2017-12-12-30798d18abd7`](#source-ctg-observation-nct01705587-2017-12-12-30798d18abd7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01705587 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-12-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01705587-2017-12-12-30798d18abd7`](#source-ctg-observation-nct01705587-2017-12-12-30798d18abd7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01705587-2017-12-12-30798d18abd7`](#source-ctg-observation-nct01705587-2017-12-12-30798d18abd7))

### Sources

<a id="source-ctg-observation-nct01705587-2017-12-12-30798d18abd7"></a>
- **ClinicalTrials.gov record NCT01705587 · retained source version 2017-12-12:30798d18abd7e81494ed4537ca6defde5dcddd74e34b989a45d7955940cd76ee** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01705587) (`ctg-observation-nct01705587-2017-12-12-30798d18abd7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01705587." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01705587-teriparatide-v1 SHA-256: 8ee2f3f719560fd8cd512ce162d73532050bed91f8dab01e584fdd8596882c70.

---

<a id="clinicaltrials-gov-nct01709110-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01709110

> PeptideScanner retained ClinicalTrials.gov record NCT01709110 at 2026-07-30T20:45:58.285Z. Its registry update date was 2019-09-23, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01709110-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-09-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01709110-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01709110-teriparatide-v1
- Content SHA-256: `ed6d30bfc829a4af13fbc92424456bcd1303649e75768731889ed54e31d65dd3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01709110 ([`ctg-observation-nct01709110-2019-09-23-5ba45f9abc24`](#source-ctg-observation-nct01709110-2019-09-23-5ba45f9abc24))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01709110 at 2026-07-30T20:45:58.285Z. Its registry update date was 2019-09-23, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01709110-2019-09-23-5ba45f9abc24`](#source-ctg-observation-nct01709110-2019-09-23-5ba45f9abc24))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01709110 at 2026-07-30T20:45:58.285Z. Its registry update date was 2019-09-23, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01709110-2019-09-23-5ba45f9abc24`](#source-ctg-observation-nct01709110-2019-09-23-5ba45f9abc24))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01709110-2019-09-23-5ba45f9abc24`](#source-ctg-observation-nct01709110-2019-09-23-5ba45f9abc24))

### Sources

<a id="source-ctg-observation-nct01709110-2019-09-23-5ba45f9abc24"></a>
- **ClinicalTrials.gov record NCT01709110 · retained source version 2019-09-23:5ba45f9abc241757d16adfeaf0946ef0bc91ea64dcba1359d08ddac625636ae1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01709110) (`ctg-observation-nct01709110-2019-09-23-5ba45f9abc24`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01709110." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01709110-teriparatide-v1 SHA-256: ed6d30bfc829a4af13fbc92424456bcd1303649e75768731889ed54e31d65dd3.

---

<a id="clinicaltrials-gov-nct01753856-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01753856

> PeptideScanner retained ClinicalTrials.gov record NCT01753856 at 2026-07-30T21:39:57.682Z. Its registry update date was 2015-10-08, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01753856-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-10-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01753856-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01753856-teriparatide-v1
- Content SHA-256: `c2f2de5da6f524261cb10d18c588e276e2cc80d31b27e3d35452e1f95ba3fc20`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01753856 ([`ctg-observation-nct01753856-2015-10-08-099a22175188`](#source-ctg-observation-nct01753856-2015-10-08-099a22175188))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01753856 at 2026-07-30T21:39:57.682Z. Its registry update date was 2015-10-08, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01753856-2015-10-08-099a22175188`](#source-ctg-observation-nct01753856-2015-10-08-099a22175188))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01753856 at 2026-07-30T21:39:57.682Z. Its registry update date was 2015-10-08, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01753856-2015-10-08-099a22175188`](#source-ctg-observation-nct01753856-2015-10-08-099a22175188))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01753856-2015-10-08-099a22175188`](#source-ctg-observation-nct01753856-2015-10-08-099a22175188))

### Sources

<a id="source-ctg-observation-nct01753856-2015-10-08-099a22175188"></a>
- **ClinicalTrials.gov record NCT01753856 · retained source version 2015-10-08:099a221751881e82978dfa643b8d669a24a6e387c384ffb5527fae7f4af07a0d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01753856) (`ctg-observation-nct01753856-2015-10-08-099a22175188`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01753856." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01753856-teriparatide-v1 SHA-256: c2f2de5da6f524261cb10d18c588e276e2cc80d31b27e3d35452e1f95ba3fc20.

---

<a id="clinicaltrials-gov-nct01796301-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT01796301

> PeptideScanner retained ClinicalTrials.gov record NCT01796301 at 2026-07-30T19:32:59.853Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct01796301-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-11-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01796301-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01796301-teriparatide-v1
- Content SHA-256: `f279674db7fe4ba97a82a852ef7558315854765425b82d142e35bddb70d75f98`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01796301 ([`ctg-observation-nct01796301-2022-11-29-747811b32ba9`](#source-ctg-observation-nct01796301-2022-11-29-747811b32ba9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01796301 at 2026-07-30T19:32:59.853Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01796301-2022-11-29-747811b32ba9`](#source-ctg-observation-nct01796301-2022-11-29-747811b32ba9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01796301 at 2026-07-30T19:32:59.853Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct01796301-2022-11-29-747811b32ba9`](#source-ctg-observation-nct01796301-2022-11-29-747811b32ba9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01796301-2022-11-29-747811b32ba9`](#source-ctg-observation-nct01796301-2022-11-29-747811b32ba9))

### Sources

<a id="source-ctg-observation-nct01796301-2022-11-29-747811b32ba9"></a>
- **ClinicalTrials.gov record NCT01796301 · retained source version 2022-11-29:747811b32ba991a04549d37eecc20411ed95c6e216c1a1a4613eab66a57023e4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01796301) (`ctg-observation-nct01796301-2022-11-29-747811b32ba9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01796301." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct01796301-teriparatide-v1 SHA-256: f279674db7fe4ba97a82a852ef7558315854765425b82d142e35bddb70d75f98.

---

<a id="clinicaltrials-gov-nct02023411-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT02023411

> PeptideScanner retained ClinicalTrials.gov record NCT02023411 at 2026-07-30T20:02:09.392Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct02023411-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-06-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02023411-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02023411-teriparatide-v1
- Content SHA-256: `c8a51f8080e43a124c24621c39766dac651ccb86f371dbfdf29010d3a7b82fc8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02023411 ([`ctg-observation-nct02023411-2021-06-30-daaa6d7fb05b`](#source-ctg-observation-nct02023411-2021-06-30-daaa6d7fb05b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02023411 at 2026-07-30T20:02:09.392Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02023411-2021-06-30-daaa6d7fb05b`](#source-ctg-observation-nct02023411-2021-06-30-daaa6d7fb05b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02023411 at 2026-07-30T20:02:09.392Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02023411-2021-06-30-daaa6d7fb05b`](#source-ctg-observation-nct02023411-2021-06-30-daaa6d7fb05b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02023411-2021-06-30-daaa6d7fb05b`](#source-ctg-observation-nct02023411-2021-06-30-daaa6d7fb05b))

### Sources

<a id="source-ctg-observation-nct02023411-2021-06-30-daaa6d7fb05b"></a>
- **ClinicalTrials.gov record NCT02023411 · retained source version 2021-06-30:daaa6d7fb05b1e772b420200aefde6556b4cf717798c1a47c07afbf1e3113203** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02023411) (`ctg-observation-nct02023411-2021-06-30-daaa6d7fb05b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02023411." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02023411-teriparatide-v1 SHA-256: c8a51f8080e43a124c24621c39766dac651ccb86f371dbfdf29010d3a7b82fc8.

---

<a id="clinicaltrials-gov-nct02025179-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT02025179

> PeptideScanner retained ClinicalTrials.gov record NCT02025179 at 2026-07-30T19:13:03.751Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct02025179-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-05-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02025179-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02025179-teriparatide-v1
- Content SHA-256: `35cd8353acc00b0512574622c66aec6afb044210632e7d55d34ff80271d597d7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02025179 ([`ctg-observation-nct02025179-2023-05-10-2ed52df8084f`](#source-ctg-observation-nct02025179-2023-05-10-2ed52df8084f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02025179 at 2026-07-30T19:13:03.751Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02025179-2023-05-10-2ed52df8084f`](#source-ctg-observation-nct02025179-2023-05-10-2ed52df8084f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02025179 at 2026-07-30T19:13:03.751Z. Its registry update date was 2023-05-10, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02025179-2023-05-10-2ed52df8084f`](#source-ctg-observation-nct02025179-2023-05-10-2ed52df8084f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02025179-2023-05-10-2ed52df8084f`](#source-ctg-observation-nct02025179-2023-05-10-2ed52df8084f))

### Sources

<a id="source-ctg-observation-nct02025179-2023-05-10-2ed52df8084f"></a>
- **ClinicalTrials.gov record NCT02025179 · retained source version 2023-05-10:2ed52df8084f0cb38420b216123c27d538a3209af435f6c4aa5b6e65884e00ec** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02025179) (`ctg-observation-nct02025179-2023-05-10-2ed52df8084f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02025179." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02025179-teriparatide-v1 SHA-256: 35cd8353acc00b0512574622c66aec6afb044210632e7d55d34ff80271d597d7.

---

<a id="clinicaltrials-gov-nct02176382-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT02176382

> PeptideScanner retained ClinicalTrials.gov record NCT02176382 at 2026-07-30T20:06:10.499Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct02176382-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-02-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02176382-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02176382-teriparatide-v1
- Content SHA-256: `edc752870e332c742da7ec9399481246c37a502307f2a47b46a08239fe3e3c54`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02176382 ([`ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4`](#source-ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02176382 at 2026-07-30T20:06:10.499Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4`](#source-ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02176382 at 2026-07-30T20:06:10.499Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4`](#source-ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4`](#source-ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4))

### Sources

<a id="source-ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4"></a>
- **ClinicalTrials.gov record NCT02176382 · retained source version 2021-02-09:fbc79a2e2fb4f31f13993de0a034521b7868803283ac9a00c503fb8a99148806** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02176382) (`ctg-observation-nct02176382-2021-02-09-fbc79a2e2fb4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02176382." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02176382-teriparatide-v1 SHA-256: edc752870e332c742da7ec9399481246c37a502307f2a47b46a08239fe3e3c54.

---

<a id="clinicaltrials-gov-nct02239523-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT02239523

> PeptideScanner retained ClinicalTrials.gov record NCT02239523 at 2026-07-30T20:53:39.666Z. Its registry update date was 2019-04-05, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct02239523-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-04-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02239523-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02239523-teriparatide-v1
- Content SHA-256: `909bdd65810fb135c37c1a51346ac88574b485bebb5a298f961a11df52265dc7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02239523 ([`ctg-observation-nct02239523-2019-04-05-5719e40e40f2`](#source-ctg-observation-nct02239523-2019-04-05-5719e40e40f2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02239523 at 2026-07-30T20:53:39.666Z. Its registry update date was 2019-04-05, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02239523-2019-04-05-5719e40e40f2`](#source-ctg-observation-nct02239523-2019-04-05-5719e40e40f2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02239523 at 2026-07-30T20:53:39.666Z. Its registry update date was 2019-04-05, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02239523-2019-04-05-5719e40e40f2`](#source-ctg-observation-nct02239523-2019-04-05-5719e40e40f2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02239523-2019-04-05-5719e40e40f2`](#source-ctg-observation-nct02239523-2019-04-05-5719e40e40f2))

### Sources

<a id="source-ctg-observation-nct02239523-2019-04-05-5719e40e40f2"></a>
- **ClinicalTrials.gov record NCT02239523 · retained source version 2019-04-05:5719e40e40f200286d9631f7289b3f71a1e93517d4e96c20a7df5ced28b3763d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02239523) (`ctg-observation-nct02239523-2019-04-05-5719e40e40f2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02239523." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02239523-teriparatide-v1 SHA-256: 909bdd65810fb135c37c1a51346ac88574b485bebb5a298f961a11df52265dc7.

---

<a id="clinicaltrials-gov-nct02416271-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT02416271

> PeptideScanner retained ClinicalTrials.gov record NCT02416271 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct02416271-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-04-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02416271-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02416271-teriparatide-v1
- Content SHA-256: `3b5b0b070863e0d3d8e5b9baba0788cfc2052bfd6f8df6cf9cdebca57edd54a0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02416271 ([`ctg-observation-nct02416271-2015-04-14-2e5287f7cbae`](#source-ctg-observation-nct02416271-2015-04-14-2e5287f7cbae))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02416271 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02416271-2015-04-14-2e5287f7cbae`](#source-ctg-observation-nct02416271-2015-04-14-2e5287f7cbae))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02416271 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02416271-2015-04-14-2e5287f7cbae`](#source-ctg-observation-nct02416271-2015-04-14-2e5287f7cbae))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02416271-2015-04-14-2e5287f7cbae`](#source-ctg-observation-nct02416271-2015-04-14-2e5287f7cbae))

### Sources

<a id="source-ctg-observation-nct02416271-2015-04-14-2e5287f7cbae"></a>
- **ClinicalTrials.gov record NCT02416271 · retained source version 2015-04-14:2e5287f7cbaeeb59262fbc1baba3868b2395a5ccab9106c9aa9e61fd3b77e9b6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02416271) (`ctg-observation-nct02416271-2015-04-14-2e5287f7cbae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02416271." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02416271-teriparatide-v1 SHA-256: 3b5b0b070863e0d3d8e5b9baba0788cfc2052bfd6f8df6cf9cdebca57edd54a0.

---

<a id="clinicaltrials-gov-nct02440581-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT02440581

> PeptideScanner retained ClinicalTrials.gov record NCT02440581 at 2026-07-30T19:17:35.692Z. Its registry update date was 2023-01-05, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct02440581-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-01-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02440581-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02440581-teriparatide-v1
- Content SHA-256: `be7bc66dd5bb21a5f95959a6d8c5d8d5e0c0b1d9940d3537c1ca74eeb4ebc372`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02440581 ([`ctg-observation-nct02440581-2023-01-05-7368fad7b20e`](#source-ctg-observation-nct02440581-2023-01-05-7368fad7b20e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02440581 at 2026-07-30T19:17:35.692Z. Its registry update date was 2023-01-05, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02440581-2023-01-05-7368fad7b20e`](#source-ctg-observation-nct02440581-2023-01-05-7368fad7b20e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02440581 at 2026-07-30T19:17:35.692Z. Its registry update date was 2023-01-05, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02440581-2023-01-05-7368fad7b20e`](#source-ctg-observation-nct02440581-2023-01-05-7368fad7b20e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02440581-2023-01-05-7368fad7b20e`](#source-ctg-observation-nct02440581-2023-01-05-7368fad7b20e))

### Sources

<a id="source-ctg-observation-nct02440581-2023-01-05-7368fad7b20e"></a>
- **ClinicalTrials.gov record NCT02440581 · retained source version 2023-01-05:7368fad7b20eb7caf91aa283e4e070756dddafc848094674303727541cbbfaca** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02440581) (`ctg-observation-nct02440581-2023-01-05-7368fad7b20e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02440581." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02440581-teriparatide-v1 SHA-256: be7bc66dd5bb21a5f95959a6d8c5d8d5e0c0b1d9940d3537c1ca74eeb4ebc372.

---

<a id="clinicaltrials-gov-nct02472782-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT02472782

> PeptideScanner retained ClinicalTrials.gov record NCT02472782 at 2026-07-30T20:57:18.711Z. Its registry update date was 2019-01-10, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct02472782-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-01-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02472782-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02472782-teriparatide-v1
- Content SHA-256: `3d66cc3c61c95e0b8b7b345a11a3916f34cf8729234902705518fdbaf91eeae2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02472782 ([`ctg-observation-nct02472782-2019-01-10-d383770b4ad2`](#source-ctg-observation-nct02472782-2019-01-10-d383770b4ad2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02472782 at 2026-07-30T20:57:18.711Z. Its registry update date was 2019-01-10, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02472782-2019-01-10-d383770b4ad2`](#source-ctg-observation-nct02472782-2019-01-10-d383770b4ad2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02472782 at 2026-07-30T20:57:18.711Z. Its registry update date was 2019-01-10, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02472782-2019-01-10-d383770b4ad2`](#source-ctg-observation-nct02472782-2019-01-10-d383770b4ad2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02472782-2019-01-10-d383770b4ad2`](#source-ctg-observation-nct02472782-2019-01-10-d383770b4ad2))

### Sources

<a id="source-ctg-observation-nct02472782-2019-01-10-d383770b4ad2"></a>
- **ClinicalTrials.gov record NCT02472782 · retained source version 2019-01-10:d383770b4ad2544649de876610dabc462868f12b955e3f8616adfb9d684b284f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02472782) (`ctg-observation-nct02472782-2019-01-10-d383770b4ad2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02472782." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02472782-teriparatide-v1 SHA-256: 3d66cc3c61c95e0b8b7b345a11a3916f34cf8729234902705518fdbaf91eeae2.

---

<a id="clinicaltrials-gov-nct02478879-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT02478879

> PeptideScanner retained ClinicalTrials.gov record NCT02478879 at 2026-07-30T21:36:16.907Z. Its registry update date was 2016-08-23, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct02478879-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-08-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02478879-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02478879-teriparatide-v1
- Content SHA-256: `b719d2b7514e7b8500dca51ca35563034996d5c9ac743f7625ea37e9577110b6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02478879 ([`ctg-observation-nct02478879-2016-08-23-6283ce764281`](#source-ctg-observation-nct02478879-2016-08-23-6283ce764281))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02478879 at 2026-07-30T21:36:16.907Z. Its registry update date was 2016-08-23, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02478879-2016-08-23-6283ce764281`](#source-ctg-observation-nct02478879-2016-08-23-6283ce764281))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02478879 at 2026-07-30T21:36:16.907Z. Its registry update date was 2016-08-23, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02478879-2016-08-23-6283ce764281`](#source-ctg-observation-nct02478879-2016-08-23-6283ce764281))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02478879-2016-08-23-6283ce764281`](#source-ctg-observation-nct02478879-2016-08-23-6283ce764281))

### Sources

<a id="source-ctg-observation-nct02478879-2016-08-23-6283ce764281"></a>
- **ClinicalTrials.gov record NCT02478879 · retained source version 2016-08-23:6283ce764281284e9349c4379a9e53d463916c520bf681d5c33e85520ec4c69b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02478879) (`ctg-observation-nct02478879-2016-08-23-6283ce764281`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02478879." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02478879-teriparatide-v1 SHA-256: b719d2b7514e7b8500dca51ca35563034996d5c9ac743f7625ea37e9577110b6.

---

<a id="clinicaltrials-gov-nct02563353-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT02563353

> PeptideScanner retained ClinicalTrials.gov record NCT02563353 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-18, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct02563353-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-09-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02563353-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02563353-teriparatide-v1
- Content SHA-256: `f40003ce8913646b18093b4dc90889acbbb97ac8a959652317749b12be0ff10f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02563353 ([`ctg-observation-nct02563353-2020-09-18-d2447baecdf2`](#source-ctg-observation-nct02563353-2020-09-18-d2447baecdf2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02563353 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-18, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02563353-2020-09-18-d2447baecdf2`](#source-ctg-observation-nct02563353-2020-09-18-d2447baecdf2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02563353 at 2026-07-30T20:22:36.942Z. Its registry update date was 2020-09-18, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct02563353-2020-09-18-d2447baecdf2`](#source-ctg-observation-nct02563353-2020-09-18-d2447baecdf2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02563353-2020-09-18-d2447baecdf2`](#source-ctg-observation-nct02563353-2020-09-18-d2447baecdf2))

### Sources

<a id="source-ctg-observation-nct02563353-2020-09-18-d2447baecdf2"></a>
- **ClinicalTrials.gov record NCT02563353 · retained source version 2020-09-18:d2447baecdf25f2c1c72df4c256e7010ea6326ab961dfee3415da7cc41bc23bd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02563353) (`ctg-observation-nct02563353-2020-09-18-d2447baecdf2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02563353." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct02563353-teriparatide-v1 SHA-256: f40003ce8913646b18093b4dc90889acbbb97ac8a959652317749b12be0ff10f.

---

<a id="clinicaltrials-gov-nct03072147-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT03072147

> PeptideScanner retained ClinicalTrials.gov record NCT03072147 at 2026-07-30T19:13:03.748Z. Its registry update date was 2023-05-12, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct03072147-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-05-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03072147-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct03072147-teriparatide-v1
- Content SHA-256: `b09449f83148dda9cd20e9eca7b287947e47c0fa81b9ebabcc2a829dd63d588f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03072147 ([`ctg-observation-nct03072147-2023-05-12-c5f4934ff99a`](#source-ctg-observation-nct03072147-2023-05-12-c5f4934ff99a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03072147 at 2026-07-30T19:13:03.748Z. Its registry update date was 2023-05-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct03072147-2023-05-12-c5f4934ff99a`](#source-ctg-observation-nct03072147-2023-05-12-c5f4934ff99a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03072147 at 2026-07-30T19:13:03.748Z. Its registry update date was 2023-05-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct03072147-2023-05-12-c5f4934ff99a`](#source-ctg-observation-nct03072147-2023-05-12-c5f4934ff99a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03072147-2023-05-12-c5f4934ff99a`](#source-ctg-observation-nct03072147-2023-05-12-c5f4934ff99a))

### Sources

<a id="source-ctg-observation-nct03072147-2023-05-12-c5f4934ff99a"></a>
- **ClinicalTrials.gov record NCT03072147 · retained source version 2023-05-12:c5f4934ff99aa44ba8e86eb4064f91c9195f57e68d1aa914a1d9d97905fab3b0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03072147) (`ctg-observation-nct03072147-2023-05-12-c5f4934ff99a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03072147." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct03072147-teriparatide-v1 SHA-256: b09449f83148dda9cd20e9eca7b287947e47c0fa81b9ebabcc2a829dd63d588f.

---

<a id="clinicaltrials-gov-nct03133195-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT03133195

> PeptideScanner retained ClinicalTrials.gov record NCT03133195 at 2026-07-30T18:32:24.991Z. Its registry update date was 2025-01-15, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct03133195-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-01-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03133195-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct03133195-teriparatide-v1
- Content SHA-256: `9637fed429cf3ddcc6cf61a25167addee6c56e2b8f3f4ec9c430576082885c1c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03133195 ([`ctg-observation-nct03133195-2025-01-15-5f44f6482530`](#source-ctg-observation-nct03133195-2025-01-15-5f44f6482530))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03133195 at 2026-07-30T18:32:24.991Z. Its registry update date was 2025-01-15, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct03133195-2025-01-15-5f44f6482530`](#source-ctg-observation-nct03133195-2025-01-15-5f44f6482530))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03133195 at 2026-07-30T18:32:24.991Z. Its registry update date was 2025-01-15, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct03133195-2025-01-15-5f44f6482530`](#source-ctg-observation-nct03133195-2025-01-15-5f44f6482530))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03133195-2025-01-15-5f44f6482530`](#source-ctg-observation-nct03133195-2025-01-15-5f44f6482530))

### Sources

<a id="source-ctg-observation-nct03133195-2025-01-15-5f44f6482530"></a>
- **ClinicalTrials.gov record NCT03133195 · retained source version 2025-01-15:5f44f6482530ecac17382f54e5bdd8bdca1c57c910d93123cbc754b29cde6253** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03133195) (`ctg-observation-nct03133195-2025-01-15-5f44f6482530`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03133195." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct03133195-teriparatide-v1 SHA-256: 9637fed429cf3ddcc6cf61a25167addee6c56e2b8f3f4ec9c430576082885c1c.

---

<a id="clinicaltrials-gov-nct03472846-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT03472846

> PeptideScanner retained ClinicalTrials.gov record NCT03472846 at 2026-07-30T19:17:35.707Z. Its registry update date was 2023-01-26, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct03472846-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-01-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03472846-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct03472846-teriparatide-v1
- Content SHA-256: `ef70ef063e49c006308aebdb3d80d5be651230b3eff96ea89f4ef339adbc5df8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03472846 ([`ctg-observation-nct03472846-2023-01-26-8117d14c33d9`](#source-ctg-observation-nct03472846-2023-01-26-8117d14c33d9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03472846 at 2026-07-30T19:17:35.707Z. Its registry update date was 2023-01-26, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct03472846-2023-01-26-8117d14c33d9`](#source-ctg-observation-nct03472846-2023-01-26-8117d14c33d9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03472846 at 2026-07-30T19:17:35.707Z. Its registry update date was 2023-01-26, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct03472846-2023-01-26-8117d14c33d9`](#source-ctg-observation-nct03472846-2023-01-26-8117d14c33d9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03472846-2023-01-26-8117d14c33d9`](#source-ctg-observation-nct03472846-2023-01-26-8117d14c33d9))

### Sources

<a id="source-ctg-observation-nct03472846-2023-01-26-8117d14c33d9"></a>
- **ClinicalTrials.gov record NCT03472846 · retained source version 2023-01-26:8117d14c33d920129d1cfb9e91be228bd30e994c8910e2c45d5f633508a8227b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03472846) (`ctg-observation-nct03472846-2023-01-26-8117d14c33d9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03472846." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct03472846-teriparatide-v1 SHA-256: ef70ef063e49c006308aebdb3d80d5be651230b3eff96ea89f4ef339adbc5df8.

---

<a id="clinicaltrials-gov-nct03770338-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT03770338

> PeptideScanner retained ClinicalTrials.gov record NCT03770338 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct03770338-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03770338-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct03770338-teriparatide-v1
- Content SHA-256: `a22ed25d264337e90dc1ffb6d8d07ba5340df6923c9e552acdeb10df9349db7c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03770338 ([`ctg-observation-nct03770338-2026-05-14-9e3e9c86e03a`](#source-ctg-observation-nct03770338-2026-05-14-9e3e9c86e03a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03770338 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct03770338-2026-05-14-9e3e9c86e03a`](#source-ctg-observation-nct03770338-2026-05-14-9e3e9c86e03a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03770338 at 2026-07-30T16:19:36.903Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct03770338-2026-05-14-9e3e9c86e03a`](#source-ctg-observation-nct03770338-2026-05-14-9e3e9c86e03a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03770338-2026-05-14-9e3e9c86e03a`](#source-ctg-observation-nct03770338-2026-05-14-9e3e9c86e03a))

### Sources

<a id="source-ctg-observation-nct03770338-2026-05-14-9e3e9c86e03a"></a>
- **ClinicalTrials.gov record NCT03770338 · retained source version 2026-05-14:9e3e9c86e03a720b0dc21c99a674219a136d6aad17c901a70610f2d972db3a8c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03770338) (`ctg-observation-nct03770338-2026-05-14-9e3e9c86e03a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03770338." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct03770338-teriparatide-v1 SHA-256: a22ed25d264337e90dc1ffb6d8d07ba5340df6923c9e552acdeb10df9349db7c.

---

<a id="clinicaltrials-gov-nct04026256-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT04026256

> PeptideScanner retained ClinicalTrials.gov record NCT04026256 at 2026-07-30T19:09:38.366Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct04026256-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-08-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04026256-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct04026256-teriparatide-v1
- Content SHA-256: `7fd334fcd4a20d4ca472f40d185c36a028d92e41fa912c3e3a3ae162f667a228`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04026256 ([`ctg-observation-nct04026256-2023-08-02-6fecc359c524`](#source-ctg-observation-nct04026256-2023-08-02-6fecc359c524))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04026256 at 2026-07-30T19:09:38.366Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct04026256-2023-08-02-6fecc359c524`](#source-ctg-observation-nct04026256-2023-08-02-6fecc359c524))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04026256 at 2026-07-30T19:09:38.366Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct04026256-2023-08-02-6fecc359c524`](#source-ctg-observation-nct04026256-2023-08-02-6fecc359c524))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04026256-2023-08-02-6fecc359c524`](#source-ctg-observation-nct04026256-2023-08-02-6fecc359c524))

### Sources

<a id="source-ctg-observation-nct04026256-2023-08-02-6fecc359c524"></a>
- **ClinicalTrials.gov record NCT04026256 · retained source version 2023-08-02:6fecc359c524f9c60cf1ecd8ea992ec474da0a9623705493d7829b00a7024da4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04026256) (`ctg-observation-nct04026256-2023-08-02-6fecc359c524`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04026256." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct04026256-teriparatide-v1 SHA-256: 7fd334fcd4a20d4ca472f40d185c36a028d92e41fa912c3e3a3ae162f667a228.

---

<a id="clinicaltrials-gov-nct04206618-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT04206618

> PeptideScanner retained ClinicalTrials.gov record NCT04206618 at 2026-07-30T20:07:13.493Z. Its registry update date was 2021-01-12, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct04206618-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-01-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04206618-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct04206618-teriparatide-v1
- Content SHA-256: `408ac691b1ccd2e70ef492a2d2ecb3b23d233014846b66b65d0252e447660c46`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04206618 ([`ctg-observation-nct04206618-2021-01-12-e95cfacc5a0b`](#source-ctg-observation-nct04206618-2021-01-12-e95cfacc5a0b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04206618 at 2026-07-30T20:07:13.493Z. Its registry update date was 2021-01-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct04206618-2021-01-12-e95cfacc5a0b`](#source-ctg-observation-nct04206618-2021-01-12-e95cfacc5a0b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04206618 at 2026-07-30T20:07:13.493Z. Its registry update date was 2021-01-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct04206618-2021-01-12-e95cfacc5a0b`](#source-ctg-observation-nct04206618-2021-01-12-e95cfacc5a0b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04206618-2021-01-12-e95cfacc5a0b`](#source-ctg-observation-nct04206618-2021-01-12-e95cfacc5a0b))

### Sources

<a id="source-ctg-observation-nct04206618-2021-01-12-e95cfacc5a0b"></a>
- **ClinicalTrials.gov record NCT04206618 · retained source version 2021-01-12:e95cfacc5a0b18d105e876a6285413d3943c3c6ac75dd1576009106461b514f1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04206618) (`ctg-observation-nct04206618-2021-01-12-e95cfacc5a0b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04206618." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct04206618-teriparatide-v1 SHA-256: 408ac691b1ccd2e70ef492a2d2ecb3b23d233014846b66b65d0252e447660c46.

---

<a id="clinicaltrials-gov-nct04522622-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT04522622

> PeptideScanner retained ClinicalTrials.gov record NCT04522622 at 2026-07-30T18:46:20.407Z. Its registry update date was 2024-04-23, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct04522622-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-04-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04522622-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct04522622-teriparatide-v1
- Content SHA-256: `ffc9f97911c9838c4d32eef822dd51cddce8fe3fbb8b063d89aefd150e244cda`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04522622 ([`ctg-observation-nct04522622-2024-04-23-588e5beff373`](#source-ctg-observation-nct04522622-2024-04-23-588e5beff373))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04522622 at 2026-07-30T18:46:20.407Z. Its registry update date was 2024-04-23, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct04522622-2024-04-23-588e5beff373`](#source-ctg-observation-nct04522622-2024-04-23-588e5beff373))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04522622 at 2026-07-30T18:46:20.407Z. Its registry update date was 2024-04-23, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct04522622-2024-04-23-588e5beff373`](#source-ctg-observation-nct04522622-2024-04-23-588e5beff373))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04522622-2024-04-23-588e5beff373`](#source-ctg-observation-nct04522622-2024-04-23-588e5beff373))

### Sources

<a id="source-ctg-observation-nct04522622-2024-04-23-588e5beff373"></a>
- **ClinicalTrials.gov record NCT04522622 · retained source version 2024-04-23:588e5beff373fbd7f59ec87dbf7dcd815798c4d10683fa591d82ec7dde79583f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04522622) (`ctg-observation-nct04522622-2024-04-23-588e5beff373`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04522622." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct04522622-teriparatide-v1 SHA-256: ffc9f97911c9838c4d32eef822dd51cddce8fe3fbb8b063d89aefd150e244cda.

---

<a id="clinicaltrials-gov-nct04589819-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT04589819

> PeptideScanner retained ClinicalTrials.gov record NCT04589819 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-13, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct04589819-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-02-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04589819-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct04589819-teriparatide-v1
- Content SHA-256: `e12fa800621c23ab582a1248a2ae0da3b5870a25b8a6bb866ce04d911ee09ad5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04589819 ([`ctg-observation-nct04589819-2023-02-13-3caae8baa175`](#source-ctg-observation-nct04589819-2023-02-13-3caae8baa175))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04589819 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-13, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct04589819-2023-02-13-3caae8baa175`](#source-ctg-observation-nct04589819-2023-02-13-3caae8baa175))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04589819 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-13, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct04589819-2023-02-13-3caae8baa175`](#source-ctg-observation-nct04589819-2023-02-13-3caae8baa175))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04589819-2023-02-13-3caae8baa175`](#source-ctg-observation-nct04589819-2023-02-13-3caae8baa175))

### Sources

<a id="source-ctg-observation-nct04589819-2023-02-13-3caae8baa175"></a>
- **ClinicalTrials.gov record NCT04589819 · retained source version 2023-02-13:3caae8baa17551c2312527a2c2e939f36af0399bcdd6e43e0412bc2144d6922b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04589819) (`ctg-observation-nct04589819-2023-02-13-3caae8baa175`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04589819." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct04589819-teriparatide-v1 SHA-256: e12fa800621c23ab582a1248a2ae0da3b5870a25b8a6bb866ce04d911ee09ad5.

---

<a id="clinicaltrials-gov-nct04750460-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT04750460

> PeptideScanner retained ClinicalTrials.gov record NCT04750460 at 2026-07-30T19:32:59.860Z. Its registry update date was 2022-11-10, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct04750460-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-11-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04750460-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct04750460-teriparatide-v1
- Content SHA-256: `5cc7bda09c060e6ffe8bbbf6d49a615599ebc1081f99c5ffd124959e67b89ccd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04750460 ([`ctg-observation-nct04750460-2022-11-10-3f17903a9155`](#source-ctg-observation-nct04750460-2022-11-10-3f17903a9155))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04750460 at 2026-07-30T19:32:59.860Z. Its registry update date was 2022-11-10, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct04750460-2022-11-10-3f17903a9155`](#source-ctg-observation-nct04750460-2022-11-10-3f17903a9155))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04750460 at 2026-07-30T19:32:59.860Z. Its registry update date was 2022-11-10, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct04750460-2022-11-10-3f17903a9155`](#source-ctg-observation-nct04750460-2022-11-10-3f17903a9155))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04750460-2022-11-10-3f17903a9155`](#source-ctg-observation-nct04750460-2022-11-10-3f17903a9155))

### Sources

<a id="source-ctg-observation-nct04750460-2022-11-10-3f17903a9155"></a>
- **ClinicalTrials.gov record NCT04750460 · retained source version 2022-11-10:3f17903a91558dd95dee0b4102d4e7082f133d513930c502d71e76c11c9832dc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04750460) (`ctg-observation-nct04750460-2022-11-10-3f17903a9155`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04750460." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct04750460-teriparatide-v1 SHA-256: 5cc7bda09c060e6ffe8bbbf6d49a615599ebc1081f99c5ffd124959e67b89ccd.

---

<a id="clinicaltrials-gov-nct04879420-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT04879420

> PeptideScanner retained ClinicalTrials.gov record NCT04879420 at 2026-07-30T19:10:42.715Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct04879420-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04879420-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct04879420-teriparatide-v1
- Content SHA-256: `5aadaf1d1ea5bfda373172794adb7051ff1cba1771816773c9cc1fa8ff37367f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04879420 ([`ctg-observation-nct04879420-2023-07-27-e9caa19827c7`](#source-ctg-observation-nct04879420-2023-07-27-e9caa19827c7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04879420 at 2026-07-30T19:10:42.715Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct04879420-2023-07-27-e9caa19827c7`](#source-ctg-observation-nct04879420-2023-07-27-e9caa19827c7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04879420 at 2026-07-30T19:10:42.715Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct04879420-2023-07-27-e9caa19827c7`](#source-ctg-observation-nct04879420-2023-07-27-e9caa19827c7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04879420-2023-07-27-e9caa19827c7`](#source-ctg-observation-nct04879420-2023-07-27-e9caa19827c7))

### Sources

<a id="source-ctg-observation-nct04879420-2023-07-27-e9caa19827c7"></a>
- **ClinicalTrials.gov record NCT04879420 · retained source version 2023-07-27:e9caa19827c7cf806fba08ac238c1422e87cddd48b6b37e9dfc79becf0df455c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04879420) (`ctg-observation-nct04879420-2023-07-27-e9caa19827c7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04879420." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct04879420-teriparatide-v1 SHA-256: 5aadaf1d1ea5bfda373172794adb7051ff1cba1771816773c9cc1fa8ff37367f.

---

<a id="clinicaltrials-gov-nct05151484-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT05151484

> PeptideScanner retained ClinicalTrials.gov record NCT05151484 at 2026-07-30T16:19:36.911Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct05151484-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05151484-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct05151484-teriparatide-v1
- Content SHA-256: `c95ab2fa00769ece1d33242455fc945bb9a647537f7bea8d4bacb7e7e2f8a9b8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05151484 ([`ctg-observation-nct05151484-2026-05-14-aef6e24e3c94`](#source-ctg-observation-nct05151484-2026-05-14-aef6e24e3c94))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05151484 at 2026-07-30T16:19:36.911Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct05151484-2026-05-14-aef6e24e3c94`](#source-ctg-observation-nct05151484-2026-05-14-aef6e24e3c94))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05151484 at 2026-07-30T16:19:36.911Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct05151484-2026-05-14-aef6e24e3c94`](#source-ctg-observation-nct05151484-2026-05-14-aef6e24e3c94))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05151484-2026-05-14-aef6e24e3c94`](#source-ctg-observation-nct05151484-2026-05-14-aef6e24e3c94))

### Sources

<a id="source-ctg-observation-nct05151484-2026-05-14-aef6e24e3c94"></a>
- **ClinicalTrials.gov record NCT05151484 · retained source version 2026-05-14:aef6e24e3c94174aa08e82b7472b42ea3098cb6e21eb6b70029c75dc4e2cb0d3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05151484) (`ctg-observation-nct05151484-2026-05-14-aef6e24e3c94`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05151484." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct05151484-teriparatide-v1 SHA-256: c95ab2fa00769ece1d33242455fc945bb9a647537f7bea8d4bacb7e7e2f8a9b8.

---

<a id="clinicaltrials-gov-nct05866029-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT05866029

> PeptideScanner retained ClinicalTrials.gov record NCT05866029 at 2026-07-30T16:25:18.004Z. Its registry update date was 2026-01-12, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct05866029-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05866029-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct05866029-teriparatide-v1
- Content SHA-256: `fa929dd67f2472afde870a9db2e99030343a27502286d8fbad10b272c51df496`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05866029 ([`ctg-observation-nct05866029-2026-01-12-e3a719a017f1`](#source-ctg-observation-nct05866029-2026-01-12-e3a719a017f1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05866029 at 2026-07-30T16:25:18.004Z. Its registry update date was 2026-01-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct05866029-2026-01-12-e3a719a017f1`](#source-ctg-observation-nct05866029-2026-01-12-e3a719a017f1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05866029 at 2026-07-30T16:25:18.004Z. Its registry update date was 2026-01-12, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct05866029-2026-01-12-e3a719a017f1`](#source-ctg-observation-nct05866029-2026-01-12-e3a719a017f1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05866029-2026-01-12-e3a719a017f1`](#source-ctg-observation-nct05866029-2026-01-12-e3a719a017f1))

### Sources

<a id="source-ctg-observation-nct05866029-2026-01-12-e3a719a017f1"></a>
- **ClinicalTrials.gov record NCT05866029 · retained source version 2026-01-12:e3a719a017f1d238950466a3cd8adb218fdc4f45b18d129e34569e51fa7e30d2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05866029) (`ctg-observation-nct05866029-2026-01-12-e3a719a017f1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05866029." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct05866029-teriparatide-v1 SHA-256: fa929dd67f2472afde870a9db2e99030343a27502286d8fbad10b272c51df496.

---

<a id="clinicaltrials-gov-nct06164795-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT06164795

> PeptideScanner retained ClinicalTrials.gov record NCT06164795 at 2026-08-10T18:10:03.919Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct06164795-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-22
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06164795-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct06164795-teriparatide-v1
- Content SHA-256: `eddb1349b4adfe36e8b3363cebc8bb5f7d7cc4b77099c11495ddeee49186219c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06164795 ([`ctg-observation-nct06164795-2026-07-22-35912a2b5b53`](#source-ctg-observation-nct06164795-2026-07-22-35912a2b5b53))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06164795 at 2026-08-10T18:10:03.919Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct06164795-2026-07-22-35912a2b5b53`](#source-ctg-observation-nct06164795-2026-07-22-35912a2b5b53))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06164795 at 2026-08-10T18:10:03.919Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct06164795-2026-07-22-35912a2b5b53`](#source-ctg-observation-nct06164795-2026-07-22-35912a2b5b53))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06164795-2026-07-22-35912a2b5b53`](#source-ctg-observation-nct06164795-2026-07-22-35912a2b5b53))

### Sources

<a id="source-ctg-observation-nct06164795-2026-07-22-35912a2b5b53"></a>
- **ClinicalTrials.gov record NCT06164795 · retained source version 2026-07-22:35912a2b5b53a73b01fb15d2960b955469aad49efa34e9436206c0d857ef775f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06164795) (`ctg-observation-nct06164795-2026-07-22-35912a2b5b53`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06164795." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct06164795-teriparatide-v1 SHA-256: eddb1349b4adfe36e8b3363cebc8bb5f7d7cc4b77099c11495ddeee49186219c.

---

<a id="clinicaltrials-gov-nct06264609-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT06264609

> PeptideScanner retained ClinicalTrials.gov record NCT06264609 at 2026-07-30T16:20:49.326Z. Its registry update date was 2026-04-01, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct06264609-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06264609-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct06264609-teriparatide-v1
- Content SHA-256: `5b06cd49713fcb298bd1cad0094574c085a15de70f314a189a3c7f0632d90228`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06264609 ([`ctg-observation-nct06264609-2026-04-01-9c49ecd11946`](#source-ctg-observation-nct06264609-2026-04-01-9c49ecd11946))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06264609 at 2026-07-30T16:20:49.326Z. Its registry update date was 2026-04-01, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct06264609-2026-04-01-9c49ecd11946`](#source-ctg-observation-nct06264609-2026-04-01-9c49ecd11946))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06264609 at 2026-07-30T16:20:49.326Z. Its registry update date was 2026-04-01, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct06264609-2026-04-01-9c49ecd11946`](#source-ctg-observation-nct06264609-2026-04-01-9c49ecd11946))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06264609-2026-04-01-9c49ecd11946`](#source-ctg-observation-nct06264609-2026-04-01-9c49ecd11946))

### Sources

<a id="source-ctg-observation-nct06264609-2026-04-01-9c49ecd11946"></a>
- **ClinicalTrials.gov record NCT06264609 · retained source version 2026-04-01:9c49ecd119464b11d6166167784dcac1fd3d41df87fdfc71e8c2028664c260d7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06264609) (`ctg-observation-nct06264609-2026-04-01-9c49ecd11946`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06264609." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct06264609-teriparatide-v1 SHA-256: 5b06cd49713fcb298bd1cad0094574c085a15de70f314a189a3c7f0632d90228.

---

<a id="clinicaltrials-gov-nct06303284-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT06303284

> PeptideScanner retained ClinicalTrials.gov record NCT06303284 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct06303284-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-03-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06303284-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct06303284-teriparatide-v1
- Content SHA-256: `ccc288f735ed2effa3109c00711ed585726254d0834ace3c5078eac6744c68a4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06303284 ([`ctg-observation-nct06303284-2024-03-18-086924e370d5`](#source-ctg-observation-nct06303284-2024-03-18-086924e370d5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06303284 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct06303284-2024-03-18-086924e370d5`](#source-ctg-observation-nct06303284-2024-03-18-086924e370d5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06303284 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct06303284-2024-03-18-086924e370d5`](#source-ctg-observation-nct06303284-2024-03-18-086924e370d5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06303284-2024-03-18-086924e370d5`](#source-ctg-observation-nct06303284-2024-03-18-086924e370d5))

### Sources

<a id="source-ctg-observation-nct06303284-2024-03-18-086924e370d5"></a>
- **ClinicalTrials.gov record NCT06303284 · retained source version 2024-03-18:086924e370d52bd2799f1b0e3b3d90d9f840d4e3447f1881113f9c4cf359bffe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06303284) (`ctg-observation-nct06303284-2024-03-18-086924e370d5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06303284." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct06303284-teriparatide-v1 SHA-256: ccc288f735ed2effa3109c00711ed585726254d0834ace3c5078eac6744c68a4.

---

<a id="clinicaltrials-gov-nct06558188-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT06558188

> PeptideScanner retained ClinicalTrials.gov record NCT06558188 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-17, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct06558188-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06558188-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct06558188-teriparatide-v1
- Content SHA-256: `9c462e2f8b169d77aa17ee23ca5df1c3cc1ee90c25b8dcd0062fd6a3ea931f89`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06558188 ([`ctg-observation-nct06558188-2026-04-17-709970993654`](#source-ctg-observation-nct06558188-2026-04-17-709970993654))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06558188 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-17, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct06558188-2026-04-17-709970993654`](#source-ctg-observation-nct06558188-2026-04-17-709970993654))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06558188 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-17, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct06558188-2026-04-17-709970993654`](#source-ctg-observation-nct06558188-2026-04-17-709970993654))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06558188-2026-04-17-709970993654`](#source-ctg-observation-nct06558188-2026-04-17-709970993654))

### Sources

<a id="source-ctg-observation-nct06558188-2026-04-17-709970993654"></a>
- **ClinicalTrials.gov record NCT06558188 · retained source version 2026-04-17:709970993654f66e1b95547004ada11f4bacb70e89efff60d696e0d69fd717ee** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06558188) (`ctg-observation-nct06558188-2026-04-17-709970993654`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06558188." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct06558188-teriparatide-v1 SHA-256: 9c462e2f8b169d77aa17ee23ca5df1c3cc1ee90c25b8dcd0062fd6a3ea931f89.

---

<a id="clinicaltrials-gov-nct07242612-teriparatide-v1"></a>

## ClinicalTrials.gov record NCT07242612

> PeptideScanner retained ClinicalTrials.gov record NCT07242612 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-21, and PeptideScanner's reviewed identity mapping was teriparatide.

- Evidence object: `story:clinicaltrials-gov-nct07242612-teriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07242612-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct07242612-teriparatide-v1
- Content SHA-256: `e032fafa2269277debd9397660805b4004f2349846f7edfa14c638f113cf5237`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07242612 ([`ctg-observation-nct07242612-2025-11-21-dbfc8ad582fd`](#source-ctg-observation-nct07242612-2025-11-21-dbfc8ad582fd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07242612 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-21, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct07242612-2025-11-21-dbfc8ad582fd`](#source-ctg-observation-nct07242612-2025-11-21-dbfc8ad582fd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07242612 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-21, and PeptideScanner's reviewed identity mapping was teriparatide. ([`ctg-observation-nct07242612-2025-11-21-dbfc8ad582fd`](#source-ctg-observation-nct07242612-2025-11-21-dbfc8ad582fd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07242612-2025-11-21-dbfc8ad582fd`](#source-ctg-observation-nct07242612-2025-11-21-dbfc8ad582fd))

### Sources

<a id="source-ctg-observation-nct07242612-2025-11-21-dbfc8ad582fd"></a>
- **ClinicalTrials.gov record NCT07242612 · retained source version 2025-11-21:dbfc8ad582fd0b2fb04b6c393fee697e2ae21e0ba931ca0692643883055d154e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07242612) (`ctg-observation-nct07242612-2025-11-21-dbfc8ad582fd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07242612." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#clinicaltrials-gov-nct07242612-teriparatide-v1 SHA-256: e032fafa2269277debd9397660805b4004f2349846f7edfa14c638f113cf5237.

---

<a id="dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10-v1"></a>

## Teriparatide DailyMed SPL version 10

> DailyMed lists Structured Product Labeling version 10 for the reviewed Teriparatide label family with a published date of 2026-09-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10:v1`
- Evidence domain: Regulatory
- Date in source: 2026-09-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10-v1
- Content SHA-256: `d5256eb82984806d07242214d91ae5618959f19c488f748439f27c904a301748`

### Claims and source pins

#### Headline

Teriparatide DailyMed SPL version 10 ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10-history))

#### Summary

DailyMed lists Structured Product Labeling version 10 for the reviewed Teriparatide label family with a published date of 2026-09-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 10 for the reviewed Teriparatide label family with a published date of 2026-09-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10-history))

### Sources

<a id="source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10-history"></a>
- **DailyMed SPL SET ID d77d40db-7f38-88eb-fd5d-4282f0642028 · SPL version 10 · published 2026-09-21 · retained ZIP SHA-256 fda54019cc7c95c30f210949dcf566bcc2461d83791c324c765f6f54ed93b422** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=d77d40db-7f38-88eb-fd5d-4282f0642028&version=10) (`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide DailyMed SPL version 10." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10-v1 SHA-256: d5256eb82984806d07242214d91ae5618959f19c488f748439f27c904a301748.

---

<a id="dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2-v1"></a>

## Teriparatide DailyMed SPL version 2

> DailyMed lists Structured Product Labeling version 2 for the reviewed Teriparatide label family with a published date of 2023-11-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2:v1`
- Evidence domain: Regulatory
- Date in source: 2023-11-20
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2-v1
- Content SHA-256: `43ba55301960a5263f52951da70b76001ef2027ba046a24c2845f8477868dfc7`

### Claims and source pins

#### Headline

Teriparatide DailyMed SPL version 2 ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2-history))

#### Summary

DailyMed lists Structured Product Labeling version 2 for the reviewed Teriparatide label family with a published date of 2023-11-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 2 for the reviewed Teriparatide label family with a published date of 2023-11-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2-history))

### Sources

<a id="source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2-history"></a>
- **DailyMed SPL SET ID d77d40db-7f38-88eb-fd5d-4282f0642028 · SPL version 2 · published 2023-11-20 · retained ZIP SHA-256 18e8c096fa685b2256151e09ddc6ee9873b7678746f9f541c6007316663cdc4b** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=d77d40db-7f38-88eb-fd5d-4282f0642028&version=2) (`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide DailyMed SPL version 2." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v2-v1 SHA-256: 43ba55301960a5263f52951da70b76001ef2027ba046a24c2845f8477868dfc7.

---

<a id="dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3-v1"></a>

## Teriparatide DailyMed SPL version 3

> DailyMed lists Structured Product Labeling version 3 for the reviewed Teriparatide label family with a published date of 2023-12-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3:v1`
- Evidence domain: Regulatory
- Date in source: 2023-12-13
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3-v1
- Content SHA-256: `8d164cc2d4e9c975c2b0c0f63cd637f65401f7ae21f719d6649b1aae2f982f57`

### Claims and source pins

#### Headline

Teriparatide DailyMed SPL version 3 ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3-history))

#### Summary

DailyMed lists Structured Product Labeling version 3 for the reviewed Teriparatide label family with a published date of 2023-12-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 3 for the reviewed Teriparatide label family with a published date of 2023-12-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3-history))

### Sources

<a id="source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3-history"></a>
- **DailyMed SPL SET ID d77d40db-7f38-88eb-fd5d-4282f0642028 · SPL version 3 · published 2023-12-13 · retained ZIP SHA-256 17c7928aac01274d2357a04e8b4dabdc3333fc9e8d074aebb25d167822eab5a7** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=d77d40db-7f38-88eb-fd5d-4282f0642028&version=3) (`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide DailyMed SPL version 3." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v3-v1 SHA-256: 8d164cc2d4e9c975c2b0c0f63cd637f65401f7ae21f719d6649b1aae2f982f57.

---

<a id="dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4-v1"></a>

## Teriparatide DailyMed SPL version 4

> DailyMed lists Structured Product Labeling version 4 for the reviewed Teriparatide label family with a published date of 2024-01-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4:v1`
- Evidence domain: Regulatory
- Date in source: 2024-01-31
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4-v1
- Content SHA-256: `5b61a6ae21451d437e1f7c892221cc9edc57624756190a37782164f40cd5164d`

### Claims and source pins

#### Headline

Teriparatide DailyMed SPL version 4 ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4-history))

#### Summary

DailyMed lists Structured Product Labeling version 4 for the reviewed Teriparatide label family with a published date of 2024-01-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 4 for the reviewed Teriparatide label family with a published date of 2024-01-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4-history))

### Sources

<a id="source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4-history"></a>
- **DailyMed SPL SET ID d77d40db-7f38-88eb-fd5d-4282f0642028 · SPL version 4 · published 2024-01-31 · retained ZIP SHA-256 ddecca9e9e5156d8f6a066e414d4c254842cf92e9288cda1c127fae1cd124973** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=d77d40db-7f38-88eb-fd5d-4282f0642028&version=4) (`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide DailyMed SPL version 4." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v4-v1 SHA-256: 5b61a6ae21451d437e1f7c892221cc9edc57624756190a37782164f40cd5164d.

---

<a id="dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5-v1"></a>

## Teriparatide DailyMed SPL version 5

> DailyMed lists Structured Product Labeling version 5 for the reviewed Teriparatide label family with a published date of 2024-07-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5:v1`
- Evidence domain: Regulatory
- Date in source: 2024-07-04
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5-v1
- Content SHA-256: `c79b6822ab7f11d7301c9a59c813a7cbb958c5f4d8293dc7970d063de78f9578`

### Claims and source pins

#### Headline

Teriparatide DailyMed SPL version 5 ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5-history))

#### Summary

DailyMed lists Structured Product Labeling version 5 for the reviewed Teriparatide label family with a published date of 2024-07-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 5 for the reviewed Teriparatide label family with a published date of 2024-07-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5-history))

### Sources

<a id="source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5-history"></a>
- **DailyMed SPL SET ID d77d40db-7f38-88eb-fd5d-4282f0642028 · SPL version 5 · published 2024-07-04 · retained ZIP SHA-256 da12c35fbadc0ba9d1518e414faf06a2c5e9ed4f862f5d53661b91fa8ca23f17** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=d77d40db-7f38-88eb-fd5d-4282f0642028&version=5) (`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide DailyMed SPL version 5." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v5-v1 SHA-256: c79b6822ab7f11d7301c9a59c813a7cbb958c5f4d8293dc7970d063de78f9578.

---

<a id="dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6-v1"></a>

## Teriparatide DailyMed SPL version 6

> DailyMed lists Structured Product Labeling version 6 for the reviewed Teriparatide label family with a published date of 2024-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6:v1`
- Evidence domain: Regulatory
- Date in source: 2024-12-30
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6-v1
- Content SHA-256: `14347ecaf4fe61d74aa96498334de9dc28dc7427b6d5a9f74173ad5bed021520`

### Claims and source pins

#### Headline

Teriparatide DailyMed SPL version 6 ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6-history))

#### Summary

DailyMed lists Structured Product Labeling version 6 for the reviewed Teriparatide label family with a published date of 2024-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 6 for the reviewed Teriparatide label family with a published date of 2024-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6-history))

### Sources

<a id="source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6-history"></a>
- **DailyMed SPL SET ID d77d40db-7f38-88eb-fd5d-4282f0642028 · SPL version 6 · published 2024-12-30 · retained ZIP SHA-256 d333cbb54ff59bec5274223cce2abf75169076a76f5f016f61d7665e130e9a9b** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=d77d40db-7f38-88eb-fd5d-4282f0642028&version=6) (`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide DailyMed SPL version 6." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v6-v1 SHA-256: 14347ecaf4fe61d74aa96498334de9dc28dc7427b6d5a9f74173ad5bed021520.

---

<a id="dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7-v1"></a>

## Teriparatide DailyMed SPL version 7

> DailyMed lists Structured Product Labeling version 7 for the reviewed Teriparatide label family with a published date of 2025-05-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7:v1`
- Evidence domain: Regulatory
- Date in source: 2025-05-12
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7-v1
- Content SHA-256: `05864b81b816daba07dc712114114e1a5cc8b33e0b7eaa902a4a59fe68c442eb`

### Claims and source pins

#### Headline

Teriparatide DailyMed SPL version 7 ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7-history))

#### Summary

DailyMed lists Structured Product Labeling version 7 for the reviewed Teriparatide label family with a published date of 2025-05-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 7 for the reviewed Teriparatide label family with a published date of 2025-05-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7-history))

### Sources

<a id="source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7-history"></a>
- **DailyMed SPL SET ID d77d40db-7f38-88eb-fd5d-4282f0642028 · SPL version 7 · published 2025-05-12 · retained ZIP SHA-256 83b0e180261faf2cab6720c8e1184c237f05c60e577ce9be61d40cd3c99bc955** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=d77d40db-7f38-88eb-fd5d-4282f0642028&version=7) (`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide DailyMed SPL version 7." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v7-v1 SHA-256: 05864b81b816daba07dc712114114e1a5cc8b33e0b7eaa902a4a59fe68c442eb.

---

<a id="dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8-v1"></a>

## Teriparatide DailyMed SPL version 8

> DailyMed lists Structured Product Labeling version 8 for the reviewed Teriparatide label family with a published date of 2025-07-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8:v1`
- Evidence domain: Regulatory
- Date in source: 2025-07-16
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8-v1
- Content SHA-256: `5a3edef2ac1d20672df0ea27a0119eef6809e4f78927d9ca90899945b2d6ad65`

### Claims and source pins

#### Headline

Teriparatide DailyMed SPL version 8 ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8-history))

#### Summary

DailyMed lists Structured Product Labeling version 8 for the reviewed Teriparatide label family with a published date of 2025-07-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 8 for the reviewed Teriparatide label family with a published date of 2025-07-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8-history))

### Sources

<a id="source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8-history"></a>
- **DailyMed SPL SET ID d77d40db-7f38-88eb-fd5d-4282f0642028 · SPL version 8 · published 2025-07-16 · retained ZIP SHA-256 8cf27ba70e1f3c16309c7e4dbf3348f0d446294a50456498e2c7dc67c8a0a894** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=d77d40db-7f38-88eb-fd5d-4282f0642028&version=8) (`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide DailyMed SPL version 8." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v8-v1 SHA-256: 5a3edef2ac1d20672df0ea27a0119eef6809e4f78927d9ca90899945b2d6ad65.

---

<a id="dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9-v1"></a>

## Teriparatide DailyMed SPL version 9

> DailyMed lists Structured Product Labeling version 9 for the reviewed Teriparatide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9:v1`
- Evidence domain: Regulatory
- Date in source: 2026-06-30
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9-v1
- Content SHA-256: `5a9ce6682013ccfbba298ab9d34b0104183c117455bd5b1b91e483126dae0aea`

### Claims and source pins

#### Headline

Teriparatide DailyMed SPL version 9 ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9-history))

#### Summary

DailyMed lists Structured Product Labeling version 9 for the reviewed Teriparatide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 9 for the reviewed Teriparatide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9-history`](#source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9-history))

### Sources

<a id="source-dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9-history"></a>
- **DailyMed SPL SET ID d77d40db-7f38-88eb-fd5d-4282f0642028 · SPL version 9 · published 2026-06-30 · retained ZIP SHA-256 3d44d13e5c26a6d99016811b324c701e16b0d18d7390d19dd9e3ee5833bb6cb8** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=d77d40db-7f38-88eb-fd5d-4282f0642028&version=9) (`dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide DailyMed SPL version 9." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#dailymed-label-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9-v1 SHA-256: 5a9ce6682013ccfbba298ab9d34b0104183c117455bd5b1b91e483126dae0aea.

---

<a id="fda-drugs-anda208569-v1"></a>

## Drugs@FDA application ANDA208569

> The official Drugs@FDA dataset lists original submission 1 for ANDA 208569 with status AP dated 2023-11-16, and names teriparatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda208569:v1`
- Evidence domain: Regulatory
- Date in source: 2023-11-16
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda208569/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-anda208569-v1
- Content SHA-256: `91a926997d7dd1c3313f87ca71fae56c317df74db6361105664f26c3648f7a6a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA208569 ([`fda-drugs-anda208569-2023-11-16-7415d9bf6641`](#source-fda-drugs-anda208569-2023-11-16-7415d9bf6641))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 208569 with status AP dated 2023-11-16, and names teriparatide among the application record's active ingredients. ([`fda-drugs-anda208569-2023-11-16-7415d9bf6641`](#source-fda-drugs-anda208569-2023-11-16-7415d9bf6641))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 208569 with status AP dated 2023-11-16, and names teriparatide among the application record's active ingredients. ([`fda-drugs-anda208569-2023-11-16-7415d9bf6641`](#source-fda-drugs-anda208569-2023-11-16-7415d9bf6641))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda208569-2023-11-16-7415d9bf6641`](#source-fda-drugs-anda208569-2023-11-16-7415d9bf6641))

### Sources

<a id="source-fda-drugs-anda208569-2023-11-16-7415d9bf6641"></a>
- **Drugs@FDA application ANDA208569 · original submission status AP · 2023-11-16 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA208569%22&limit=1) (`fda-drugs-anda208569-2023-11-16-7415d9bf6641`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA208569." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-anda208569-v1 SHA-256: 91a926997d7dd1c3313f87ca71fae56c317df74db6361105664f26c3648f7a6a.

---

<a id="fda-drugs-anda211097-v1"></a>

## Drugs@FDA application ANDA211097

> The official Drugs@FDA dataset lists original submission 1 for ANDA 211097 with status AP dated 2023-11-16, and names teriparatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda211097:v1`
- Evidence domain: Regulatory
- Date in source: 2023-11-16
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda211097/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-anda211097-v1
- Content SHA-256: `fe1dac727605041687c1044792f17e55e38fc2e106067b7a9b1b52d2c42a4b7a`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA211097 ([`fda-drugs-anda211097-2023-11-16-2855aa79a2e2`](#source-fda-drugs-anda211097-2023-11-16-2855aa79a2e2))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 211097 with status AP dated 2023-11-16, and names teriparatide among the application record's active ingredients. ([`fda-drugs-anda211097-2023-11-16-2855aa79a2e2`](#source-fda-drugs-anda211097-2023-11-16-2855aa79a2e2))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 211097 with status AP dated 2023-11-16, and names teriparatide among the application record's active ingredients. ([`fda-drugs-anda211097-2023-11-16-2855aa79a2e2`](#source-fda-drugs-anda211097-2023-11-16-2855aa79a2e2))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda211097-2023-11-16-2855aa79a2e2`](#source-fda-drugs-anda211097-2023-11-16-2855aa79a2e2))

### Sources

<a id="source-fda-drugs-anda211097-2023-11-16-2855aa79a2e2"></a>
- **Drugs@FDA application ANDA211097 · original submission status AP · 2023-11-16 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA211097%22&limit=1) (`fda-drugs-anda211097-2023-11-16-2855aa79a2e2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA211097." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-anda211097-v1 SHA-256: fe1dac727605041687c1044792f17e55e38fc2e106067b7a9b1b52d2c42a4b7a.

---

<a id="fda-drugs-anda213641-v1"></a>

## Drugs@FDA application ANDA213641

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213641 with status AP dated 2025-12-12, and names teriparatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213641:v1`
- Evidence domain: Regulatory
- Date in source: 2025-12-12
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213641/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-anda213641-v1
- Content SHA-256: `ed5e3a298e82c331366141aaa0484eb8a0d49172a94274d7425e300c12188ccd`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213641 ([`fda-drugs-anda213641-2025-12-12-ea2cc0030786`](#source-fda-drugs-anda213641-2025-12-12-ea2cc0030786))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213641 with status AP dated 2025-12-12, and names teriparatide among the application record's active ingredients. ([`fda-drugs-anda213641-2025-12-12-ea2cc0030786`](#source-fda-drugs-anda213641-2025-12-12-ea2cc0030786))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213641 with status AP dated 2025-12-12, and names teriparatide among the application record's active ingredients. ([`fda-drugs-anda213641-2025-12-12-ea2cc0030786`](#source-fda-drugs-anda213641-2025-12-12-ea2cc0030786))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213641-2025-12-12-ea2cc0030786`](#source-fda-drugs-anda213641-2025-12-12-ea2cc0030786))

### Sources

<a id="source-fda-drugs-anda213641-2025-12-12-ea2cc0030786"></a>
- **Drugs@FDA application ANDA213641 · original submission status AP · 2025-12-12 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213641%22&limit=1) (`fda-drugs-anda213641-2025-12-12-ea2cc0030786`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213641." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-anda213641-v1 SHA-256: ed5e3a298e82c331366141aaa0484eb8a0d49172a94274d7425e300c12188ccd.

---

<a id="fda-drugs-anda214412-v1"></a>

## Drugs@FDA application ANDA214412

> The official Drugs@FDA dataset lists original submission 1 for ANDA 214412 with status AP dated 2026-10-23, and names teriparatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda214412:v1`
- Evidence domain: Regulatory
- Date in source: 2026-10-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda214412/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-anda214412-v1
- Content SHA-256: `a7c1340842e33c27dd394e1de3919596857efbc0e666b2b18c90c44ad49d6c6d`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA214412 ([`fda-drugs-anda214412-2026-10-23-57b5e048e2bf`](#source-fda-drugs-anda214412-2026-10-23-57b5e048e2bf))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 214412 with status AP dated 2026-10-23, and names teriparatide among the application record's active ingredients. ([`fda-drugs-anda214412-2026-10-23-57b5e048e2bf`](#source-fda-drugs-anda214412-2026-10-23-57b5e048e2bf))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 214412 with status AP dated 2026-10-23, and names teriparatide among the application record's active ingredients. ([`fda-drugs-anda214412-2026-10-23-57b5e048e2bf`](#source-fda-drugs-anda214412-2026-10-23-57b5e048e2bf))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda214412-2026-10-23-57b5e048e2bf`](#source-fda-drugs-anda214412-2026-10-23-57b5e048e2bf))

### Sources

<a id="source-fda-drugs-anda214412-2026-10-23-57b5e048e2bf"></a>
- **Drugs@FDA application ANDA214412 · original submission status AP · 2026-10-23 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA214412%22&limit=1) (`fda-drugs-anda214412-2026-10-23-57b5e048e2bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA214412." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-anda214412-v1 SHA-256: a7c1340842e33c27dd394e1de3919596857efbc0e666b2b18c90c44ad49d6c6d.

---

<a id="fda-drugs-nda021318-v1"></a>

## Drugs@FDA application NDA021318

> The official Drugs@FDA dataset lists original submission 1 for NDA 021318 with status AP dated 2002-11-26, and names teriparatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021318:v1`
- Evidence domain: Regulatory
- Date in source: 2002-11-26
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021318/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-nda021318-v1
- Content SHA-256: `996883c653061fb2361561c7dfdec4e25ed580887228dd5c0364daae52fe32b0`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021318 ([`fda-drugs-nda021318-2002-11-26-2f4c2df07e0a`](#source-fda-drugs-nda021318-2002-11-26-2f4c2df07e0a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021318 with status AP dated 2002-11-26, and names teriparatide among the application record's active ingredients. ([`fda-drugs-nda021318-2002-11-26-2f4c2df07e0a`](#source-fda-drugs-nda021318-2002-11-26-2f4c2df07e0a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021318 with status AP dated 2002-11-26, and names teriparatide among the application record's active ingredients. ([`fda-drugs-nda021318-2002-11-26-2f4c2df07e0a`](#source-fda-drugs-nda021318-2002-11-26-2f4c2df07e0a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021318-2002-11-26-2f4c2df07e0a`](#source-fda-drugs-nda021318-2002-11-26-2f4c2df07e0a))

### Sources

<a id="source-fda-drugs-nda021318-2002-11-26-2f4c2df07e0a"></a>
- **Drugs@FDA application NDA021318 · original submission status AP · 2002-11-26 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021318%22&limit=1) (`fda-drugs-nda021318-2002-11-26-2f4c2df07e0a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021318." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-nda021318-v1 SHA-256: 996883c653061fb2361561c7dfdec4e25ed580887228dd5c0364daae52fe32b0.

---

<a id="fda-drugs-nda211939-v1"></a>

## Drugs@FDA application NDA211939

> The official Drugs@FDA dataset lists original submission 1 for NDA 211939 with status AP dated 2019-10-04, and names teriparatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda211939:v1`
- Evidence domain: Regulatory
- Date in source: 2019-10-04
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda211939/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-nda211939-v1
- Content SHA-256: `2a7fc30e8be9aab1a5804174b53eb3aa673967b1b9a0e666e0b6b78bb675dc86`

### Claims and source pins

#### Headline

Drugs@FDA application NDA211939 ([`fda-drugs-nda211939-2019-10-04-4790820cc8d4`](#source-fda-drugs-nda211939-2019-10-04-4790820cc8d4))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 211939 with status AP dated 2019-10-04, and names teriparatide among the application record's active ingredients. ([`fda-drugs-nda211939-2019-10-04-4790820cc8d4`](#source-fda-drugs-nda211939-2019-10-04-4790820cc8d4))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 211939 with status AP dated 2019-10-04, and names teriparatide among the application record's active ingredients. ([`fda-drugs-nda211939-2019-10-04-4790820cc8d4`](#source-fda-drugs-nda211939-2019-10-04-4790820cc8d4))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda211939-2019-10-04-4790820cc8d4`](#source-fda-drugs-nda211939-2019-10-04-4790820cc8d4))

### Sources

<a id="source-fda-drugs-nda211939-2019-10-04-4790820cc8d4"></a>
- **Drugs@FDA application NDA211939 · original submission status AP · 2019-10-04 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA211939%22&limit=1) (`fda-drugs-nda211939-2019-10-04-4790820cc8d4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA211939." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-nda211939-v1 SHA-256: 2a7fc30e8be9aab1a5804174b53eb3aa673967b1b9a0e666e0b6b78bb675dc86.

---

<a id="fda-drugs-nda218771-v1"></a>

## Drugs@FDA application NDA218771

> The official Drugs@FDA dataset lists original submission 1 for NDA 218771 with status AP dated 2024-06-04, and names teriparatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda218771:v1`
- Evidence domain: Regulatory
- Date in source: 2024-06-04
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda218771/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-nda218771-v1
- Content SHA-256: `1f3b02ed5c92a707b44fd171356a87ab79864d5671ca55dbb59a0b21cb083e38`

### Claims and source pins

#### Headline

Drugs@FDA application NDA218771 ([`fda-drugs-nda218771-2024-06-04-4293d16697eb`](#source-fda-drugs-nda218771-2024-06-04-4293d16697eb))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 218771 with status AP dated 2024-06-04, and names teriparatide among the application record's active ingredients. ([`fda-drugs-nda218771-2024-06-04-4293d16697eb`](#source-fda-drugs-nda218771-2024-06-04-4293d16697eb))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 218771 with status AP dated 2024-06-04, and names teriparatide among the application record's active ingredients. ([`fda-drugs-nda218771-2024-06-04-4293d16697eb`](#source-fda-drugs-nda218771-2024-06-04-4293d16697eb))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda218771-2024-06-04-4293d16697eb`](#source-fda-drugs-nda218771-2024-06-04-4293d16697eb))

### Sources

<a id="source-fda-drugs-nda218771-2024-06-04-4293d16697eb"></a>
- **Drugs@FDA application NDA218771 · original submission status AP · 2024-06-04 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA218771%22&limit=1) (`fda-drugs-nda218771-2024-06-04-4293d16697eb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA218771." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#fda-drugs-nda218771-v1 SHA-256: 1f3b02ed5c92a707b44fd171356a87ab79864d5671ca55dbb59a0b21cb083e38.

---

<a id="federal-register-2024-18997-v1"></a>

## Federal Register notice 2024-18997

> The Federal Register published notice 2024-18997, attributed to FDA and its parent HHS department, on 2024-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Teriparatide.

- Evidence object: `story:federal-register-2024-18997:v1`
- Evidence domain: Regulatory
- Date in source: 2024-08-23
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2024-18997/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#federal-register-2024-18997-v1
- Content SHA-256: `ba8c19d4bb9d667f2890d6706c7843177344e3c8b73c38f7c1e4fa748b133649`

### Claims and source pins

#### Headline

Federal Register notice 2024-18997 ([`federal-register-2024-18997-4a95bef8c53b`](#source-federal-register-2024-18997-4a95bef8c53b))

#### Summary

The Federal Register published notice 2024-18997, attributed to FDA and its parent HHS department, on 2024-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Teriparatide. ([`federal-register-2024-18997-4a95bef8c53b`](#source-federal-register-2024-18997-4a95bef8c53b))

#### Paragraph 1

The Federal Register published notice 2024-18997, attributed to FDA and its parent HHS department, on 2024-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Teriparatide. ([`federal-register-2024-18997-4a95bef8c53b`](#source-federal-register-2024-18997-4a95bef8c53b))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2024-18997-4a95bef8c53b`](#source-federal-register-2024-18997-4a95bef8c53b))

### Sources

<a id="source-federal-register-2024-18997-4a95bef8c53b"></a>
- **Federal Register notice 2024-18997 · published 2024-08-23 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2024-08-23/pdf/2024-18997.pdf) (`federal-register-2024-18997-4a95bef8c53b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2024-18997." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#federal-register-2024-18997-v1 SHA-256: ba8c19d4bb9d667f2890d6706c7843177344e3c8b73c38f7c1e4fa748b133649.

---

<a id="federal-register-99-24595-v1"></a>

## Federal Register notice 99-24595

> The Federal Register published notice 99-24595, attributed to FDA and its parent HHS department, on 1999-09-22. Its official title is “Wallace Laboratories et al.; Withdrawal of Approval of 18 New Drug Applications and 44 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Teriparatide.

- Evidence object: `story:federal-register-99-24595:v1`
- Evidence domain: Regulatory
- Date in source: 1999-09-22
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-99-24595/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#federal-register-99-24595-v1
- Content SHA-256: `3acfda4cea9ced2b6d7c78dba3eeabfcfdb398050a7f6c970fba66ab7e7f955e`

### Claims and source pins

#### Headline

Federal Register notice 99-24595 ([`federal-register-99-24595-237c9fcac808`](#source-federal-register-99-24595-237c9fcac808))

#### Summary

The Federal Register published notice 99-24595, attributed to FDA and its parent HHS department, on 1999-09-22. Its official title is “Wallace Laboratories et al.; Withdrawal of Approval of 18 New Drug Applications and 44 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Teriparatide. ([`federal-register-99-24595-237c9fcac808`](#source-federal-register-99-24595-237c9fcac808))

#### Paragraph 1

The Federal Register published notice 99-24595, attributed to FDA and its parent HHS department, on 1999-09-22. Its official title is “Wallace Laboratories et al.; Withdrawal of Approval of 18 New Drug Applications and 44 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Teriparatide. ([`federal-register-99-24595-237c9fcac808`](#source-federal-register-99-24595-237c9fcac808))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-99-24595-237c9fcac808`](#source-federal-register-99-24595-237c9fcac808))

### Sources

<a id="source-federal-register-99-24595-237c9fcac808"></a>
- **Federal Register notice 99-24595 · published 1999-09-22 · Wallace Laboratories et al.; Withdrawal of Approval of 18 New Drug Applications and 44 Abbreviated New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-1999-09-22/pdf/99-24595.pdf) (`federal-register-99-24595-237c9fcac808`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 99-24595." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#federal-register-99-24595-v1 SHA-256: 3acfda4cea9ced2b6d7c78dba3eeabfcfdb398050a7f6c970fba66ab7e7f955e.

---

<a id="pubmed-pmid-12571538-teriparatide-v1"></a>

## Teriparatide (forteo) for osteoporsis.

> PubMed lists PMID 12571538 in The Medical letter on drugs and therapeutics as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2003-02-03 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12571538-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12571538-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-12571538-teriparatide-v1
- Content SHA-256: `57f64991884b96a40e4673dc321d08b8435ff7eaf2c44cbe172536e72953ae93`

### Claims and source pins

#### Headline

Teriparatide (forteo) for osteoporsis. ([`pubmed-observation-pmid-12571538-2013-11-21-dddce1ceb373`](#source-pubmed-observation-pmid-12571538-2013-11-21-dddce1ceb373))

#### Summary

PubMed lists PMID 12571538 in The Medical letter on drugs and therapeutics as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2003-02-03 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12571538-2013-11-21-dddce1ceb373`](#source-pubmed-observation-pmid-12571538-2013-11-21-dddce1ceb373))

#### Paragraph 1

PubMed lists PMID 12571538 in The Medical letter on drugs and therapeutics as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2003-02-03 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12571538-2013-11-21-dddce1ceb373`](#source-pubmed-observation-pmid-12571538-2013-11-21-dddce1ceb373))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12571538-2013-11-21-dddce1ceb373`](#source-pubmed-observation-pmid-12571538-2013-11-21-dddce1ceb373))

### Sources

<a id="source-pubmed-observation-pmid-12571538-2013-11-21-dddce1ceb373"></a>
- **Teriparatide (forteo) for osteoporsis. · retained source version 1:2013-11-21:current:dddce1ceb37366550dd5994cf5fdf17694c4efe10a1757d3437b12075e4497f7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12571538/) (`pubmed-observation-pmid-12571538-2013-11-21-dddce1ceb373`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide (forteo) for osteoporsis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-12571538-teriparatide-v1 SHA-256: 57f64991884b96a40e4673dc321d08b8435ff7eaf2c44cbe172536e72953ae93.

---

<a id="pubmed-pmid-14610756-teriparatide-v1"></a>

## Treating osteoporosis with teriparatide: many unknowns?

> PubMed lists PMID 14610756 in Issues in emerging health technologies as Comparative Study, Journal Article, with publication-date metadata of 2003-11 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-14610756-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-14610756-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-14610756-teriparatide-v1
- Content SHA-256: `faad2acd0e9f56a9861d328e5835304356a3329525f3d1ab97dce9baa9b82a94`

### Claims and source pins

#### Headline

Treating osteoporosis with teriparatide: many unknowns? ([`pubmed-observation-pmid-14610756-2013-11-21-7cc6c1e3eefb`](#source-pubmed-observation-pmid-14610756-2013-11-21-7cc6c1e3eefb))

#### Summary

PubMed lists PMID 14610756 in Issues in emerging health technologies as Comparative Study, Journal Article, with publication-date metadata of 2003-11 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14610756-2013-11-21-7cc6c1e3eefb`](#source-pubmed-observation-pmid-14610756-2013-11-21-7cc6c1e3eefb))

#### Paragraph 1

PubMed lists PMID 14610756 in Issues in emerging health technologies as Comparative Study, Journal Article, with publication-date metadata of 2003-11 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14610756-2013-11-21-7cc6c1e3eefb`](#source-pubmed-observation-pmid-14610756-2013-11-21-7cc6c1e3eefb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-14610756-2013-11-21-7cc6c1e3eefb`](#source-pubmed-observation-pmid-14610756-2013-11-21-7cc6c1e3eefb))

### Sources

<a id="source-pubmed-observation-pmid-14610756-2013-11-21-7cc6c1e3eefb"></a>
- **Treating osteoporosis with teriparatide: many unknowns? · retained source version 1:2013-11-21:current:7cc6c1e3eefbf7aa612637536bf387f720983446fb6be27606cd935fff57347f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/14610756/) (`pubmed-observation-pmid-14610756-2013-11-21-7cc6c1e3eefb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treating osteoporosis with teriparatide: many unknowns?" Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-14610756-teriparatide-v1 SHA-256: faad2acd0e9f56a9861d328e5835304356a3329525f3d1ab97dce9baa9b82a94.

---

<a id="pubmed-pmid-14627183-teriparatide-v1"></a>

## Teriparatide (rhPTH 1-34) for the treatment of osteoporosis.

> PubMed lists PMID 14627183 in International journal of clinical practice as Journal Article, Review, with publication-date metadata of 2003-10 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-14627183-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-14627183-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-14627183-teriparatide-v1
- Content SHA-256: `f090ddfd9ae65d8610b504d45046ce00593a7853d100f82dcbc25dd790edde31`

### Claims and source pins

#### Headline

Teriparatide (rhPTH 1-34) for the treatment of osteoporosis. ([`pubmed-observation-pmid-14627183-2013-11-21-159383b72e57`](#source-pubmed-observation-pmid-14627183-2013-11-21-159383b72e57))

#### Summary

PubMed lists PMID 14627183 in International journal of clinical practice as Journal Article, Review, with publication-date metadata of 2003-10 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14627183-2013-11-21-159383b72e57`](#source-pubmed-observation-pmid-14627183-2013-11-21-159383b72e57))

#### Paragraph 1

PubMed lists PMID 14627183 in International journal of clinical practice as Journal Article, Review, with publication-date metadata of 2003-10 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14627183-2013-11-21-159383b72e57`](#source-pubmed-observation-pmid-14627183-2013-11-21-159383b72e57))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-14627183-2013-11-21-159383b72e57`](#source-pubmed-observation-pmid-14627183-2013-11-21-159383b72e57))

### Sources

<a id="source-pubmed-observation-pmid-14627183-2013-11-21-159383b72e57"></a>
- **Teriparatide (rhPTH 1-34) for the treatment of osteoporosis. · retained source version 1:2013-11-21:current:159383b72e577850a74233f628fbed57e0ff0a5df42fb3325ec5003098d90fc2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/14627183/) (`pubmed-observation-pmid-14627183-2013-11-21-159383b72e57`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide (rhPTH 1-34) for the treatment of osteoporosis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-14627183-teriparatide-v1 SHA-256: f090ddfd9ae65d8610b504d45046ce00593a7853d100f82dcbc25dd790edde31.

---

<a id="pubmed-pmid-14685711-teriparatide-v1"></a>

## \[Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium\].

> PubMed lists PMID 14685711 in Zeitschrift fur Rheumatologie as Comparative Study, English Abstract, Journal Article, Review, with publication-date metadata of 2003-12 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-14685711-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-14685711-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-14685711-teriparatide-v1
- Content SHA-256: `e15589c4670887129c0f928ba450b183a9b357746ff8865582978692b3b053c2`

### Claims and source pins

#### Headline

\[Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium\]. ([`pubmed-observation-pmid-14685711-2013-11-21-6b5a3f426351`](#source-pubmed-observation-pmid-14685711-2013-11-21-6b5a3f426351))

#### Summary

PubMed lists PMID 14685711 in Zeitschrift fur Rheumatologie as Comparative Study, English Abstract, Journal Article, Review, with publication-date metadata of 2003-12 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14685711-2013-11-21-6b5a3f426351`](#source-pubmed-observation-pmid-14685711-2013-11-21-6b5a3f426351))

#### Paragraph 1

PubMed lists PMID 14685711 in Zeitschrift fur Rheumatologie as Comparative Study, English Abstract, Journal Article, Review, with publication-date metadata of 2003-12 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14685711-2013-11-21-6b5a3f426351`](#source-pubmed-observation-pmid-14685711-2013-11-21-6b5a3f426351))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-14685711-2013-11-21-6b5a3f426351`](#source-pubmed-observation-pmid-14685711-2013-11-21-6b5a3f426351))

### Sources

<a id="source-pubmed-observation-pmid-14685711-2013-11-21-6b5a3f426351"></a>
- **\[Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium\]. · retained source version 1:2013-11-21:current:6b5a3f4263511ea8e8c12cf4b3d8915b4caa7d3f74530b049c33a02767238eeb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/14685711/) (`pubmed-observation-pmid-14685711-2013-11-21-6b5a3f426351`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-14685711-teriparatide-v1 SHA-256: e15589c4670887129c0f928ba450b183a9b357746ff8865582978692b3b053c2.

---

<a id="pubmed-pmid-14742769-teriparatide-v1"></a>

## Teriparatide for severe osteoporosis.

> PubMed lists PMID 14742769 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2003-12-30 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-14742769-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-14742769-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-14742769-teriparatide-v1
- Content SHA-256: `70cc9aea595ce863a45b4beacbbff060e7ca358ecb29111417a1cbca7931907c`

### Claims and source pins

#### Headline

Teriparatide for severe osteoporosis. ([`pubmed-observation-pmid-14742769-2013-11-21-5d080718744b`](#source-pubmed-observation-pmid-14742769-2013-11-21-5d080718744b))

#### Summary

PubMed lists PMID 14742769 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2003-12-30 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14742769-2013-11-21-5d080718744b`](#source-pubmed-observation-pmid-14742769-2013-11-21-5d080718744b))

#### Paragraph 1

PubMed lists PMID 14742769 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2003-12-30 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14742769-2013-11-21-5d080718744b`](#source-pubmed-observation-pmid-14742769-2013-11-21-5d080718744b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-14742769-2013-11-21-5d080718744b`](#source-pubmed-observation-pmid-14742769-2013-11-21-5d080718744b))

### Sources

<a id="source-pubmed-observation-pmid-14742769-2013-11-21-5d080718744b"></a>
- **Teriparatide for severe osteoporosis. · retained source version 1:2013-11-21:current:5d080718744b8cd30dc5f6f18f0e1adc732449dd2e212c9737105764ae577a26** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/14742769/) (`pubmed-observation-pmid-14742769-2013-11-21-5d080718744b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide for severe osteoporosis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-14742769-teriparatide-v1 SHA-256: 70cc9aea595ce863a45b4beacbbff060e7ca358ecb29111417a1cbca7931907c.

---

<a id="pubmed-pmid-15117021-teriparatide-v1"></a>

## Teriparatide (Forteo) for osteoporosis.

> PubMed lists PMID 15117021 in American family physician as Journal Article, with publication-date metadata of 2004-04-15 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15117021-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15117021-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-15117021-teriparatide-v1
- Content SHA-256: `f88d1bf1c38c81164f718ffa18aaf9c0efc2ea772055e2b3786864f084c42a52`

### Claims and source pins

#### Headline

Teriparatide (Forteo) for osteoporosis. ([`pubmed-observation-pmid-15117021-2013-11-21-3c10d9a635b9`](#source-pubmed-observation-pmid-15117021-2013-11-21-3c10d9a635b9))

#### Summary

PubMed lists PMID 15117021 in American family physician as Journal Article, with publication-date metadata of 2004-04-15 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15117021-2013-11-21-3c10d9a635b9`](#source-pubmed-observation-pmid-15117021-2013-11-21-3c10d9a635b9))

#### Paragraph 1

PubMed lists PMID 15117021 in American family physician as Journal Article, with publication-date metadata of 2004-04-15 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15117021-2013-11-21-3c10d9a635b9`](#source-pubmed-observation-pmid-15117021-2013-11-21-3c10d9a635b9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15117021-2013-11-21-3c10d9a635b9`](#source-pubmed-observation-pmid-15117021-2013-11-21-3c10d9a635b9))

### Sources

<a id="source-pubmed-observation-pmid-15117021-2013-11-21-3c10d9a635b9"></a>
- **Teriparatide (Forteo) for osteoporosis. · retained source version 1:2013-11-21:current:3c10d9a635b93b7825eb6c5fe75d6e62f8ba99a9822457cc6e607414777750c5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15117021/) (`pubmed-observation-pmid-15117021-2013-11-21-3c10d9a635b9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide (Forteo) for osteoporosis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-15117021-teriparatide-v1 SHA-256: f88d1bf1c38c81164f718ffa18aaf9c0efc2ea772055e2b3786864f084c42a52.

---

<a id="pubmed-pmid-15228497-teriparatide-v1"></a>

## Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.

> PubMed lists PMID 15228497 in Basic & clinical pharmacology & toxicology as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2004-06 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15228497-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15228497-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-15228497-teriparatide-v1
- Content SHA-256: `92edaf9c5a9aa6d25236ef285352dadd7b00d2b53f2d3c9e8974a4a0c918b126`

### Claims and source pins

#### Headline

Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. ([`pubmed-observation-pmid-15228497-2013-11-21-b275f2532021`](#source-pubmed-observation-pmid-15228497-2013-11-21-b275f2532021))

#### Summary

PubMed lists PMID 15228497 in Basic & clinical pharmacology & toxicology as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2004-06 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15228497-2013-11-21-b275f2532021`](#source-pubmed-observation-pmid-15228497-2013-11-21-b275f2532021))

#### Paragraph 1

PubMed lists PMID 15228497 in Basic & clinical pharmacology & toxicology as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2004-06 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15228497-2013-11-21-b275f2532021`](#source-pubmed-observation-pmid-15228497-2013-11-21-b275f2532021))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15228497-2013-11-21-b275f2532021`](#source-pubmed-observation-pmid-15228497-2013-11-21-b275f2532021))

### Sources

<a id="source-pubmed-observation-pmid-15228497-2013-11-21-b275f2532021"></a>
- **Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. · retained source version 1:2013-11-21:current:b275f25320218cc5a24086db6b1a89e3a2a90793f8acea334fd2d8828f69a99a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15228497/) (`pubmed-observation-pmid-15228497-2013-11-21-b275f2532021`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-15228497-teriparatide-v1 SHA-256: 92edaf9c5a9aa6d25236ef285352dadd7b00d2b53f2d3c9e8974a4a0c918b126.

---

<a id="pubmed-pmid-15347166-teriparatide-v1"></a>

## \[Teriparatide (human recombinant 1-34 parathyroid hormone)--a new treatment regimen for severe osteoporosis\].

> PubMed lists PMID 15347166 in Ugeskrift for laeger as Journal Article, Review, with publication-date metadata of 2004-08-02 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15347166-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15347166-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-15347166-teriparatide-v1
- Content SHA-256: `f0557a577cdd860f9af0b7dd9fe70e0713069af05840fff3a536db3f3afae435`

### Claims and source pins

#### Headline

\[Teriparatide (human recombinant 1-34 parathyroid hormone)--a new treatment regimen for severe osteoporosis\]. ([`pubmed-observation-pmid-15347166-2013-11-21-83eebfdbbdcc`](#source-pubmed-observation-pmid-15347166-2013-11-21-83eebfdbbdcc))

#### Summary

PubMed lists PMID 15347166 in Ugeskrift for laeger as Journal Article, Review, with publication-date metadata of 2004-08-02 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15347166-2013-11-21-83eebfdbbdcc`](#source-pubmed-observation-pmid-15347166-2013-11-21-83eebfdbbdcc))

#### Paragraph 1

PubMed lists PMID 15347166 in Ugeskrift for laeger as Journal Article, Review, with publication-date metadata of 2004-08-02 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15347166-2013-11-21-83eebfdbbdcc`](#source-pubmed-observation-pmid-15347166-2013-11-21-83eebfdbbdcc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15347166-2013-11-21-83eebfdbbdcc`](#source-pubmed-observation-pmid-15347166-2013-11-21-83eebfdbbdcc))

### Sources

<a id="source-pubmed-observation-pmid-15347166-2013-11-21-83eebfdbbdcc"></a>
- **\[Teriparatide (human recombinant 1-34 parathyroid hormone)--a new treatment regimen for severe osteoporosis\]. · retained source version 1:2013-11-21:current:83eebfdbbdcc8565d2b8ba515596dd85aed57c94019e5f7bc710d5b187a17fda** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15347166/) (`pubmed-observation-pmid-15347166-2013-11-21-83eebfdbbdcc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Teriparatide (human recombinant 1-34 parathyroid hormone)--a new treatment regimen for severe osteoporosis\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-15347166-teriparatide-v1 SHA-256: f0557a577cdd860f9af0b7dd9fe70e0713069af05840fff3a536db3f3afae435.

---

<a id="pubmed-pmid-15587764-teriparatide-v1"></a>

## Teriparatide for postmenopausal osteoporosis.

> PubMed lists PMID 15587764 in Drug and therapeutics bulletin as Journal Article, Review, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15587764-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15587764-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-15587764-teriparatide-v1
- Content SHA-256: `9884c7ef39c3e1b7b654e381507aa67d5b89ee3c944b9aad1ecf7436a89e07b9`

### Claims and source pins

#### Headline

Teriparatide for postmenopausal osteoporosis. ([`pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956`](#source-pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956))

#### Summary

PubMed lists PMID 15587764 in Drug and therapeutics bulletin as Journal Article, Review, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956`](#source-pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956))

#### Paragraph 1

PubMed lists PMID 15587764 in Drug and therapeutics bulletin as Journal Article, Review, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956`](#source-pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956`](#source-pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956))

### Sources

<a id="source-pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956"></a>
- **Teriparatide for postmenopausal osteoporosis. · retained source version 1:2013-11-21:current:1a9eea2a3956c3f4159f4466e89b99a923eafe806e5cb9e81cf3a771768da3ca** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15587764/) (`pubmed-observation-pmid-15587764-2013-11-21-1a9eea2a3956`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide for postmenopausal osteoporosis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-15587764-teriparatide-v1 SHA-256: 9884c7ef39c3e1b7b654e381507aa67d5b89ee3c944b9aad1ecf7436a89e07b9.

---

<a id="pubmed-pmid-15747448-teriparatide-v1"></a>

## Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.

> PubMed lists PMID 15747448 in Prescrire international as Comparative Study, Journal Article, with publication-date metadata of 2005-02 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15747448-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15747448-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-15747448-teriparatide-v1
- Content SHA-256: `afac44ca007d6d130909b701cdb3ef43bf582769e6744e475a8345f8b55cc29d`

### Claims and source pins

#### Headline

Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid. ([`pubmed-observation-pmid-15747448-2013-11-21-932218b3a6d3`](#source-pubmed-observation-pmid-15747448-2013-11-21-932218b3a6d3))

#### Summary

PubMed lists PMID 15747448 in Prescrire international as Comparative Study, Journal Article, with publication-date metadata of 2005-02 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15747448-2013-11-21-932218b3a6d3`](#source-pubmed-observation-pmid-15747448-2013-11-21-932218b3a6d3))

#### Paragraph 1

PubMed lists PMID 15747448 in Prescrire international as Comparative Study, Journal Article, with publication-date metadata of 2005-02 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15747448-2013-11-21-932218b3a6d3`](#source-pubmed-observation-pmid-15747448-2013-11-21-932218b3a6d3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15747448-2013-11-21-932218b3a6d3`](#source-pubmed-observation-pmid-15747448-2013-11-21-932218b3a6d3))

### Sources

<a id="source-pubmed-observation-pmid-15747448-2013-11-21-932218b3a6d3"></a>
- **Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid. · retained source version 1:2013-11-21:current:932218b3a6d3317d8cde8349f2abe234898b80e2beb616230a1b4c70c879c8ad** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15747448/) (`pubmed-observation-pmid-15747448-2013-11-21-932218b3a6d3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-15747448-teriparatide-v1 SHA-256: afac44ca007d6d130909b701cdb3ef43bf582769e6744e475a8345f8b55cc29d.

---

<a id="pubmed-pmid-16684431-teriparatide-v1"></a>

## Initial experience with teriparatide in the United States.

> PubMed lists PMID 16684431 in Current medical research and opinion as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006-04 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16684431-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16684431-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-16684431-teriparatide-v1
- Content SHA-256: `b6a819b18e64382cffade694b1012f6d274f72aec9fe7862609df05eb342353c`

### Claims and source pins

#### Headline

Initial experience with teriparatide in the United States. ([`pubmed-observation-pmid-16684431-2013-11-21-85823488c3d4`](#source-pubmed-observation-pmid-16684431-2013-11-21-85823488c3d4))

#### Summary

PubMed lists PMID 16684431 in Current medical research and opinion as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006-04 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16684431-2013-11-21-85823488c3d4`](#source-pubmed-observation-pmid-16684431-2013-11-21-85823488c3d4))

#### Paragraph 1

PubMed lists PMID 16684431 in Current medical research and opinion as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006-04 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16684431-2013-11-21-85823488c3d4`](#source-pubmed-observation-pmid-16684431-2013-11-21-85823488c3d4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16684431-2013-11-21-85823488c3d4`](#source-pubmed-observation-pmid-16684431-2013-11-21-85823488c3d4))

### Sources

<a id="source-pubmed-observation-pmid-16684431-2013-11-21-85823488c3d4"></a>
- **Initial experience with teriparatide in the United States. · retained source version 1:2013-11-21:current:85823488c3d427ea1f8fdda0e0e95ef35ff92f34f825bf7af62e27eba0e2bb22** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16684431/) (`pubmed-observation-pmid-16684431-2013-11-21-85823488c3d4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Initial experience with teriparatide in the United States." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-16684431-teriparatide-v1 SHA-256: b6a819b18e64382cffade694b1012f6d274f72aec9fe7862609df05eb342353c.

---

<a id="pubmed-pmid-18021497-teriparatide-v1"></a>

## Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance.

> PubMed lists PMID 18021497 in Current medical research and opinion as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-12 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18021497-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18021497-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-18021497-teriparatide-v1
- Content SHA-256: `af07a9eadf96f4d03c67cc07ba57dac0ba11e8e9234ce63e8619b51783984a1a`

### Claims and source pins

#### Headline

Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance. ([`pubmed-observation-pmid-18021497-2013-11-21-9b393dcb116d`](#source-pubmed-observation-pmid-18021497-2013-11-21-9b393dcb116d))

#### Summary

PubMed lists PMID 18021497 in Current medical research and opinion as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-12 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18021497-2013-11-21-9b393dcb116d`](#source-pubmed-observation-pmid-18021497-2013-11-21-9b393dcb116d))

#### Paragraph 1

PubMed lists PMID 18021497 in Current medical research and opinion as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-12 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18021497-2013-11-21-9b393dcb116d`](#source-pubmed-observation-pmid-18021497-2013-11-21-9b393dcb116d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18021497-2013-11-21-9b393dcb116d`](#source-pubmed-observation-pmid-18021497-2013-11-21-9b393dcb116d))

### Sources

<a id="source-pubmed-observation-pmid-18021497-2013-11-21-9b393dcb116d"></a>
- **Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance. · retained source version 1:2013-11-21:current:9b393dcb116d314acf0da804b903ea993231287b24212ef9e300de0f500f73e4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18021497/) (`pubmed-observation-pmid-18021497-2013-11-21-9b393dcb116d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-18021497-teriparatide-v1 SHA-256: af07a9eadf96f4d03c67cc07ba57dac0ba11e8e9234ce63e8619b51783984a1a.

---

<a id="pubmed-pmid-18182888-teriparatide-v1"></a>

## Teriparatide and orthopedic surgery.

> PubMed lists PMID 18182888 in Aging clinical and experimental research as Journal Article, with publication-date metadata of 2007-08 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18182888-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18182888-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-18182888-teriparatide-v1
- Content SHA-256: `e387fe7c78111e4a9637b586cd8b7788be84a72ced30d6909cac3f183a6239d2`

### Claims and source pins

#### Headline

Teriparatide and orthopedic surgery. ([`pubmed-observation-pmid-18182888-2013-11-21-68c07c58229d`](#source-pubmed-observation-pmid-18182888-2013-11-21-68c07c58229d))

#### Summary

PubMed lists PMID 18182888 in Aging clinical and experimental research as Journal Article, with publication-date metadata of 2007-08 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18182888-2013-11-21-68c07c58229d`](#source-pubmed-observation-pmid-18182888-2013-11-21-68c07c58229d))

#### Paragraph 1

PubMed lists PMID 18182888 in Aging clinical and experimental research as Journal Article, with publication-date metadata of 2007-08 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18182888-2013-11-21-68c07c58229d`](#source-pubmed-observation-pmid-18182888-2013-11-21-68c07c58229d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18182888-2013-11-21-68c07c58229d`](#source-pubmed-observation-pmid-18182888-2013-11-21-68c07c58229d))

### Sources

<a id="source-pubmed-observation-pmid-18182888-2013-11-21-68c07c58229d"></a>
- **Teriparatide and orthopedic surgery. · retained source version 1:2013-11-21:current:68c07c58229d1ffdf89283f5cbf2a0798a3e71b38fb61b87006c712b38b5a6de** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18182888/) (`pubmed-observation-pmid-18182888-2013-11-21-68c07c58229d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide and orthopedic surgery." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-18182888-teriparatide-v1 SHA-256: e387fe7c78111e4a9637b586cd8b7788be84a72ced30d6909cac3f183a6239d2.

---

<a id="pubmed-pmid-18334980-teriparatide-v1"></a>

## PubMed record PMID 18334980

> PeptideScanner retained PubMed bibliographic metadata for PMID 18334980 at 2026-07-30T22:38:13.898Z. PubMed recorded a metadata revision date of 2008-04-28 and an Entrez history date of 2008-03-13. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-18334980-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2008-04-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18334980-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-18334980-teriparatide-v1
- Content SHA-256: `e2eb1fecb835fbfd33e1babd0ec2cf0e0fdd6f69e5d094dcab9c5efcf806ef7c`

### Claims and source pins

#### Headline

PubMed record PMID 18334980 ([`pubmed-observation-pmid-18334980-2008-04-28-fd92ebb18b3d`](#source-pubmed-observation-pmid-18334980-2008-04-28-fd92ebb18b3d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 18334980 at 2026-07-30T22:38:13.898Z. PubMed recorded a metadata revision date of 2008-04-28 and an Entrez history date of 2008-03-13. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18334980-2008-04-28-fd92ebb18b3d`](#source-pubmed-observation-pmid-18334980-2008-04-28-fd92ebb18b3d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 18334980 at 2026-07-30T22:38:13.898Z. PubMed recorded a metadata revision date of 2008-04-28 and an Entrez history date of 2008-03-13. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18334980-2008-04-28-fd92ebb18b3d`](#source-pubmed-observation-pmid-18334980-2008-04-28-fd92ebb18b3d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18334980-2008-04-28-fd92ebb18b3d`](#source-pubmed-observation-pmid-18334980-2008-04-28-fd92ebb18b3d))

### Sources

<a id="source-pubmed-observation-pmid-18334980-2008-04-28-fd92ebb18b3d"></a>
- **PubMed record PMID 18334980 · retained source version 1:2008-04-28:current:fd92ebb18b3d2cc045617967d718512cc29d99dd492b7247a7e2620e1e3766c8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18334980/) (`pubmed-observation-pmid-18334980-2008-04-28-fd92ebb18b3d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 18334980." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-18334980-teriparatide-v1 SHA-256: e2eb1fecb835fbfd33e1babd0ec2cf0e0fdd6f69e5d094dcab9c5efcf806ef7c.

---

<a id="pubmed-pmid-18477986-teriparatide-v1"></a>

## PubMed record PMID 18477986

> PeptideScanner retained PubMed bibliographic metadata for PMID 18477986 at 2026-07-30T22:38:13.910Z. PubMed recorded a metadata revision date of 2008-06-23 and an Entrez history date of 2008-05-15. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-18477986-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2008-06-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18477986-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-18477986-teriparatide-v1
- Content SHA-256: `7064d5e095639fa19b17bfc67c53d60b3e8e2b4459dae1616c49387d662e37e1`

### Claims and source pins

#### Headline

PubMed record PMID 18477986 ([`pubmed-observation-pmid-18477986-2008-06-23-f9038fc5ee3d`](#source-pubmed-observation-pmid-18477986-2008-06-23-f9038fc5ee3d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 18477986 at 2026-07-30T22:38:13.910Z. PubMed recorded a metadata revision date of 2008-06-23 and an Entrez history date of 2008-05-15. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18477986-2008-06-23-f9038fc5ee3d`](#source-pubmed-observation-pmid-18477986-2008-06-23-f9038fc5ee3d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 18477986 at 2026-07-30T22:38:13.910Z. PubMed recorded a metadata revision date of 2008-06-23 and an Entrez history date of 2008-05-15. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18477986-2008-06-23-f9038fc5ee3d`](#source-pubmed-observation-pmid-18477986-2008-06-23-f9038fc5ee3d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18477986-2008-06-23-f9038fc5ee3d`](#source-pubmed-observation-pmid-18477986-2008-06-23-f9038fc5ee3d))

### Sources

<a id="source-pubmed-observation-pmid-18477986-2008-06-23-f9038fc5ee3d"></a>
- **PubMed record PMID 18477986 · retained source version 1:2008-06-23:current:f9038fc5ee3dabb5e6b808a8972e6712497a6254720e518b08175c3fa650ee93** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18477986/) (`pubmed-observation-pmid-18477986-2008-06-23-f9038fc5ee3d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 18477986." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-18477986-teriparatide-v1 SHA-256: 7064d5e095639fa19b17bfc67c53d60b3e8e2b4459dae1616c49387d662e37e1.

---

<a id="pubmed-pmid-18623910-teriparatide-v1"></a>

## PubMed record PMID 18623910

> PeptideScanner retained PubMed bibliographic metadata for PMID 18623910 at 2026-07-30T22:38:13.927Z. PubMed recorded a metadata revision date of 2008-07-14 and an Entrez history date of 2008-07-16. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-18623910-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2008-07-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18623910-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-18623910-teriparatide-v1
- Content SHA-256: `91aac14e5f79c26adb346b7c6cca1d5d9905a00787d1444ec7c712144cbd10af`

### Claims and source pins

#### Headline

PubMed record PMID 18623910 ([`pubmed-observation-pmid-18623910-2008-07-14-2069cdf08cfb`](#source-pubmed-observation-pmid-18623910-2008-07-14-2069cdf08cfb))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 18623910 at 2026-07-30T22:38:13.927Z. PubMed recorded a metadata revision date of 2008-07-14 and an Entrez history date of 2008-07-16. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18623910-2008-07-14-2069cdf08cfb`](#source-pubmed-observation-pmid-18623910-2008-07-14-2069cdf08cfb))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 18623910 at 2026-07-30T22:38:13.927Z. PubMed recorded a metadata revision date of 2008-07-14 and an Entrez history date of 2008-07-16. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18623910-2008-07-14-2069cdf08cfb`](#source-pubmed-observation-pmid-18623910-2008-07-14-2069cdf08cfb))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18623910-2008-07-14-2069cdf08cfb`](#source-pubmed-observation-pmid-18623910-2008-07-14-2069cdf08cfb))

### Sources

<a id="source-pubmed-observation-pmid-18623910-2008-07-14-2069cdf08cfb"></a>
- **PubMed record PMID 18623910 · retained source version 1:2008-07-14:current:2069cdf08cfb078f426a3a223e33f68a4e8007fe7402c8416e4c2f9598fd25e6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18623910/) (`pubmed-observation-pmid-18623910-2008-07-14-2069cdf08cfb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 18623910." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-18623910-teriparatide-v1 SHA-256: 91aac14e5f79c26adb346b7c6cca1d5d9905a00787d1444ec7c712144cbd10af.

---

<a id="pubmed-pmid-18843769-teriparatide-v1"></a>

## Early callus formation in human hip fracture treated with internal fixation and teriparatide.

> PubMed lists PMID 18843769 in The Journal of rheumatology as Case Reports, Letter, with publication-date metadata of 2008-10 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18843769-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18843769-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-18843769-teriparatide-v1
- Content SHA-256: `2076f947626932ec2c361bfb1d540db7b577a8c0fc78f605f3b0587df85034ab`

### Claims and source pins

#### Headline

Early callus formation in human hip fracture treated with internal fixation and teriparatide. ([`pubmed-observation-pmid-18843769-2013-11-21-eaeb5f94017f`](#source-pubmed-observation-pmid-18843769-2013-11-21-eaeb5f94017f))

#### Summary

PubMed lists PMID 18843769 in The Journal of rheumatology as Case Reports, Letter, with publication-date metadata of 2008-10 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18843769-2013-11-21-eaeb5f94017f`](#source-pubmed-observation-pmid-18843769-2013-11-21-eaeb5f94017f))

#### Paragraph 1

PubMed lists PMID 18843769 in The Journal of rheumatology as Case Reports, Letter, with publication-date metadata of 2008-10 (month precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18843769-2013-11-21-eaeb5f94017f`](#source-pubmed-observation-pmid-18843769-2013-11-21-eaeb5f94017f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18843769-2013-11-21-eaeb5f94017f`](#source-pubmed-observation-pmid-18843769-2013-11-21-eaeb5f94017f))

### Sources

<a id="source-pubmed-observation-pmid-18843769-2013-11-21-eaeb5f94017f"></a>
- **Early callus formation in human hip fracture treated with internal fixation and teriparatide. · retained source version 1:2013-11-21:current:eaeb5f94017f68f85f64acfe6eb90866273c9309441e37918697abacc0730ac4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18843769/) (`pubmed-observation-pmid-18843769-2013-11-21-eaeb5f94017f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Early callus formation in human hip fracture treated with internal fixation and teriparatide." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-18843769-teriparatide-v1 SHA-256: 2076f947626932ec2c361bfb1d540db7b577a8c0fc78f605f3b0587df85034ab.

---

<a id="pubmed-pmid-22840755-teriparatide-v1"></a>

## PubMed record PMID 22840755

> PeptideScanner retained PubMed bibliographic metadata for PMID 22840755 at 2026-07-30T21:57:01.388Z. PubMed recorded a metadata revision date of 2013-02-01 and an Entrez history date of 2012-07-31. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-22840755-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-02-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22840755-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-22840755-teriparatide-v1
- Content SHA-256: `412eb7b80e9bc3c83ffb8687ca860499a2009aa427557ea0f755a095005f7b24`

### Claims and source pins

#### Headline

PubMed record PMID 22840755 ([`pubmed-observation-pmid-22840755-2013-02-01-e8fe61c4f69d`](#source-pubmed-observation-pmid-22840755-2013-02-01-e8fe61c4f69d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 22840755 at 2026-07-30T21:57:01.388Z. PubMed recorded a metadata revision date of 2013-02-01 and an Entrez history date of 2012-07-31. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22840755-2013-02-01-e8fe61c4f69d`](#source-pubmed-observation-pmid-22840755-2013-02-01-e8fe61c4f69d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 22840755 at 2026-07-30T21:57:01.388Z. PubMed recorded a metadata revision date of 2013-02-01 and an Entrez history date of 2012-07-31. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22840755-2013-02-01-e8fe61c4f69d`](#source-pubmed-observation-pmid-22840755-2013-02-01-e8fe61c4f69d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22840755-2013-02-01-e8fe61c4f69d`](#source-pubmed-observation-pmid-22840755-2013-02-01-e8fe61c4f69d))

### Sources

<a id="source-pubmed-observation-pmid-22840755-2013-02-01-e8fe61c4f69d"></a>
- **PubMed record PMID 22840755 · retained source version 1:2013-02-01:current:e8fe61c4f69d9d2c50b3ffca7dea8590ab0b79431b358105c4947a0f96ffa79c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22840755/) (`pubmed-observation-pmid-22840755-2013-02-01-e8fe61c4f69d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 22840755." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-22840755-teriparatide-v1 SHA-256: 412eb7b80e9bc3c83ffb8687ca860499a2009aa427557ea0f755a095005f7b24.

---

<a id="pubmed-pmid-22986396-teriparatide-v1"></a>

## PubMed record PMID 22986396

> PeptideScanner retained PubMed bibliographic metadata for PMID 22986396 at 2026-07-30T22:15:26.556Z. PubMed recorded a metadata revision date of 2012-09-18 and an Entrez history date of 2012-09-19. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-22986396-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2012-09-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22986396-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-22986396-teriparatide-v1
- Content SHA-256: `a44a895eba3bb177ab92f5a2db2d2dd4fff35e03e7c7330090176a7447dfab35`

### Claims and source pins

#### Headline

PubMed record PMID 22986396 ([`pubmed-observation-pmid-22986396-2012-09-18-e565eb933666`](#source-pubmed-observation-pmid-22986396-2012-09-18-e565eb933666))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 22986396 at 2026-07-30T22:15:26.556Z. PubMed recorded a metadata revision date of 2012-09-18 and an Entrez history date of 2012-09-19. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22986396-2012-09-18-e565eb933666`](#source-pubmed-observation-pmid-22986396-2012-09-18-e565eb933666))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 22986396 at 2026-07-30T22:15:26.556Z. PubMed recorded a metadata revision date of 2012-09-18 and an Entrez history date of 2012-09-19. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22986396-2012-09-18-e565eb933666`](#source-pubmed-observation-pmid-22986396-2012-09-18-e565eb933666))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22986396-2012-09-18-e565eb933666`](#source-pubmed-observation-pmid-22986396-2012-09-18-e565eb933666))

### Sources

<a id="source-pubmed-observation-pmid-22986396-2012-09-18-e565eb933666"></a>
- **PubMed record PMID 22986396 · retained source version 1:2012-09-18:current:e565eb9336667316bbdeb008032951c81d8dc20bf40cf058a4536f5ba7f73b4e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22986396/) (`pubmed-observation-pmid-22986396-2012-09-18-e565eb933666`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 22986396." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-22986396-teriparatide-v1 SHA-256: a44a895eba3bb177ab92f5a2db2d2dd4fff35e03e7c7330090176a7447dfab35.

---

<a id="pubmed-pmid-23897194-teriparatide-v1"></a>

## PubMed record PMID 23897194

> PeptideScanner retained PubMed bibliographic metadata for PMID 23897194 at 2026-07-30T21:57:02.018Z. PubMed recorded a metadata revision date of 2013-07-30 and an Entrez history date of 2013-07-31. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-23897194-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-07-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23897194-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-23897194-teriparatide-v1
- Content SHA-256: `160aedddfd07cb286279c30f67b46269b3778ce9758c74832a4f3cb790737d58`

### Claims and source pins

#### Headline

PubMed record PMID 23897194 ([`pubmed-observation-pmid-23897194-2013-07-30-d69f7b3107e4`](#source-pubmed-observation-pmid-23897194-2013-07-30-d69f7b3107e4))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 23897194 at 2026-07-30T21:57:02.018Z. PubMed recorded a metadata revision date of 2013-07-30 and an Entrez history date of 2013-07-31. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23897194-2013-07-30-d69f7b3107e4`](#source-pubmed-observation-pmid-23897194-2013-07-30-d69f7b3107e4))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 23897194 at 2026-07-30T21:57:02.018Z. PubMed recorded a metadata revision date of 2013-07-30 and an Entrez history date of 2013-07-31. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23897194-2013-07-30-d69f7b3107e4`](#source-pubmed-observation-pmid-23897194-2013-07-30-d69f7b3107e4))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23897194-2013-07-30-d69f7b3107e4`](#source-pubmed-observation-pmid-23897194-2013-07-30-d69f7b3107e4))

### Sources

<a id="source-pubmed-observation-pmid-23897194-2013-07-30-d69f7b3107e4"></a>
- **PubMed record PMID 23897194 · retained source version 1:2013-07-30:current:d69f7b3107e4132faee42393ef3ae3bb2aece8deddf47b0e1a538b4c811fbc32** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23897194/) (`pubmed-observation-pmid-23897194-2013-07-30-d69f7b3107e4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 23897194." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-23897194-teriparatide-v1 SHA-256: 160aedddfd07cb286279c30f67b46269b3778ce9758c74832a4f3cb790737d58.

---

<a id="pubmed-pmid-23982227-teriparatide-v1"></a>

## PubMed record PMID 23982227

> PeptideScanner retained PubMed bibliographic metadata for PMID 23982227 at 2026-07-30T21:57:02.020Z. PubMed recorded a metadata revision date of 2013-09-16 and an Entrez history date of 2013-08-29. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-23982227-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-09-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23982227-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-23982227-teriparatide-v1
- Content SHA-256: `90d1c94432cdd87f416b93fd18d06c6749ba3483a660bee2fd5f91eaf4eab6e1`

### Claims and source pins

#### Headline

PubMed record PMID 23982227 ([`pubmed-observation-pmid-23982227-2013-09-16-bf4a2733fa64`](#source-pubmed-observation-pmid-23982227-2013-09-16-bf4a2733fa64))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 23982227 at 2026-07-30T21:57:02.020Z. PubMed recorded a metadata revision date of 2013-09-16 and an Entrez history date of 2013-08-29. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23982227-2013-09-16-bf4a2733fa64`](#source-pubmed-observation-pmid-23982227-2013-09-16-bf4a2733fa64))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 23982227 at 2026-07-30T21:57:02.020Z. PubMed recorded a metadata revision date of 2013-09-16 and an Entrez history date of 2013-08-29. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-23982227-2013-09-16-bf4a2733fa64`](#source-pubmed-observation-pmid-23982227-2013-09-16-bf4a2733fa64))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23982227-2013-09-16-bf4a2733fa64`](#source-pubmed-observation-pmid-23982227-2013-09-16-bf4a2733fa64))

### Sources

<a id="source-pubmed-observation-pmid-23982227-2013-09-16-bf4a2733fa64"></a>
- **PubMed record PMID 23982227 · retained source version 1:2013-09-16:current:bf4a2733fa6453c65defec7b33c2918cc90ab2948deef3ed7e7bf86b52654b7d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23982227/) (`pubmed-observation-pmid-23982227-2013-09-16-bf4a2733fa64`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 23982227." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-23982227-teriparatide-v1 SHA-256: 90d1c94432cdd87f416b93fd18d06c6749ba3483a660bee2fd5f91eaf4eab6e1.

---

<a id="pubmed-pmid-24026625-teriparatide-v1"></a>

## PubMed record PMID 24026625

> PeptideScanner retained PubMed bibliographic metadata for PMID 24026625 at 2026-07-30T21:57:02.022Z. PubMed recorded a metadata revision date of 2013-09-26 and an Entrez history date of 2013-09-13. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-24026625-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-09-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24026625-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-24026625-teriparatide-v1
- Content SHA-256: `77d57aa7ad941a51455d3a1a4ac47e8af81903278e6af6d024f21ff915ea25c2`

### Claims and source pins

#### Headline

PubMed record PMID 24026625 ([`pubmed-observation-pmid-24026625-2013-09-26-eab89c561e85`](#source-pubmed-observation-pmid-24026625-2013-09-26-eab89c561e85))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 24026625 at 2026-07-30T21:57:02.022Z. PubMed recorded a metadata revision date of 2013-09-26 and an Entrez history date of 2013-09-13. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-24026625-2013-09-26-eab89c561e85`](#source-pubmed-observation-pmid-24026625-2013-09-26-eab89c561e85))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 24026625 at 2026-07-30T21:57:02.022Z. PubMed recorded a metadata revision date of 2013-09-26 and an Entrez history date of 2013-09-13. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-24026625-2013-09-26-eab89c561e85`](#source-pubmed-observation-pmid-24026625-2013-09-26-eab89c561e85))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24026625-2013-09-26-eab89c561e85`](#source-pubmed-observation-pmid-24026625-2013-09-26-eab89c561e85))

### Sources

<a id="source-pubmed-observation-pmid-24026625-2013-09-26-eab89c561e85"></a>
- **PubMed record PMID 24026625 · retained source version 1:2013-09-26:current:eab89c561e859280076ce8cf902b28a475cb03ed1febd28784c97e8f5ce09edc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24026625/) (`pubmed-observation-pmid-24026625-2013-09-26-eab89c561e85`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 24026625." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-24026625-teriparatide-v1 SHA-256: 77d57aa7ad941a51455d3a1a4ac47e8af81903278e6af6d024f21ff915ea25c2.

---

<a id="pubmed-pmid-24076523-teriparatide-v1"></a>

## PubMed record PMID 24076523

> PeptideScanner retained PubMed bibliographic metadata for PMID 24076523 at 2026-07-30T21:57:02.024Z. PubMed recorded a metadata revision date of 2013-10-04 and an Entrez history date of 2013-10-01. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-24076523-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-10-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24076523-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-24076523-teriparatide-v1
- Content SHA-256: `d8357b3a4f826f2ee406bc33bb3a3f337137b2fd4eeb4552628c1e671527039d`

### Claims and source pins

#### Headline

PubMed record PMID 24076523 ([`pubmed-observation-pmid-24076523-2013-10-04-3520a8fd2ca4`](#source-pubmed-observation-pmid-24076523-2013-10-04-3520a8fd2ca4))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 24076523 at 2026-07-30T21:57:02.024Z. PubMed recorded a metadata revision date of 2013-10-04 and an Entrez history date of 2013-10-01. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-24076523-2013-10-04-3520a8fd2ca4`](#source-pubmed-observation-pmid-24076523-2013-10-04-3520a8fd2ca4))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 24076523 at 2026-07-30T21:57:02.024Z. PubMed recorded a metadata revision date of 2013-10-04 and an Entrez history date of 2013-10-01. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-24076523-2013-10-04-3520a8fd2ca4`](#source-pubmed-observation-pmid-24076523-2013-10-04-3520a8fd2ca4))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24076523-2013-10-04-3520a8fd2ca4`](#source-pubmed-observation-pmid-24076523-2013-10-04-3520a8fd2ca4))

### Sources

<a id="source-pubmed-observation-pmid-24076523-2013-10-04-3520a8fd2ca4"></a>
- **PubMed record PMID 24076523 · retained source version 1:2013-10-04:current:3520a8fd2ca43e30fb56cada0d9a8628954d29d9ba284ffffef769e74a77607b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24076523/) (`pubmed-observation-pmid-24076523-2013-10-04-3520a8fd2ca4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 24076523." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-24076523-teriparatide-v1 SHA-256: d8357b3a4f826f2ee406bc33bb3a3f337137b2fd4eeb4552628c1e671527039d.

---

<a id="pubmed-pmid-26044820-teriparatide-v1"></a>

## Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS).

> PubMed lists PMID 26044820 in BMC musculoskeletal disorders as Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-06-05 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26044820-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26044820-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-26044820-teriparatide-v1
- Content SHA-256: `41175ca067b822e331910701c16092312a5e47ab90bb1fbfcf5c1ceb338881dd`

### Claims and source pins

#### Headline

Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS). ([`pubmed-observation-pmid-26044820-2026-05-18-c0063f129f2b`](#source-pubmed-observation-pmid-26044820-2026-05-18-c0063f129f2b))

#### Summary

PubMed lists PMID 26044820 in BMC musculoskeletal disorders as Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-06-05 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26044820-2026-05-18-c0063f129f2b`](#source-pubmed-observation-pmid-26044820-2026-05-18-c0063f129f2b))

#### Paragraph 1

PubMed lists PMID 26044820 in BMC musculoskeletal disorders as Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-06-05 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26044820-2026-05-18-c0063f129f2b`](#source-pubmed-observation-pmid-26044820-2026-05-18-c0063f129f2b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26044820-2026-05-18-c0063f129f2b`](#source-pubmed-observation-pmid-26044820-2026-05-18-c0063f129f2b))

### Sources

<a id="source-pubmed-observation-pmid-26044820-2026-05-18-c0063f129f2b"></a>
- **Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS). · retained source version 1:2026-05-18:current:c0063f129f2bb27b4573de16faffd3d7fc1c562d4b5b15f9b8df8210e5a00fa0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26044820/) (`pubmed-observation-pmid-26044820-2026-05-18-c0063f129f2b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS)." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-26044820-teriparatide-v1 SHA-256: 41175ca067b822e331910701c16092312a5e47ab90bb1fbfcf5c1ceb338881dd.

---

<a id="pubmed-pmid-31408164-teriparatide-v1"></a>

## Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use".

> PubMed lists PMID 31408164 in The Journal of clinical endocrinology and metabolism as Comment, Letter, with publication-date metadata of 2019-12-01 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31408164-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31408164-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-31408164-teriparatide-v1
- Content SHA-256: `fdace41cfff6a7058cf48614ae486884b375850bbf2baa7d3821afe8da967d77`

### Claims and source pins

#### Headline

Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use". ([`pubmed-observation-pmid-31408164-2026-08-13-0c195f7d324c`](#source-pubmed-observation-pmid-31408164-2026-08-13-0c195f7d324c))

#### Summary

PubMed lists PMID 31408164 in The Journal of clinical endocrinology and metabolism as Comment, Letter, with publication-date metadata of 2019-12-01 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31408164-2026-08-13-0c195f7d324c`](#source-pubmed-observation-pmid-31408164-2026-08-13-0c195f7d324c))

#### Paragraph 1

PubMed lists PMID 31408164 in The Journal of clinical endocrinology and metabolism as Comment, Letter, with publication-date metadata of 2019-12-01 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31408164-2026-08-13-0c195f7d324c`](#source-pubmed-observation-pmid-31408164-2026-08-13-0c195f7d324c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31408164-2026-08-13-0c195f7d324c`](#source-pubmed-observation-pmid-31408164-2026-08-13-0c195f7d324c))

### Sources

<a id="source-pubmed-observation-pmid-31408164-2026-08-13-0c195f7d324c"></a>
- **Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use". · retained source version 1:2026-08-13:current:0c195f7d324c89cff9eb353f7b605ec0a8fce5cef121d97d66b320fe11d22cd8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31408164/) (`pubmed-observation-pmid-31408164-2026-08-13-0c195f7d324c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Letter to the Editor: 'Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use'." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-31408164-teriparatide-v1 SHA-256: fdace41cfff6a7058cf48614ae486884b375850bbf2baa7d3821afe8da967d77.

---

<a id="pubmed-pmid-38923284-teriparatide-v1"></a>

## Bioequivalence of Recombinant Human Teriparatide Injection in Healthy Adult Female Subjects in the Fasting State.

> PubMed lists PMID 38923284 in Clinical pharmacology in drug development as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-06-24 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38923284-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38923284-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-38923284-teriparatide-v1
- Content SHA-256: `322fcb97ff04b6764719ec909ed61a5f76e46b388f221c0b0b4cdd2c62cc8963`

### Claims and source pins

#### Headline

Bioequivalence of Recombinant Human Teriparatide Injection in Healthy Adult Female Subjects in the Fasting State. ([`pubmed-observation-pmid-38923284-2026-07-01-88f56341ed12`](#source-pubmed-observation-pmid-38923284-2026-07-01-88f56341ed12))

#### Summary

PubMed lists PMID 38923284 in Clinical pharmacology in drug development as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-06-24 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38923284-2026-07-01-88f56341ed12`](#source-pubmed-observation-pmid-38923284-2026-07-01-88f56341ed12))

#### Paragraph 1

PubMed lists PMID 38923284 in Clinical pharmacology in drug development as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-06-24 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38923284-2026-07-01-88f56341ed12`](#source-pubmed-observation-pmid-38923284-2026-07-01-88f56341ed12))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38923284-2026-07-01-88f56341ed12`](#source-pubmed-observation-pmid-38923284-2026-07-01-88f56341ed12))

### Sources

<a id="source-pubmed-observation-pmid-38923284-2026-07-01-88f56341ed12"></a>
- **Bioequivalence of Recombinant Human Teriparatide Injection in Healthy Adult Female Subjects in the Fasting State. · retained source version 1:2026-07-01:current:88f56341ed1294272ab32ea3a3c258c536254fbf533ba6ec400eef7b447f7b77** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38923284/) (`pubmed-observation-pmid-38923284-2026-07-01-88f56341ed12`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bioequivalence of Recombinant Human Teriparatide Injection in Healthy Adult Female Subjects in the Fasting State." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-38923284-teriparatide-v1 SHA-256: 322fcb97ff04b6764719ec909ed61a5f76e46b388f221c0b0b4cdd2c62cc8963.

---

<a id="pubmed-pmid-40657227-teriparatide-v1"></a>

## Can Intermittent Teriparatide Facilitate Supraphysiological-Rate Distraction Osteogenesis? A Feasibility Study in the Rabbit Tibial Lengthening Model.

> PubMed lists PMID 40657227 in Indian journal of orthopaedics as Journal Article, with publication-date metadata of 2025-05-27 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40657227-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40657227-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-40657227-teriparatide-v1
- Content SHA-256: `771cd52ed32306eb84afb35ac0ffd664bb702d021c35c812ec58bf48b66eda17`

### Claims and source pins

#### Headline

Can Intermittent Teriparatide Facilitate Supraphysiological-Rate Distraction Osteogenesis? A Feasibility Study in the Rabbit Tibial Lengthening Model. ([`pubmed-observation-pmid-40657227-2026-05-28-e4be8bfed586`](#source-pubmed-observation-pmid-40657227-2026-05-28-e4be8bfed586))

#### Summary

PubMed lists PMID 40657227 in Indian journal of orthopaedics as Journal Article, with publication-date metadata of 2025-05-27 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40657227-2026-05-28-e4be8bfed586`](#source-pubmed-observation-pmid-40657227-2026-05-28-e4be8bfed586))

#### Paragraph 1

PubMed lists PMID 40657227 in Indian journal of orthopaedics as Journal Article, with publication-date metadata of 2025-05-27 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40657227-2026-05-28-e4be8bfed586`](#source-pubmed-observation-pmid-40657227-2026-05-28-e4be8bfed586))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40657227-2026-05-28-e4be8bfed586`](#source-pubmed-observation-pmid-40657227-2026-05-28-e4be8bfed586))

### Sources

<a id="source-pubmed-observation-pmid-40657227-2026-05-28-e4be8bfed586"></a>
- **Can Intermittent Teriparatide Facilitate Supraphysiological-Rate Distraction Osteogenesis? A Feasibility Study in the Rabbit Tibial Lengthening Model. · retained source version 1:2026-05-28:current:e4be8bfed5868780fd4f6ec3f4ae613b95442941a50938979db4eda1359b20ee** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40657227/) (`pubmed-observation-pmid-40657227-2026-05-28-e4be8bfed586`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Can Intermittent Teriparatide Facilitate Supraphysiological-Rate Distraction Osteogenesis? A Feasibility Study in the Rabbit Tibial Lengthening Model." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-40657227-teriparatide-v1 SHA-256: 771cd52ed32306eb84afb35ac0ffd664bb702d021c35c812ec58bf48b66eda17.

---

<a id="pubmed-pmid-40978515-teriparatide-v1"></a>

## PubMed record PMID 40978515

> PeptideScanner retained PubMed bibliographic metadata for PMID 40978515 at 2026-08-10T10:49:06.968Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2025-09-22. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-40978515-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-02
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40978515-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-40978515-teriparatide-v1
- Content SHA-256: `46040842852af3d2720e55ef01176191c9c398098bc8a59e1afc86bfb5c34c71`

### Claims and source pins

#### Headline

PubMed record PMID 40978515 ([`pubmed-observation-pmid-40978515-2026-08-02-e8b65cebf778`](#source-pubmed-observation-pmid-40978515-2026-08-02-e8b65cebf778))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 40978515 at 2026-08-10T10:49:06.968Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2025-09-22. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40978515-2026-08-02-e8b65cebf778`](#source-pubmed-observation-pmid-40978515-2026-08-02-e8b65cebf778))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 40978515 at 2026-08-10T10:49:06.968Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2025-09-22. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40978515-2026-08-02-e8b65cebf778`](#source-pubmed-observation-pmid-40978515-2026-08-02-e8b65cebf778))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40978515-2026-08-02-e8b65cebf778`](#source-pubmed-observation-pmid-40978515-2026-08-02-e8b65cebf778))

### Sources

<a id="source-pubmed-observation-pmid-40978515-2026-08-02-e8b65cebf778"></a>
- **PubMed record PMID 40978515 · retained source version 1:2026-08-02:current:e8b65cebf77861d6b4a0ff96109573e7ca5f439b1c5ae2daa478add68dd8ea16** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40978515/) (`pubmed-observation-pmid-40978515-2026-08-02-e8b65cebf778`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 40978515." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-40978515-teriparatide-v1 SHA-256: 46040842852af3d2720e55ef01176191c9c398098bc8a59e1afc86bfb5c34c71.

---

<a id="pubmed-pmid-41272927-teriparatide-v1"></a>

## PubMed record PMID 41272927

> PeptideScanner retained PubMed bibliographic metadata for PMID 41272927 at 2026-08-10T10:49:06.999Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2025-11-22. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41272927-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41272927-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41272927-teriparatide-v1
- Content SHA-256: `e55ca6a106c48584aefaa6b227303bdd73c0f60d699766889f81a0b7a5840934`

### Claims and source pins

#### Headline

PubMed record PMID 41272927 ([`pubmed-observation-pmid-41272927-2026-08-03-87e5b79fd514`](#source-pubmed-observation-pmid-41272927-2026-08-03-87e5b79fd514))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41272927 at 2026-08-10T10:49:06.999Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2025-11-22. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41272927-2026-08-03-87e5b79fd514`](#source-pubmed-observation-pmid-41272927-2026-08-03-87e5b79fd514))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41272927 at 2026-08-10T10:49:06.999Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2025-11-22. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41272927-2026-08-03-87e5b79fd514`](#source-pubmed-observation-pmid-41272927-2026-08-03-87e5b79fd514))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41272927-2026-08-03-87e5b79fd514`](#source-pubmed-observation-pmid-41272927-2026-08-03-87e5b79fd514))

### Sources

<a id="source-pubmed-observation-pmid-41272927-2026-08-03-87e5b79fd514"></a>
- **PubMed record PMID 41272927 · retained source version 1:2026-08-03:current:87e5b79fd514427c04fa8e2ed5d82bebcec4c86575c484da2db4ee160a7690b5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41272927/) (`pubmed-observation-pmid-41272927-2026-08-03-87e5b79fd514`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41272927." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41272927-teriparatide-v1 SHA-256: e55ca6a106c48584aefaa6b227303bdd73c0f60d699766889f81a0b7a5840934.

---

<a id="pubmed-pmid-41311271-teriparatide-v1"></a>

## Bonegraft Using Octacalcium Phosphate Collagen Composite with Teriparatide and Polylactic Acid Cage.

> PubMed lists PMID 41311271 in Tissue engineering. Part A as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-02-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41311271-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41311271-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41311271-teriparatide-v1
- Content SHA-256: `d9601f20b23e93bf4aba272de1586164ae4cc2a40034b1d239b9305ccf5cf605`

### Claims and source pins

#### Headline

Bonegraft Using Octacalcium Phosphate Collagen Composite with Teriparatide and Polylactic Acid Cage. ([`pubmed-observation-pmid-41311271-2026-06-10-c8d2102ecbb1`](#source-pubmed-observation-pmid-41311271-2026-06-10-c8d2102ecbb1))

#### Summary

PubMed lists PMID 41311271 in Tissue engineering. Part A as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-02-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41311271-2026-06-10-c8d2102ecbb1`](#source-pubmed-observation-pmid-41311271-2026-06-10-c8d2102ecbb1))

#### Paragraph 1

PubMed lists PMID 41311271 in Tissue engineering. Part A as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-02-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41311271-2026-06-10-c8d2102ecbb1`](#source-pubmed-observation-pmid-41311271-2026-06-10-c8d2102ecbb1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41311271-2026-06-10-c8d2102ecbb1`](#source-pubmed-observation-pmid-41311271-2026-06-10-c8d2102ecbb1))

### Sources

<a id="source-pubmed-observation-pmid-41311271-2026-06-10-c8d2102ecbb1"></a>
- **Bonegraft Using Octacalcium Phosphate Collagen Composite with Teriparatide and Polylactic Acid Cage. · retained source version 1:2026-06-10:current:c8d2102ecbb13f8924f34e34b242109b5ca59f5cd003224deac90fb0ead716b7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41311271/) (`pubmed-observation-pmid-41311271-2026-06-10-c8d2102ecbb1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bonegraft Using Octacalcium Phosphate Collagen Composite with Teriparatide and Polylactic Acid Cage." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41311271-teriparatide-v1 SHA-256: d9601f20b23e93bf4aba272de1586164ae4cc2a40034b1d239b9305ccf5cf605.

---

<a id="pubmed-pmid-41400755-teriparatide-v1"></a>

## Persistence of romosozumab vs. teriparatide in Japanese older adults aged ≥ 75 years with osteoporosis: a population-based cohort study.

> PubMed lists PMID 41400755 in Archives of osteoporosis as Journal Article, Comparative Study, with publication-date metadata of 2025-12-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41400755-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-13
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41400755-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41400755-teriparatide-v1
- Content SHA-256: `670329d9e4ece6d905a1b6697045b79588907fbc150712d8cb2eaf118054ea47`

### Claims and source pins

#### Headline

Persistence of romosozumab vs. teriparatide in Japanese older adults aged ≥ 75 years with osteoporosis: a population-based cohort study. ([`pubmed-observation-pmid-41400755-2026-07-13-94464d7c3554`](#source-pubmed-observation-pmid-41400755-2026-07-13-94464d7c3554))

#### Summary

PubMed lists PMID 41400755 in Archives of osteoporosis as Journal Article, Comparative Study, with publication-date metadata of 2025-12-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41400755-2026-07-13-94464d7c3554`](#source-pubmed-observation-pmid-41400755-2026-07-13-94464d7c3554))

#### Paragraph 1

PubMed lists PMID 41400755 in Archives of osteoporosis as Journal Article, Comparative Study, with publication-date metadata of 2025-12-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41400755-2026-07-13-94464d7c3554`](#source-pubmed-observation-pmid-41400755-2026-07-13-94464d7c3554))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41400755-2026-07-13-94464d7c3554`](#source-pubmed-observation-pmid-41400755-2026-07-13-94464d7c3554))

### Sources

<a id="source-pubmed-observation-pmid-41400755-2026-07-13-94464d7c3554"></a>
- **Persistence of romosozumab vs. teriparatide in Japanese older adults aged ≥ 75 years with osteoporosis: a population-based cohort study. · retained source version 1:2026-07-13:current:94464d7c3554ad2e6441b5e68666164e9ec330a5cb3f96f4b14d947ea54fa017** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41400755/) (`pubmed-observation-pmid-41400755-2026-07-13-94464d7c3554`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Persistence of romosozumab vs. teriparatide in Japanese older adults aged ≥ 75 years with osteoporosis: a population-based cohort study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41400755-teriparatide-v1 SHA-256: 670329d9e4ece6d905a1b6697045b79588907fbc150712d8cb2eaf118054ea47.

---

<a id="pubmed-pmid-41686215-teriparatide-v1"></a>

## PubMed record PMID 41686215

> PeptideScanner retained PubMed bibliographic metadata for PMID 41686215 at 2026-08-10T18:13:40.663Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-02-13. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41686215-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41686215-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41686215-teriparatide-v1
- Content SHA-256: `567e88186669b472d3f46a76fd2d7e434bf55098ad49bdffd5d43b073ef9392f`

### Claims and source pins

#### Headline

PubMed record PMID 41686215 ([`pubmed-observation-pmid-41686215-2026-07-26-4c47157b31c4`](#source-pubmed-observation-pmid-41686215-2026-07-26-4c47157b31c4))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41686215 at 2026-08-10T18:13:40.663Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-02-13. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41686215-2026-07-26-4c47157b31c4`](#source-pubmed-observation-pmid-41686215-2026-07-26-4c47157b31c4))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41686215 at 2026-08-10T18:13:40.663Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-02-13. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41686215-2026-07-26-4c47157b31c4`](#source-pubmed-observation-pmid-41686215-2026-07-26-4c47157b31c4))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41686215-2026-07-26-4c47157b31c4`](#source-pubmed-observation-pmid-41686215-2026-07-26-4c47157b31c4))

### Sources

<a id="source-pubmed-observation-pmid-41686215-2026-07-26-4c47157b31c4"></a>
- **PubMed record PMID 41686215 · retained source version 1:2026-07-26:current:4c47157b31c4ccf73f3d3c1a909a6e483d80acc77322037088ad86717896d11b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41686215/) (`pubmed-observation-pmid-41686215-2026-07-26-4c47157b31c4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41686215." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41686215-teriparatide-v1 SHA-256: 567e88186669b472d3f46a76fd2d7e434bf55098ad49bdffd5d43b073ef9392f.

---

<a id="pubmed-pmid-41748193-teriparatide-v1"></a>

## PubMed record PMID 41748193

> PeptideScanner retained PubMed bibliographic metadata for PMID 41748193 at 2026-08-10T10:49:08.774Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-02-26. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41748193-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41748193-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41748193-teriparatide-v1
- Content SHA-256: `13cee97ce3b1efc9060cd658bb6b6174902c75c103e66e6626be2fb672ed4c7b`

### Claims and source pins

#### Headline

PubMed record PMID 41748193 ([`pubmed-observation-pmid-41748193-2026-08-03-07ebfee91e88`](#source-pubmed-observation-pmid-41748193-2026-08-03-07ebfee91e88))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41748193 at 2026-08-10T10:49:08.774Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-02-26. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41748193-2026-08-03-07ebfee91e88`](#source-pubmed-observation-pmid-41748193-2026-08-03-07ebfee91e88))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41748193 at 2026-08-10T10:49:08.774Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-02-26. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41748193-2026-08-03-07ebfee91e88`](#source-pubmed-observation-pmid-41748193-2026-08-03-07ebfee91e88))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41748193-2026-08-03-07ebfee91e88`](#source-pubmed-observation-pmid-41748193-2026-08-03-07ebfee91e88))

### Sources

<a id="source-pubmed-observation-pmid-41748193-2026-08-03-07ebfee91e88"></a>
- **PubMed record PMID 41748193 · retained source version 1:2026-08-03:current:07ebfee91e8823a30d3ef65e694e83d3a4b1750386a1311d9b71c993e527adf2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41748193/) (`pubmed-observation-pmid-41748193-2026-08-03-07ebfee91e88`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41748193." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41748193-teriparatide-v1 SHA-256: 13cee97ce3b1efc9060cd658bb6b6174902c75c103e66e6626be2fb672ed4c7b.

---

<a id="pubmed-pmid-41852535-teriparatide-v1"></a>

## Targeted drug repurposing in medication-related osteonecrosis of the jaw: a review of teriparatide and pentoxifylline/α-tocopherol protocols.

> PubMed lists PMID 41852535 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41852535-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41852535-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41852535-teriparatide-v1
- Content SHA-256: `4bbf95fa6465b790d7512f4aa9852d2553de028e9de67ca2f403c545d3fa6d9b`

### Claims and source pins

#### Headline

Targeted drug repurposing in medication-related osteonecrosis of the jaw: a review of teriparatide and pentoxifylline/α-tocopherol protocols. ([`pubmed-observation-pmid-41852535-2026-08-13-11eeba203e0a`](#source-pubmed-observation-pmid-41852535-2026-08-13-11eeba203e0a))

#### Summary

PubMed lists PMID 41852535 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41852535-2026-08-13-11eeba203e0a`](#source-pubmed-observation-pmid-41852535-2026-08-13-11eeba203e0a))

#### Paragraph 1

PubMed lists PMID 41852535 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41852535-2026-08-13-11eeba203e0a`](#source-pubmed-observation-pmid-41852535-2026-08-13-11eeba203e0a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41852535-2026-08-13-11eeba203e0a`](#source-pubmed-observation-pmid-41852535-2026-08-13-11eeba203e0a))

### Sources

<a id="source-pubmed-observation-pmid-41852535-2026-08-13-11eeba203e0a"></a>
- **Targeted drug repurposing in medication-related osteonecrosis of the jaw: a review of teriparatide and pentoxifylline/α-tocopherol protocols. · retained source version 1:2026-08-13:current:11eeba203e0a0e4145e347e28669368d99491319cc69ea17a61edb80947cf969** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41852535/) (`pubmed-observation-pmid-41852535-2026-08-13-11eeba203e0a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Targeted drug repurposing in medication-related osteonecrosis of the jaw: a review of teriparatide and pentoxifylline/α-tocopherol protocols." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41852535-teriparatide-v1 SHA-256: 4bbf95fa6465b790d7512f4aa9852d2553de028e9de67ca2f403c545d3fa6d9b.

---

<a id="pubmed-pmid-41904726-teriparatide-v1"></a>

## PubMed record PMID 41904726

> PeptideScanner retained PubMed bibliographic metadata for PMID 41904726 at 2026-08-10T10:49:08.825Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-03-29. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41904726-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41904726-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41904726-teriparatide-v1
- Content SHA-256: `86dccdf7f277a64c707ec7fbd0a30b1b19600c59acb1785cca268419a39361ff`

### Claims and source pins

#### Headline

PubMed record PMID 41904726 ([`pubmed-observation-pmid-41904726-2026-08-06-cb26307cb440`](#source-pubmed-observation-pmid-41904726-2026-08-06-cb26307cb440))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41904726 at 2026-08-10T10:49:08.825Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-03-29. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41904726-2026-08-06-cb26307cb440`](#source-pubmed-observation-pmid-41904726-2026-08-06-cb26307cb440))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41904726 at 2026-08-10T10:49:08.825Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-03-29. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41904726-2026-08-06-cb26307cb440`](#source-pubmed-observation-pmid-41904726-2026-08-06-cb26307cb440))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41904726-2026-08-06-cb26307cb440`](#source-pubmed-observation-pmid-41904726-2026-08-06-cb26307cb440))

### Sources

<a id="source-pubmed-observation-pmid-41904726-2026-08-06-cb26307cb440"></a>
- **PubMed record PMID 41904726 · retained source version 1:2026-08-06:current:cb26307cb440d55f29f9855e2e4decfa46247ecb3a837a4b8e412e2894cfb54d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41904726/) (`pubmed-observation-pmid-41904726-2026-08-06-cb26307cb440`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41904726." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41904726-teriparatide-v1 SHA-256: 86dccdf7f277a64c707ec7fbd0a30b1b19600c59acb1785cca268419a39361ff.

---

<a id="pubmed-pmid-41949681-teriparatide-v1"></a>

## PubMed record PMID 41949681

> PeptideScanner retained PubMed bibliographic metadata for PMID 41949681 at 2026-08-10T10:49:08.835Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-04-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41949681-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41949681-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41949681-teriparatide-v1
- Content SHA-256: `036d6c845d6566b983f2ae311a3329550a448a94dc3c888c418361703c22c220`

### Claims and source pins

#### Headline

PubMed record PMID 41949681 ([`pubmed-observation-pmid-41949681-2026-08-06-5894a3cc3bd8`](#source-pubmed-observation-pmid-41949681-2026-08-06-5894a3cc3bd8))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41949681 at 2026-08-10T10:49:08.835Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-04-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41949681-2026-08-06-5894a3cc3bd8`](#source-pubmed-observation-pmid-41949681-2026-08-06-5894a3cc3bd8))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41949681 at 2026-08-10T10:49:08.835Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-04-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41949681-2026-08-06-5894a3cc3bd8`](#source-pubmed-observation-pmid-41949681-2026-08-06-5894a3cc3bd8))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41949681-2026-08-06-5894a3cc3bd8`](#source-pubmed-observation-pmid-41949681-2026-08-06-5894a3cc3bd8))

### Sources

<a id="source-pubmed-observation-pmid-41949681-2026-08-06-5894a3cc3bd8"></a>
- **PubMed record PMID 41949681 · retained source version 1:2026-08-06:current:5894a3cc3bd8ae78a53d2a4cf037dd246613cab341f885f629fd318f4f4bc995** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41949681/) (`pubmed-observation-pmid-41949681-2026-08-06-5894a3cc3bd8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41949681." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41949681-teriparatide-v1 SHA-256: 036d6c845d6566b983f2ae311a3329550a448a94dc3c888c418361703c22c220.

---

<a id="pubmed-pmid-41950644-teriparatide-v1"></a>

## Development of 1 month core-shell microspheres combination formulation containing teriparatide for osteoporosis treatment.

> PubMed lists PMID 41950644 in Biomaterials as Journal Article, with publication-date metadata of 2026-04-05 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41950644-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-14
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41950644-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41950644-teriparatide-v1
- Content SHA-256: `2e65b34a41b08fd95bf8a00bba0e9878671176ad1523bb0d31af1ceb6b849560`

### Claims and source pins

#### Headline

Development of 1 month core-shell microspheres combination formulation containing teriparatide for osteoporosis treatment. ([`pubmed-observation-pmid-41950644-2026-07-14-138dc8b36d3f`](#source-pubmed-observation-pmid-41950644-2026-07-14-138dc8b36d3f))

#### Summary

PubMed lists PMID 41950644 in Biomaterials as Journal Article, with publication-date metadata of 2026-04-05 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41950644-2026-07-14-138dc8b36d3f`](#source-pubmed-observation-pmid-41950644-2026-07-14-138dc8b36d3f))

#### Paragraph 1

PubMed lists PMID 41950644 in Biomaterials as Journal Article, with publication-date metadata of 2026-04-05 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41950644-2026-07-14-138dc8b36d3f`](#source-pubmed-observation-pmid-41950644-2026-07-14-138dc8b36d3f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41950644-2026-07-14-138dc8b36d3f`](#source-pubmed-observation-pmid-41950644-2026-07-14-138dc8b36d3f))

### Sources

<a id="source-pubmed-observation-pmid-41950644-2026-07-14-138dc8b36d3f"></a>
- **Development of 1 month core-shell microspheres combination formulation containing teriparatide for osteoporosis treatment. · retained source version 1:2026-07-14:current:138dc8b36d3f34b7269528edda14cf873c453bd97108618ae60e24966dcbc49c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41950644/) (`pubmed-observation-pmid-41950644-2026-07-14-138dc8b36d3f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Development of 1 month core-shell microspheres combination formulation containing teriparatide for osteoporosis treatment." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41950644-teriparatide-v1 SHA-256: 2e65b34a41b08fd95bf8a00bba0e9878671176ad1523bb0d31af1ceb6b849560.

---

<a id="pubmed-pmid-41987916-teriparatide-v1"></a>

## Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB.

> PubMed lists PMID 41987916 in JIMD reports as Journal Article, with publication-date metadata of 2026-04-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41987916-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41987916-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41987916-teriparatide-v1
- Content SHA-256: `fc24d0b769641add308ee9f2149d4ac8c7de0184cb51bb22dccc3683509c7471`

### Claims and source pins

#### Headline

Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB. ([`pubmed-observation-pmid-41987916-2026-08-13-8f7a6b5d5355`](#source-pubmed-observation-pmid-41987916-2026-08-13-8f7a6b5d5355))

#### Summary

PubMed lists PMID 41987916 in JIMD reports as Journal Article, with publication-date metadata of 2026-04-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41987916-2026-08-13-8f7a6b5d5355`](#source-pubmed-observation-pmid-41987916-2026-08-13-8f7a6b5d5355))

#### Paragraph 1

PubMed lists PMID 41987916 in JIMD reports as Journal Article, with publication-date metadata of 2026-04-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41987916-2026-08-13-8f7a6b5d5355`](#source-pubmed-observation-pmid-41987916-2026-08-13-8f7a6b5d5355))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41987916-2026-08-13-8f7a6b5d5355`](#source-pubmed-observation-pmid-41987916-2026-08-13-8f7a6b5d5355))

### Sources

<a id="source-pubmed-observation-pmid-41987916-2026-08-13-8f7a6b5d5355"></a>
- **Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB. · retained source version 1:2026-08-13:current:8f7a6b5d5355ee9550f5bfbc0ea2400cfcf5d942402e5b481a5b34c92598d092** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41987916/) (`pubmed-observation-pmid-41987916-2026-08-13-8f7a6b5d5355`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41987916-teriparatide-v1 SHA-256: fc24d0b769641add308ee9f2149d4ac8c7de0184cb51bb22dccc3683509c7471.

---

<a id="pubmed-pmid-41999058-teriparatide-v1"></a>

## PubMed record PMID 41999058

> PeptideScanner retained PubMed bibliographic metadata for PMID 41999058 at 2026-08-10T10:49:08.848Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-04-18. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41999058-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41999058-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41999058-teriparatide-v1
- Content SHA-256: `b27ff5e2b235503d87df4186e51cbf1d125401f70b8729ad079714373b7c03cc`

### Claims and source pins

#### Headline

PubMed record PMID 41999058 ([`pubmed-observation-pmid-41999058-2026-07-30-e1a569d8bdd5`](#source-pubmed-observation-pmid-41999058-2026-07-30-e1a569d8bdd5))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41999058 at 2026-08-10T10:49:08.848Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-04-18. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41999058-2026-07-30-e1a569d8bdd5`](#source-pubmed-observation-pmid-41999058-2026-07-30-e1a569d8bdd5))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41999058 at 2026-08-10T10:49:08.848Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-04-18. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41999058-2026-07-30-e1a569d8bdd5`](#source-pubmed-observation-pmid-41999058-2026-07-30-e1a569d8bdd5))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41999058-2026-07-30-e1a569d8bdd5`](#source-pubmed-observation-pmid-41999058-2026-07-30-e1a569d8bdd5))

### Sources

<a id="source-pubmed-observation-pmid-41999058-2026-07-30-e1a569d8bdd5"></a>
- **PubMed record PMID 41999058 · retained source version 1:2026-07-30:current:e1a569d8bdd575c40a304b6c2cc35d92ba649c95e4b6495a391d5505aec20396** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41999058/) (`pubmed-observation-pmid-41999058-2026-07-30-e1a569d8bdd5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41999058." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-41999058-teriparatide-v1 SHA-256: b27ff5e2b235503d87df4186e51cbf1d125401f70b8729ad079714373b7c03cc.

---

<a id="pubmed-pmid-42022682-teriparatide-v1"></a>

## Comparing Teriparatide and Bisphosphonates for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of RCTs.

> PubMed lists PMID 42022682 in Health science reports as Journal Article, Review, with publication-date metadata of 2026-03-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42022682-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42022682-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42022682-teriparatide-v1
- Content SHA-256: `391f0579e8909451a0a598283bc7815bca1c0216cd2f4a296ddd152239cc21d1`

### Claims and source pins

#### Headline

Comparing Teriparatide and Bisphosphonates for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of RCTs. ([`pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac`](#source-pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac))

#### Summary

PubMed lists PMID 42022682 in Health science reports as Journal Article, Review, with publication-date metadata of 2026-03-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac`](#source-pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac))

#### Paragraph 1

PubMed lists PMID 42022682 in Health science reports as Journal Article, Review, with publication-date metadata of 2026-03-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac`](#source-pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac`](#source-pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac))

### Sources

<a id="source-pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac"></a>
- **Comparing Teriparatide and Bisphosphonates for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of RCTs. · retained source version 1:2026-08-13:current:7d54bf4840ac5fd2a4e97b9f12fb252d111c2c3b2586ecae8ca745977c37c4d4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42022682/) (`pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comparing Teriparatide and Bisphosphonates for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of RCTs." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42022682-teriparatide-v1 SHA-256: 391f0579e8909451a0a598283bc7815bca1c0216cd2f4a296ddd152239cc21d1.

---

<a id="pubmed-pmid-42058698-teriparatide-v1"></a>

## Acute use of teriparatide and palopegteriparatide in the management of hungry bone syndrome following parathyroidectomy.

> PubMed lists PMID 42058698 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-04-28 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42058698-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42058698-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42058698-teriparatide-v1
- Content SHA-256: `9acd64c3a69b56572ab8dd8f48a5bd9253acdaa7eefdb317ebb8599e47b0c742`

### Claims and source pins

#### Headline

Acute use of teriparatide and palopegteriparatide in the management of hungry bone syndrome following parathyroidectomy. ([`pubmed-observation-pmid-42058698-2026-08-13-7f65e384716d`](#source-pubmed-observation-pmid-42058698-2026-08-13-7f65e384716d))

#### Summary

PubMed lists PMID 42058698 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-04-28 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42058698-2026-08-13-7f65e384716d`](#source-pubmed-observation-pmid-42058698-2026-08-13-7f65e384716d))

#### Paragraph 1

PubMed lists PMID 42058698 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-04-28 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42058698-2026-08-13-7f65e384716d`](#source-pubmed-observation-pmid-42058698-2026-08-13-7f65e384716d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42058698-2026-08-13-7f65e384716d`](#source-pubmed-observation-pmid-42058698-2026-08-13-7f65e384716d))

### Sources

<a id="source-pubmed-observation-pmid-42058698-2026-08-13-7f65e384716d"></a>
- **Acute use of teriparatide and palopegteriparatide in the management of hungry bone syndrome following parathyroidectomy. · retained source version 1:2026-08-13:current:7f65e384716dd6476de3e6e48a96075d9c3488791d66d13569f92bbe8d841064** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42058698/) (`pubmed-observation-pmid-42058698-2026-08-13-7f65e384716d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Acute use of teriparatide and palopegteriparatide in the management of hungry bone syndrome following parathyroidectomy." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42058698-teriparatide-v1 SHA-256: 9acd64c3a69b56572ab8dd8f48a5bd9253acdaa7eefdb317ebb8599e47b0c742.

---

<a id="pubmed-pmid-42083710-teriparatide-v1"></a>

## A Comparison Between Bisphosphonates and Teriparatide in the Treatment of Postmenopausal Osteoporosis: A Systematic Review.

> PubMed lists PMID 42083710 in Cureus as Journal Article, Review, with publication-date metadata of 2026-04-03 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42083710-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42083710-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42083710-teriparatide-v1
- Content SHA-256: `f3f8344a68bc399265b4880807f2cd555850118389ce5bc3fefaff797731c478`

### Claims and source pins

#### Headline

A Comparison Between Bisphosphonates and Teriparatide in the Treatment of Postmenopausal Osteoporosis: A Systematic Review. ([`pubmed-observation-pmid-42083710-2026-08-13-fefe26906d6a`](#source-pubmed-observation-pmid-42083710-2026-08-13-fefe26906d6a))

#### Summary

PubMed lists PMID 42083710 in Cureus as Journal Article, Review, with publication-date metadata of 2026-04-03 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42083710-2026-08-13-fefe26906d6a`](#source-pubmed-observation-pmid-42083710-2026-08-13-fefe26906d6a))

#### Paragraph 1

PubMed lists PMID 42083710 in Cureus as Journal Article, Review, with publication-date metadata of 2026-04-03 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42083710-2026-08-13-fefe26906d6a`](#source-pubmed-observation-pmid-42083710-2026-08-13-fefe26906d6a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42083710-2026-08-13-fefe26906d6a`](#source-pubmed-observation-pmid-42083710-2026-08-13-fefe26906d6a))

### Sources

<a id="source-pubmed-observation-pmid-42083710-2026-08-13-fefe26906d6a"></a>
- **A Comparison Between Bisphosphonates and Teriparatide in the Treatment of Postmenopausal Osteoporosis: A Systematic Review. · retained source version 1:2026-08-13:current:fefe26906d6ad69924bc6c60f4405ffbd6270c9bd298323652a1c2a9a7d0e1d8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42083710/) (`pubmed-observation-pmid-42083710-2026-08-13-fefe26906d6a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A Comparison Between Bisphosphonates and Teriparatide in the Treatment of Postmenopausal Osteoporosis: A Systematic Review." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42083710-teriparatide-v1 SHA-256: f3f8344a68bc399265b4880807f2cd555850118389ce5bc3fefaff797731c478.

---

<a id="pubmed-pmid-42133304-teriparatide-v1"></a>

## Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.

> PubMed lists PMID 42133304 in JAMA as Journal Article, Randomized Controlled Trial, Multicenter Study, with publication-date metadata of 2026-07-14 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42133304-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-15
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42133304-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42133304-teriparatide-v1
- Content SHA-256: `a36b380e874b156b29129968cbe26cbee7dab89b11d00cab7a88b456f38924cf`

### Claims and source pins

#### Headline

Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial. ([`pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3`](#source-pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3))

#### Summary

PubMed lists PMID 42133304 in JAMA as Journal Article, Randomized Controlled Trial, Multicenter Study, with publication-date metadata of 2026-07-14 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3`](#source-pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3))

#### Paragraph 1

PubMed lists PMID 42133304 in JAMA as Journal Article, Randomized Controlled Trial, Multicenter Study, with publication-date metadata of 2026-07-14 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3`](#source-pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3`](#source-pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3))

### Sources

<a id="source-pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3"></a>
- **Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial. · retained source version 1:2026-07-15:current:b413e30416a35b6b7cbd6cd1f0e8f020dd1cb507da91e5910b8c165b3df61cc9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42133304/) (`pubmed-observation-pmid-42133304-2026-07-15-b413e30416a3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42133304-teriparatide-v1 SHA-256: a36b380e874b156b29129968cbe26cbee7dab89b11d00cab7a88b456f38924cf.

---

<a id="pubmed-pmid-42133336-teriparatide-v1"></a>

## Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: Research Summary.

> PubMed lists PMID 42133336 in JAMA as Journal Article, with publication-date metadata of 2026-07-14 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42133336-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-14
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42133336-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42133336-teriparatide-v1
- Content SHA-256: `99c09fe655087908957360ce7f5a34c4a44933ea6973a0285d6247f589ce01e1`

### Claims and source pins

#### Headline

Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: Research Summary. ([`pubmed-observation-pmid-42133336-2026-07-14-381aa989bff1`](#source-pubmed-observation-pmid-42133336-2026-07-14-381aa989bff1))

#### Summary

PubMed lists PMID 42133336 in JAMA as Journal Article, with publication-date metadata of 2026-07-14 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42133336-2026-07-14-381aa989bff1`](#source-pubmed-observation-pmid-42133336-2026-07-14-381aa989bff1))

#### Paragraph 1

PubMed lists PMID 42133336 in JAMA as Journal Article, with publication-date metadata of 2026-07-14 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42133336-2026-07-14-381aa989bff1`](#source-pubmed-observation-pmid-42133336-2026-07-14-381aa989bff1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42133336-2026-07-14-381aa989bff1`](#source-pubmed-observation-pmid-42133336-2026-07-14-381aa989bff1))

### Sources

<a id="source-pubmed-observation-pmid-42133336-2026-07-14-381aa989bff1"></a>
- **Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: Research Summary. · retained source version 1:2026-07-14:current:381aa989bff10cc48bf0b5541140d580d790babd29f47878456612c2b50185e0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42133336/) (`pubmed-observation-pmid-42133336-2026-07-14-381aa989bff1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: Research Summary." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42133336-teriparatide-v1 SHA-256: 99c09fe655087908957360ce7f5a34c4a44933ea6973a0285d6247f589ce01e1.

---

<a id="pubmed-pmid-42294947-teriparatide-v1"></a>

## PubMed record PMID 42294947

> PeptideScanner retained PubMed bibliographic metadata for PMID 42294947 at 2026-08-10T18:13:52.269Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42294947-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42294947-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42294947-teriparatide-v1
- Content SHA-256: `ee503de16024df61469c50793534f93ef77f4ca0e555bf86c6f2514fe40bab28`

### Claims and source pins

#### Headline

PubMed record PMID 42294947 ([`pubmed-observation-pmid-42294947-2026-07-26-360cd1844dca`](#source-pubmed-observation-pmid-42294947-2026-07-26-360cd1844dca))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42294947 at 2026-08-10T18:13:52.269Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42294947-2026-07-26-360cd1844dca`](#source-pubmed-observation-pmid-42294947-2026-07-26-360cd1844dca))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42294947 at 2026-08-10T18:13:52.269Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42294947-2026-07-26-360cd1844dca`](#source-pubmed-observation-pmid-42294947-2026-07-26-360cd1844dca))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42294947-2026-07-26-360cd1844dca`](#source-pubmed-observation-pmid-42294947-2026-07-26-360cd1844dca))

### Sources

<a id="source-pubmed-observation-pmid-42294947-2026-07-26-360cd1844dca"></a>
- **PubMed record PMID 42294947 · retained source version 1:2026-07-26:current:360cd1844dca853c6444edfab0e799328e6e8a99b418d4979fcab279943268e3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42294947/) (`pubmed-observation-pmid-42294947-2026-07-26-360cd1844dca`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42294947." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42294947-teriparatide-v1 SHA-256: ee503de16024df61469c50793534f93ef77f4ca0e555bf86c6f2514fe40bab28.

---

<a id="pubmed-pmid-42355862-teriparatide-v1"></a>

## PubMed record PMID 42355862

> PeptideScanner retained PubMed bibliographic metadata for PMID 42355862 at 2026-08-10T18:13:53.757Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42355862-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42355862-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42355862-teriparatide-v1
- Content SHA-256: `870a76b695fbad00f650eeade2d8f19aa61b480ca2c80ac9af948e7fe7f9240f`

### Claims and source pins

#### Headline

PubMed record PMID 42355862 ([`pubmed-observation-pmid-42355862-2026-07-26-ddc55df54b77`](#source-pubmed-observation-pmid-42355862-2026-07-26-ddc55df54b77))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42355862 at 2026-08-10T18:13:53.757Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42355862-2026-07-26-ddc55df54b77`](#source-pubmed-observation-pmid-42355862-2026-07-26-ddc55df54b77))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42355862 at 2026-08-10T18:13:53.757Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42355862-2026-07-26-ddc55df54b77`](#source-pubmed-observation-pmid-42355862-2026-07-26-ddc55df54b77))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42355862-2026-07-26-ddc55df54b77`](#source-pubmed-observation-pmid-42355862-2026-07-26-ddc55df54b77))

### Sources

<a id="source-pubmed-observation-pmid-42355862-2026-07-26-ddc55df54b77"></a>
- **PubMed record PMID 42355862 · retained source version 1:2026-07-26:current:ddc55df54b77feed6ef41b528bb03ec439434d53adb9c2dc5d71b70212538d96** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42355862/) (`pubmed-observation-pmid-42355862-2026-07-26-ddc55df54b77`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42355862." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42355862-teriparatide-v1 SHA-256: 870a76b695fbad00f650eeade2d8f19aa61b480ca2c80ac9af948e7fe7f9240f.

---

<a id="pubmed-pmid-42355866-teriparatide-v1"></a>

## PubMed record PMID 42355866

> PeptideScanner retained PubMed bibliographic metadata for PMID 42355866 at 2026-08-10T18:13:53.757Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42355866-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42355866-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42355866-teriparatide-v1
- Content SHA-256: `6ca53d06cbfc6a9be8b6911a0f4cdc12d6a94632ae64812adb92a764868be527`

### Claims and source pins

#### Headline

PubMed record PMID 42355866 ([`pubmed-observation-pmid-42355866-2026-07-26-b2177dd97521`](#source-pubmed-observation-pmid-42355866-2026-07-26-b2177dd97521))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42355866 at 2026-08-10T18:13:53.757Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42355866-2026-07-26-b2177dd97521`](#source-pubmed-observation-pmid-42355866-2026-07-26-b2177dd97521))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42355866 at 2026-08-10T18:13:53.757Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42355866-2026-07-26-b2177dd97521`](#source-pubmed-observation-pmid-42355866-2026-07-26-b2177dd97521))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42355866-2026-07-26-b2177dd97521`](#source-pubmed-observation-pmid-42355866-2026-07-26-b2177dd97521))

### Sources

<a id="source-pubmed-observation-pmid-42355866-2026-07-26-b2177dd97521"></a>
- **PubMed record PMID 42355866 · retained source version 1:2026-07-26:current:b2177dd97521c3ee8afe509f67d7b81bfed70b25838103cc23450208b59ea46f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42355866/) (`pubmed-observation-pmid-42355866-2026-07-26-b2177dd97521`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42355866." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42355866-teriparatide-v1 SHA-256: 6ca53d06cbfc6a9be8b6911a0f4cdc12d6a94632ae64812adb92a764868be527.

---

<a id="pubmed-pmid-42398904-teriparatide-v1"></a>

## PubMed record PMID 42398904

> PeptideScanner retained PubMed bibliographic metadata for PMID 42398904 at 2026-08-10T18:13:53.834Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-03. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42398904-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42398904-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42398904-teriparatide-v1
- Content SHA-256: `18d1dd9f29fe6d356d0c26960b6fa81efd596b6eab5a9fa65c615429211a7d61`

### Claims and source pins

#### Headline

PubMed record PMID 42398904 ([`pubmed-observation-pmid-42398904-2026-07-29-43db71ef4eb8`](#source-pubmed-observation-pmid-42398904-2026-07-29-43db71ef4eb8))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42398904 at 2026-08-10T18:13:53.834Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-03. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42398904-2026-07-29-43db71ef4eb8`](#source-pubmed-observation-pmid-42398904-2026-07-29-43db71ef4eb8))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42398904 at 2026-08-10T18:13:53.834Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-03. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42398904-2026-07-29-43db71ef4eb8`](#source-pubmed-observation-pmid-42398904-2026-07-29-43db71ef4eb8))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42398904-2026-07-29-43db71ef4eb8`](#source-pubmed-observation-pmid-42398904-2026-07-29-43db71ef4eb8))

### Sources

<a id="source-pubmed-observation-pmid-42398904-2026-07-29-43db71ef4eb8"></a>
- **PubMed record PMID 42398904 · retained source version 1:2026-07-29:current:43db71ef4eb8f207d6d8afbd6285192186a319911b9187af401c04dd4aaacd63** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42398904/) (`pubmed-observation-pmid-42398904-2026-07-29-43db71ef4eb8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42398904." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42398904-teriparatide-v1 SHA-256: 18d1dd9f29fe6d356d0c26960b6fa81efd596b6eab5a9fa65c615429211a7d61.

---

<a id="pubmed-pmid-42501079-teriparatide-v1"></a>

## PubMed record PMID 42501079

> PeptideScanner retained PubMed bibliographic metadata for PMID 42501079 at 2026-08-10T10:49:10.788Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-07-25. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42501079-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-07
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42501079-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42501079-teriparatide-v1
- Content SHA-256: `108f6d1cf8a043a6e4187a29d8f2aeb01d6f6d4c80a55667b6451fe0c5ff817d`

### Claims and source pins

#### Headline

PubMed record PMID 42501079 ([`pubmed-observation-pmid-42501079-2026-08-07-b7436481b921`](#source-pubmed-observation-pmid-42501079-2026-08-07-b7436481b921))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42501079 at 2026-08-10T10:49:10.788Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-07-25. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42501079-2026-08-07-b7436481b921`](#source-pubmed-observation-pmid-42501079-2026-08-07-b7436481b921))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42501079 at 2026-08-10T10:49:10.788Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-07-25. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42501079-2026-08-07-b7436481b921`](#source-pubmed-observation-pmid-42501079-2026-08-07-b7436481b921))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42501079-2026-08-07-b7436481b921`](#source-pubmed-observation-pmid-42501079-2026-08-07-b7436481b921))

### Sources

<a id="source-pubmed-observation-pmid-42501079-2026-08-07-b7436481b921"></a>
- **PubMed record PMID 42501079 · retained source version 1:2026-08-07:current:b7436481b921373a5fd33be4a92d310f92617c414b934a35b6ff8cd2e7e886b6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42501079/) (`pubmed-observation-pmid-42501079-2026-08-07-b7436481b921`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42501079." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42501079-teriparatide-v1 SHA-256: 108f6d1cf8a043a6e4187a29d8f2aeb01d6f6d4c80a55667b6451fe0c5ff817d.

---

<a id="pubmed-pmid-42513596-teriparatide-v1"></a>

## PubMed record PMID 42513596

> PeptideScanner retained PubMed bibliographic metadata for PMID 42513596 at 2026-08-10T10:49:12.877Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42513596-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42513596-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42513596-teriparatide-v1
- Content SHA-256: `4f7e89de991137be47b71d4756a27f99511c6fc53a44e17463ee01da8e439813`

### Claims and source pins

#### Headline

PubMed record PMID 42513596 ([`pubmed-observation-pmid-42513596-2026-07-30-86affca5c503`](#source-pubmed-observation-pmid-42513596-2026-07-30-86affca5c503))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42513596 at 2026-08-10T10:49:12.877Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42513596-2026-07-30-86affca5c503`](#source-pubmed-observation-pmid-42513596-2026-07-30-86affca5c503))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42513596 at 2026-08-10T10:49:12.877Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42513596-2026-07-30-86affca5c503`](#source-pubmed-observation-pmid-42513596-2026-07-30-86affca5c503))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42513596-2026-07-30-86affca5c503`](#source-pubmed-observation-pmid-42513596-2026-07-30-86affca5c503))

### Sources

<a id="source-pubmed-observation-pmid-42513596-2026-07-30-86affca5c503"></a>
- **PubMed record PMID 42513596 · retained source version 1:2026-07-30:current:86affca5c5039184e41b4d79d2f75dfe34ad2e134af430201e31014256b54c6b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42513596/) (`pubmed-observation-pmid-42513596-2026-07-30-86affca5c503`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42513596." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42513596-teriparatide-v1 SHA-256: 4f7e89de991137be47b71d4756a27f99511c6fc53a44e17463ee01da8e439813.

---

<a id="pubmed-pmid-42516799-teriparatide-v1"></a>

## PubMed record PMID 42516799

> PeptideScanner retained PubMed bibliographic metadata for PMID 42516799 at 2026-08-10T18:13:56.766Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42516799-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42516799-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42516799-teriparatide-v1
- Content SHA-256: `b67d9ad89657ef0960bf5fab68eb9f6f190daf4d82e7986b2850d30e44f0490a`

### Claims and source pins

#### Headline

PubMed record PMID 42516799 ([`pubmed-observation-pmid-42516799-2026-07-29-d689b6c47aef`](#source-pubmed-observation-pmid-42516799-2026-07-29-d689b6c47aef))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42516799 at 2026-08-10T18:13:56.766Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42516799-2026-07-29-d689b6c47aef`](#source-pubmed-observation-pmid-42516799-2026-07-29-d689b6c47aef))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42516799 at 2026-08-10T18:13:56.766Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42516799-2026-07-29-d689b6c47aef`](#source-pubmed-observation-pmid-42516799-2026-07-29-d689b6c47aef))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42516799-2026-07-29-d689b6c47aef`](#source-pubmed-observation-pmid-42516799-2026-07-29-d689b6c47aef))

### Sources

<a id="source-pubmed-observation-pmid-42516799-2026-07-29-d689b6c47aef"></a>
- **PubMed record PMID 42516799 · retained source version 1:2026-07-29:current:d689b6c47aefcd052c6ad940ceb40573783c795ceac9180bea3fded971cc001e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42516799/) (`pubmed-observation-pmid-42516799-2026-07-29-d689b6c47aef`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42516799." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42516799-teriparatide-v1 SHA-256: b67d9ad89657ef0960bf5fab68eb9f6f190daf4d82e7986b2850d30e44f0490a.

---

<a id="pubmed-pmid-42521191-teriparatide-v1"></a>

## PubMed record PMID 42521191

> PeptideScanner retained PubMed bibliographic metadata for PMID 42521191 at 2026-08-10T18:13:56.780Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42521191-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-28
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42521191-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42521191-teriparatide-v1
- Content SHA-256: `d744104533ec8223088fa6322e6eb88c7e6c47eea407185c7ae3673944007100`

### Claims and source pins

#### Headline

PubMed record PMID 42521191 ([`pubmed-observation-pmid-42521191-2026-07-28-d7a7361c8a76`](#source-pubmed-observation-pmid-42521191-2026-07-28-d7a7361c8a76))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42521191 at 2026-08-10T18:13:56.780Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42521191-2026-07-28-d7a7361c8a76`](#source-pubmed-observation-pmid-42521191-2026-07-28-d7a7361c8a76))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42521191 at 2026-08-10T18:13:56.780Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42521191-2026-07-28-d7a7361c8a76`](#source-pubmed-observation-pmid-42521191-2026-07-28-d7a7361c8a76))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42521191-2026-07-28-d7a7361c8a76`](#source-pubmed-observation-pmid-42521191-2026-07-28-d7a7361c8a76))

### Sources

<a id="source-pubmed-observation-pmid-42521191-2026-07-28-d7a7361c8a76"></a>
- **PubMed record PMID 42521191 · retained source version 1:2026-07-28:current:d7a7361c8a76009bcda865899c81bb9a0e0f1f527b5fc745f3f999f94fd03053** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42521191/) (`pubmed-observation-pmid-42521191-2026-07-28-d7a7361c8a76`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42521191." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42521191-teriparatide-v1 SHA-256: d744104533ec8223088fa6322e6eb88c7e6c47eea407185c7ae3673944007100.

---

<a id="pubmed-pmid-42532234-teriparatide-v1"></a>

## PubMed record PMID 42532234

> PeptideScanner retained PubMed bibliographic metadata for PMID 42532234 at 2026-08-10T10:49:12.924Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-07-30. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42532234-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42532234-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42532234-teriparatide-v1
- Content SHA-256: `481668e212e8bd8975a4cb0b54b90657fa9738af2c994965a2fab0d28c276929`

### Claims and source pins

#### Headline

PubMed record PMID 42532234 ([`pubmed-observation-pmid-42532234-2026-08-03-59b360539c23`](#source-pubmed-observation-pmid-42532234-2026-08-03-59b360539c23))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42532234 at 2026-08-10T10:49:12.924Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-07-30. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42532234-2026-08-03-59b360539c23`](#source-pubmed-observation-pmid-42532234-2026-08-03-59b360539c23))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42532234 at 2026-08-10T10:49:12.924Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-07-30. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42532234-2026-08-03-59b360539c23`](#source-pubmed-observation-pmid-42532234-2026-08-03-59b360539c23))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42532234-2026-08-03-59b360539c23`](#source-pubmed-observation-pmid-42532234-2026-08-03-59b360539c23))

### Sources

<a id="source-pubmed-observation-pmid-42532234-2026-08-03-59b360539c23"></a>
- **PubMed record PMID 42532234 · retained source version 1:2026-08-03:current:59b360539c23ff2bf77da9710d8c9088a1ea2a55cde6fbf09e54ec94650dbc9f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42532234/) (`pubmed-observation-pmid-42532234-2026-08-03-59b360539c23`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42532234." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42532234-teriparatide-v1 SHA-256: 481668e212e8bd8975a4cb0b54b90657fa9738af2c994965a2fab0d28c276929.

---

<a id="pubmed-pmid-42568899-teriparatide-v1"></a>

## PubMed record PMID 42568899

> PeptideScanner retained PubMed bibliographic metadata for PMID 42568899 at 2026-08-10T10:49:13.608Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42568899-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-08
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42568899-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42568899-teriparatide-v1
- Content SHA-256: `1825ac43866362e85f600a47959cf70cdd7add2b04bcb82c86a1bea30e8e5f16`

### Claims and source pins

#### Headline

PubMed record PMID 42568899 ([`pubmed-observation-pmid-42568899-2026-08-08-75428158b25f`](#source-pubmed-observation-pmid-42568899-2026-08-08-75428158b25f))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42568899 at 2026-08-10T10:49:13.608Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42568899-2026-08-08-75428158b25f`](#source-pubmed-observation-pmid-42568899-2026-08-08-75428158b25f))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42568899 at 2026-08-10T10:49:13.608Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42568899-2026-08-08-75428158b25f`](#source-pubmed-observation-pmid-42568899-2026-08-08-75428158b25f))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42568899-2026-08-08-75428158b25f`](#source-pubmed-observation-pmid-42568899-2026-08-08-75428158b25f))

### Sources

<a id="source-pubmed-observation-pmid-42568899-2026-08-08-75428158b25f"></a>
- **PubMed record PMID 42568899 · retained source version 1:2026-08-08:current:75428158b25ffca585cfb873491f481ba825f6bf9d465537893b1aa4087b2307** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42568899/) (`pubmed-observation-pmid-42568899-2026-08-08-75428158b25f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42568899." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42568899-teriparatide-v1 SHA-256: 1825ac43866362e85f600a47959cf70cdd7add2b04bcb82c86a1bea30e8e5f16.

---

<a id="pubmed-pmid-42570209-teriparatide-v1"></a>

## PubMed record PMID 42570209

> PeptideScanner retained PubMed bibliographic metadata for PMID 42570209 at 2026-08-10T10:49:13.625Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42570209-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-08
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42570209-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42570209-teriparatide-v1
- Content SHA-256: `cdb6515edee6ef4ceb9fe03158aafb1622be4c4e7dd49a8a6c5f2c7da63ed378`

### Claims and source pins

#### Headline

PubMed record PMID 42570209 ([`pubmed-observation-pmid-42570209-2026-08-08-b48a54969798`](#source-pubmed-observation-pmid-42570209-2026-08-08-b48a54969798))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42570209 at 2026-08-10T10:49:13.625Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42570209-2026-08-08-b48a54969798`](#source-pubmed-observation-pmid-42570209-2026-08-08-b48a54969798))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42570209 at 2026-08-10T10:49:13.625Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug teriparatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42570209-2026-08-08-b48a54969798`](#source-pubmed-observation-pmid-42570209-2026-08-08-b48a54969798))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42570209-2026-08-08-b48a54969798`](#source-pubmed-observation-pmid-42570209-2026-08-08-b48a54969798))

### Sources

<a id="source-pubmed-observation-pmid-42570209-2026-08-08-b48a54969798"></a>
- **PubMed record PMID 42570209 · retained source version 1:2026-08-08:current:b48a54969798769292ad861baad3e2e149d765e7fb49b4a079dfc8e8ebfdc0eb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42570209/) (`pubmed-observation-pmid-42570209-2026-08-08-b48a54969798`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42570209." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42570209-teriparatide-v1 SHA-256: cdb6515edee6ef4ceb9fe03158aafb1622be4c4e7dd49a8a6c5f2c7da63ed378.

---

<a id="pubmed-pmid-42592840-teriparatide-v1"></a>

## Transient teriparatide for postoperative hypocalcaemia with hungry bone features.

> PubMed lists PMID 42592840 in European journal of endocrinology as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42592840-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42592840-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42592840-teriparatide-v1
- Content SHA-256: `81e2fca559e818adace69eabf6d4d3bde3665b51877da38643188f687031a6e1`

### Claims and source pins

#### Headline

Transient teriparatide for postoperative hypocalcaemia with hungry bone features. ([`pubmed-observation-pmid-42592840-2026-08-13-0f6ffb1496a7`](#source-pubmed-observation-pmid-42592840-2026-08-13-0f6ffb1496a7))

#### Summary

PubMed lists PMID 42592840 in European journal of endocrinology as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42592840-2026-08-13-0f6ffb1496a7`](#source-pubmed-observation-pmid-42592840-2026-08-13-0f6ffb1496a7))

#### Paragraph 1

PubMed lists PMID 42592840 in European journal of endocrinology as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42592840-2026-08-13-0f6ffb1496a7`](#source-pubmed-observation-pmid-42592840-2026-08-13-0f6ffb1496a7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42592840-2026-08-13-0f6ffb1496a7`](#source-pubmed-observation-pmid-42592840-2026-08-13-0f6ffb1496a7))

### Sources

<a id="source-pubmed-observation-pmid-42592840-2026-08-13-0f6ffb1496a7"></a>
- **Transient teriparatide for postoperative hypocalcaemia with hungry bone features. · retained source version 1:2026-08-13:current:0f6ffb1496a74165eb5c939d991b5700d438f11e534205cbca1b357615213068** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42592840/) (`pubmed-observation-pmid-42592840-2026-08-13-0f6ffb1496a7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Transient teriparatide for postoperative hypocalcaemia with hungry bone features." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42592840-teriparatide-v1 SHA-256: 81e2fca559e818adace69eabf6d4d3bde3665b51877da38643188f687031a6e1.

---

<a id="pubmed-pmid-42751062-teriparatide-v1"></a>

## Medication-related osteonecrosis of the external auditory canal and treatment with teriparatide.

> PubMed lists PMID 42751062 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-09-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42751062-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-18
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42751062-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42751062-teriparatide-v1
- Content SHA-256: `3d9075f636a85f2eec6e3603567c23552b2d4586daba0f635479cd5d6afbe973`

### Claims and source pins

#### Headline

Medication-related osteonecrosis of the external auditory canal and treatment with teriparatide. ([`pubmed-observation-pmid-42751062-2026-09-18-94b6e760f99f`](#source-pubmed-observation-pmid-42751062-2026-09-18-94b6e760f99f))

#### Summary

PubMed lists PMID 42751062 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-09-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42751062-2026-09-18-94b6e760f99f`](#source-pubmed-observation-pmid-42751062-2026-09-18-94b6e760f99f))

#### Paragraph 1

PubMed lists PMID 42751062 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-09-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42751062-2026-09-18-94b6e760f99f`](#source-pubmed-observation-pmid-42751062-2026-09-18-94b6e760f99f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42751062-2026-09-18-94b6e760f99f`](#source-pubmed-observation-pmid-42751062-2026-09-18-94b6e760f99f))

### Sources

<a id="source-pubmed-observation-pmid-42751062-2026-09-18-94b6e760f99f"></a>
- **Medication-related osteonecrosis of the external auditory canal and treatment with teriparatide. · retained source version 1:2026-09-18:current:94b6e760f99fe040ee5247cc91a76d58061f432e10be3cfa799dbf904439ef3f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42751062/) (`pubmed-observation-pmid-42751062-2026-09-18-94b6e760f99f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Medication-related osteonecrosis of the external auditory canal and treatment with teriparatide." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42751062-teriparatide-v1 SHA-256: 3d9075f636a85f2eec6e3603567c23552b2d4586daba0f635479cd5d6afbe973.

---

<a id="pubmed-pmid-42797243-teriparatide-v1"></a>

## Dendritic Mesoporous Silica-Modified Decellularized Bone Matrix Scaffold for Sustained Teriparatide Delivery in Bone Defect Repair: Characterization, Drug Release, and In Vitro Biological Performance.

> PubMed lists PMID 42797243 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-08-26 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42797243-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-29
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42797243-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42797243-teriparatide-v1
- Content SHA-256: `1fa672c6301f77604625e6fc94558307349faa4d7e5fc34499bea094479345a1`

### Claims and source pins

#### Headline

Dendritic Mesoporous Silica-Modified Decellularized Bone Matrix Scaffold for Sustained Teriparatide Delivery in Bone Defect Repair: Characterization, Drug Release, and In Vitro Biological Performance. ([`pubmed-observation-pmid-42797243-2026-09-29-5085ca3ad2d2`](#source-pubmed-observation-pmid-42797243-2026-09-29-5085ca3ad2d2))

#### Summary

PubMed lists PMID 42797243 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-08-26 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42797243-2026-09-29-5085ca3ad2d2`](#source-pubmed-observation-pmid-42797243-2026-09-29-5085ca3ad2d2))

#### Paragraph 1

PubMed lists PMID 42797243 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-08-26 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42797243-2026-09-29-5085ca3ad2d2`](#source-pubmed-observation-pmid-42797243-2026-09-29-5085ca3ad2d2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42797243-2026-09-29-5085ca3ad2d2`](#source-pubmed-observation-pmid-42797243-2026-09-29-5085ca3ad2d2))

### Sources

<a id="source-pubmed-observation-pmid-42797243-2026-09-29-5085ca3ad2d2"></a>
- **Dendritic Mesoporous Silica-Modified Decellularized Bone Matrix Scaffold for Sustained Teriparatide Delivery in Bone Defect Repair: Characterization, Drug Release, and In Vitro Biological Performance. · retained source version 1:2026-09-29:current:5085ca3ad2d25909fe48aa3429696353497a95d308cbd37ab6817876d09c1bd6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42797243/) (`pubmed-observation-pmid-42797243-2026-09-29-5085ca3ad2d2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dendritic Mesoporous Silica-Modified Decellularized Bone Matrix Scaffold for Sustained Teriparatide Delivery in Bone Defect Repair: Characterization, Drug Release, and In Vitro Biological Performance." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42797243-teriparatide-v1 SHA-256: 1fa672c6301f77604625e6fc94558307349faa4d7e5fc34499bea094479345a1.

---

<a id="pubmed-pmid-42876896-teriparatide-v1"></a>

## Conservative Treatment with Adjunctive Use of Teriparatide for Periprosthetic Humeral Fractures after Reverse Total Shoulder Arthroplasty: A Report of 6 Cases.

> PubMed lists PMID 42876896 in Clinics in orthopedic surgery as Journal Article, Case Reports, with publication-date metadata of 2026-09-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42876896-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-19
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42876896-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42876896-teriparatide-v1
- Content SHA-256: `6c520db395403243b89b5dae98b382f20dd62906fa626c1d12be9da1188a938c`

### Claims and source pins

#### Headline

Conservative Treatment with Adjunctive Use of Teriparatide for Periprosthetic Humeral Fractures after Reverse Total Shoulder Arthroplasty: A Report of 6 Cases. ([`pubmed-observation-pmid-42876896-2026-10-19-3dcc70ea97e6`](#source-pubmed-observation-pmid-42876896-2026-10-19-3dcc70ea97e6))

#### Summary

PubMed lists PMID 42876896 in Clinics in orthopedic surgery as Journal Article, Case Reports, with publication-date metadata of 2026-09-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42876896-2026-10-19-3dcc70ea97e6`](#source-pubmed-observation-pmid-42876896-2026-10-19-3dcc70ea97e6))

#### Paragraph 1

PubMed lists PMID 42876896 in Clinics in orthopedic surgery as Journal Article, Case Reports, with publication-date metadata of 2026-09-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42876896-2026-10-19-3dcc70ea97e6`](#source-pubmed-observation-pmid-42876896-2026-10-19-3dcc70ea97e6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42876896-2026-10-19-3dcc70ea97e6`](#source-pubmed-observation-pmid-42876896-2026-10-19-3dcc70ea97e6))

### Sources

<a id="source-pubmed-observation-pmid-42876896-2026-10-19-3dcc70ea97e6"></a>
- **Conservative Treatment with Adjunctive Use of Teriparatide for Periprosthetic Humeral Fractures after Reverse Total Shoulder Arthroplasty: A Report of 6 Cases. · retained source version 1:2026-10-19:current:3dcc70ea97e63ef8390b0530e741b599ac6641514ec63c43ed4a6079f5584e5e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42876896/) (`pubmed-observation-pmid-42876896-2026-10-19-3dcc70ea97e6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Conservative Treatment with Adjunctive Use of Teriparatide for Periprosthetic Humeral Fractures after Reverse Total Shoulder Arthroplasty: A Report of 6 Cases." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42876896-teriparatide-v1 SHA-256: 6c520db395403243b89b5dae98b382f20dd62906fa626c1d12be9da1188a938c.

---

<a id="pubmed-pmid-42926909-teriparatide-v1"></a>

## Bone-targeting engineered exosomes delivering teriparatide mRNA for the treatment of osteoporosis.

> PubMed lists PMID 42926909 in Regenerative therapy as Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42926909-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-26
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42926909-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42926909-teriparatide-v1
- Content SHA-256: `1088a13246452e1b7209d338f9a77446c41420bee073a130b90839447d13311d`

### Claims and source pins

#### Headline

Bone-targeting engineered exosomes delivering teriparatide mRNA for the treatment of osteoporosis. ([`pubmed-observation-pmid-42926909-2026-10-26-e8fb7de8524e`](#source-pubmed-observation-pmid-42926909-2026-10-26-e8fb7de8524e))

#### Summary

PubMed lists PMID 42926909 in Regenerative therapy as Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42926909-2026-10-26-e8fb7de8524e`](#source-pubmed-observation-pmid-42926909-2026-10-26-e8fb7de8524e))

#### Paragraph 1

PubMed lists PMID 42926909 in Regenerative therapy as Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42926909-2026-10-26-e8fb7de8524e`](#source-pubmed-observation-pmid-42926909-2026-10-26-e8fb7de8524e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42926909-2026-10-26-e8fb7de8524e`](#source-pubmed-observation-pmid-42926909-2026-10-26-e8fb7de8524e))

### Sources

<a id="source-pubmed-observation-pmid-42926909-2026-10-26-e8fb7de8524e"></a>
- **Bone-targeting engineered exosomes delivering teriparatide mRNA for the treatment of osteoporosis. · retained source version 1:2026-10-26:current:e8fb7de8524ee580723d4afca1e66455352723c7ad70c600a121b3dc9c88098a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42926909/) (`pubmed-observation-pmid-42926909-2026-10-26-e8fb7de8524e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bone-targeting engineered exosomes delivering teriparatide mRNA for the treatment of osteoporosis." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42926909-teriparatide-v1 SHA-256: 1088a13246452e1b7209d338f9a77446c41420bee073a130b90839447d13311d.

---

<a id="pubmed-pmid-42995581-teriparatide-v1"></a>

## Perioperative teriparatide use in osteopenic and osteoporotic patients undergoing multi- and long-segment posterior spinal fusion.

> PubMed lists PMID 42995581 in BMC musculoskeletal disorders as Journal Article, with publication-date metadata of 2026-08-11 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42995581-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42995581-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42995581-teriparatide-v1
- Content SHA-256: `6306df8c5690f79025bb8f8704b090b6afc82367d154653bfc6441903be62a3b`

### Claims and source pins

#### Headline

Perioperative teriparatide use in osteopenic and osteoporotic patients undergoing multi- and long-segment posterior spinal fusion. ([`pubmed-observation-pmid-42995581-2026-11-09-02b83d92faa9`](#source-pubmed-observation-pmid-42995581-2026-11-09-02b83d92faa9))

#### Summary

PubMed lists PMID 42995581 in BMC musculoskeletal disorders as Journal Article, with publication-date metadata of 2026-08-11 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42995581-2026-11-09-02b83d92faa9`](#source-pubmed-observation-pmid-42995581-2026-11-09-02b83d92faa9))

#### Paragraph 1

PubMed lists PMID 42995581 in BMC musculoskeletal disorders as Journal Article, with publication-date metadata of 2026-08-11 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42995581-2026-11-09-02b83d92faa9`](#source-pubmed-observation-pmid-42995581-2026-11-09-02b83d92faa9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42995581-2026-11-09-02b83d92faa9`](#source-pubmed-observation-pmid-42995581-2026-11-09-02b83d92faa9))

### Sources

<a id="source-pubmed-observation-pmid-42995581-2026-11-09-02b83d92faa9"></a>
- **Perioperative teriparatide use in osteopenic and osteoporotic patients undergoing multi- and long-segment posterior spinal fusion. · retained source version 1:2026-11-09:current:02b83d92faa911e377451ffbc895a2416f0c1f9a7fc979a2911ff9ed669e1b09** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42995581/) (`pubmed-observation-pmid-42995581-2026-11-09-02b83d92faa9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Perioperative teriparatide use in osteopenic and osteoporotic patients undergoing multi- and long-segment posterior spinal fusion." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-42995581-teriparatide-v1 SHA-256: 6306df8c5690f79025bb8f8704b090b6afc82367d154653bfc6441903be62a3b.

---

<a id="pubmed-pmid-43018567-teriparatide-v1"></a>

## Development of Long-Acting Teriparatide Analogues through Iterative Peptide Scanning and Site-Specific Modification by Serine/Threonine Ligation.

> PubMed lists PMID 43018567 in Journal of medicinal chemistry as Journal Article, with publication-date metadata of 2026-11-12 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-43018567-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-12
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-43018567-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-43018567-teriparatide-v1
- Content SHA-256: `2c32087e1853858f9ad54259402e6aaedc65124732babbbce37db2f5f959104e`

### Claims and source pins

#### Headline

Development of Long-Acting Teriparatide Analogues through Iterative Peptide Scanning and Site-Specific Modification by Serine/Threonine Ligation. ([`pubmed-observation-pmid-43018567-2026-11-12-1b770adb1b35`](#source-pubmed-observation-pmid-43018567-2026-11-12-1b770adb1b35))

#### Summary

PubMed lists PMID 43018567 in Journal of medicinal chemistry as Journal Article, with publication-date metadata of 2026-11-12 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43018567-2026-11-12-1b770adb1b35`](#source-pubmed-observation-pmid-43018567-2026-11-12-1b770adb1b35))

#### Paragraph 1

PubMed lists PMID 43018567 in Journal of medicinal chemistry as Journal Article, with publication-date metadata of 2026-11-12 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43018567-2026-11-12-1b770adb1b35`](#source-pubmed-observation-pmid-43018567-2026-11-12-1b770adb1b35))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-43018567-2026-11-12-1b770adb1b35`](#source-pubmed-observation-pmid-43018567-2026-11-12-1b770adb1b35))

### Sources

<a id="source-pubmed-observation-pmid-43018567-2026-11-12-1b770adb1b35"></a>
- **Development of Long-Acting Teriparatide Analogues through Iterative Peptide Scanning and Site-Specific Modification by Serine/Threonine Ligation. · retained source version 1:2026-11-12:current:1b770adb1b35c6590e8c685921d3db6477c8ec1604d3cf7a80fb65836548a67f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/43018567/) (`pubmed-observation-pmid-43018567-2026-11-12-1b770adb1b35`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Development of Long-Acting Teriparatide Analogues through Iterative Peptide Scanning and Site-Specific Modification by Serine/Threonine Ligation." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/teriparatide.json#pubmed-pmid-43018567-teriparatide-v1 SHA-256: 2c32087e1853858f9ad54259402e6aaedc65124732babbbce37db2f5f959104e.

